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   I	  
Summary	  
	  
Malaria	  infects	  200	  million	  people	  and	  causes	  more	  than	  500	  000	  deaths	  
worldwide	  annually.	  Infection	  by	  Plasmodium	  falciparum	  can	  lead	  to	  development	  of	  
cerebral	  malaria,	  a	  fulminant	  and	  often	  fatal	  complication.	  In	  the	  mouse	  model	  
termed	  experimental	  cerebral	  malaria	  (ECM),	  C57BL/6J	  mice	  develop	  a	  severe	  
neurological	  complication	  when	  infected	  with	  Plasmodium	  berghei	  strain	  ANKA	  
(PbA)	  that	  shares	  many	  features	  with	  cerebral	  malaria	  in	  humans.	  	  
	  
CD8+	  T	  cells	  are	  essential	  for	  development	  of	  experimental	  cerebral	  malaria	  
(ECM),	  but	  the	  epitopes	  recognized	  by	  these	  CD8+	  T	  cells	  were	  unknown.	  To	  search	  
for	  novel	  epitopes,	  we	  constructed	  a	  PbA	  cDNA	  library	  and	  expressed	  it	  in	  EL4	  cells	  
(C57BL/6	  background)	  .	  A	  novel	  method	  involving	  phosphorothioate-­‐linked	  random	  
primers	  and	  translational	  coupling	  was	  developed	  to	  enrich	  the	  cDNA	  library	  for	  in-­‐
frame	  inserts.	  In	  the	  EL4	  cells,	  potential	  PbA	  epitopes	  are	  processed	  and	  presented	  
on	  the	  cell	  surface	  bound	  to	  MHC	  class	  I	  molecules.	  Concurrently,	  TCRs	  from	  CD8+	  T	  
cells	  sequestered	  in	  the	  brains	  of	  mice	  with	  ECM	  were	  cloned	  and	  expressed	  in	  
separate	  T	  reporter	  cell	  lines	  harbouring	  a	  LacZ	  cassette	  controlled	  by	  an	  NFAT	  
promoter.	  Each	  T	  reporter	  cell	  line	  was	  used	  to	  screen	  the	  PbA	  cDNA	  library,	  to	  
identify	  and	  clone	  transduced	  EL4	  cells	  able	  to	  trigger	  TCR	  ligation	  and	  hence	  lacZ	  
expression.	  Sequencing	  the	  cDNA	  inserts	  led	  to	  the	  identification	  of	  GAP50	  and	  
bergheilysin	  as	  two	  antigens	  that	  are	  recognized	  by	  CD8+	  T	  cells	  in	  mice	  during	  
infection.	  The	  epitopes	  were	  found	  to	  be	  SQLLNAKYL	  (Pb1)	  and	  IITDFENL	  	  (Pb2)	  
respectively,	  by	  generating	  and	  testing	  candidate	  peptide-­‐MHC	  tetramers.	  	  
	   II	  
	  
With	  the	  peptide-­‐MHC	  tetramers	  for	  Pb1,	  Pb2	  and	  F4	  (an	  epitope	  reported	  in	  
the	  literature	  midway	  through	  this	  project),	  we	  were	  able	  to	  characterize	  the	  
antigen-­‐specific	  CD8+	  T	  cell	  response	  during	  ECM.	  CD8+	  T	  cells	  specific	  for	  each	  of	  the	  
three	  epitopes	  were	  induced	  in	  infected	  mice,	  expressing	  IFNγ,	  granzyme	  B,	  LFA-­‐
1high,	  and	  CXCR3	  in	  the	  spleen,	  with	  downregulation	  of	  CXCR3	  in	  cells	  in	  the	  brain.	  
These	  markers	  are	  associated	  with	  pathogenicity,	  thus	  their	  expression	  by	  CD8+	  T	  
cells	  in	  mice	  not	  succumbing	  to	  ECM	  seems	  contradictory.	  The	  apparent	  
contradiction	  was	  resolved	  when	  we	  discovered	  that	  only	  mice	  with	  ECM	  cross-­‐
present	  high	  levels	  of	  malaria	  epitopes	  in	  the	  brain	  microvasculature,	  showing	  that	  
this	  is	  the	  essential	  feature	  that	  determines	  ECM	  susceptibility.	  Accordingly,	  CD8+	  T	  
cells	  recognizing	  Pb1,	  Pb2	  and	  F4	  have	  the	  capacity	  to	  damage	  these	  cells	  and	  
disrupt	  the	  blood-­‐brain	  barrier,	  presumably	  leading	  to	  onset	  of	  ECM	  development	  
during	  infection.	  Tolerizing	  mice	  towards	  these	  three	  peptides	  could	  not	  protect	  
infected	  mice	  against	  ECM,	  suggesting	  that	  ECM	  is	  caused	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Introduction	  
	  
Malaria,	  an	  ancient	  disease	  
	  
Malaria	  is	  a	  blood-­‐borne	  disease	  caused	  by	  Plasmodium	  protozoan	  parasites	  
and	  is	  transmitted	  by	  mosquitoes	  of	  the	  Anopheles	  genus.	  This	  disease	  is	  estimated	  
to	  be	  more	  than	  100,000	  years	  ago,	  about	  the	  same	  age	  as	  the	  modern	  human	  race	  
(1).	  It	  is	  hypothesized	  that	  these	  parasites	  originated	  from	  an	  ancestor	  protozoa	  that	  
gained	  the	  ability	  to	  parasitize	  and	  replicate	  sexually	  in	  early	  aquatic	  invertebrates	  
(2).	  As	  the	  first	  modern	  mosquitoes	  appeared	  circa	  150	  million	  years	  ago,	  some	  
parasites	  mutated	  and	  gained	  the	  ability	  to	  develop	  an	  asexual	  life	  cycle	  in	  the	  hosts	  
that	  the	  mosquitoes	  feed	  on,	  including	  early	  birds,	  reptiles,	  mammals	  and	  eventually	  
humans.	  When	  human	  agriculture	  started	  more	  than	  10,000	  years	  ago	  (3),	  the	  
congregation	  of	  large	  human	  populations	  close	  to	  sources	  of	  water	  presented	  an	  
environmental	  adaption	  of	  mosquitoes	  from	  zoophilic	  to	  increasingly	  anthropophilic,	  
causing	  the	  parasites	  to	  co-­‐evolve	  together	  (4,	  5).	  The	  periodic	  fevers	  and	  chills	  that	  
characterize	  malaria	  have	  been	  documented	  in	  the	  ancient	  civilizations	  of	  ancient	  
Egypt	  (6),	  China	  (7),	  and	  Rome.	  It	  was	  erroneously	  believed	  that	  the	  mists	  (mala	  =	  
bad,	  aria	  =	  air)	  from	  the	  marshes	  and	  swamplands	  were	  the	  cause	  of	  this	  disease,	  
giving	  rise	  to	  the	  name	  (8).	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Currently,	  malaria	  causes	  over	  200	  million	  infections	  and	  500,000	  deaths	  
worldwide	  annually,	  with	  children	  accounting	  for	  70%	  of	  the	  fatalities	  (9).	  Five	  
Plasmodium	  species	  are	  known	  to	  infect	  humans	  –	  P.	  falciparum,	  P.	  vivax,	  P.	  ovale,	  P.	  
malariae	  and	  P.	  knowlesi.	  Of	  these,	  P.	  falciparum	  is	  considered	  the	  most	  dangerous	  
as	  it	  accounts	  for	  the	  wide	  majority	  of	  deaths,	  and	  thus	  remains	  the	  main	  focus	  of	  
research	  to	  develop	  therapeutic	  and	  elimination	  strategies.	  P.	  vivax	  is	  gaining	  
attention	  due	  to	  its	  larger	  geographic	  distribution	  and	  its	  ability	  to	  develop	  into	  
hypnozoites,	  a	  dormant	  stage	  in	  the	  liver	  capable	  of	  causing	  disease	  relapses	  that	  
can	  remain	  undetected	  for	  up	  to	  30	  years.	  
	  
Geographically,	  malaria	  transmission	  is	  spread	  broadly	  across	  the	  tropical	  
parts	  of	  the	  world	  (figure	  1),	  concentrated	  mainly	  in	  sub-­‐Saharan	  Africa,	  parts	  of	  
South	  America,	  India	  and	  Southeast	  Asia,	  with	  sub-­‐Saharan	  Africa	  being	  the	  site	  of	  
Figure	  1:	  Transmission	  of	  malaria	  in	  the	  world	  as	  at	  2013.	  Diagram	  reproduced	  
from	  (9).	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most	  fatalities	  (9).	  These	  areas	  generally	  have	  high	  levels	  of	  precipitation	  and	  
humidity,	  and	  together	  with	  the	  warm	  temperatures,	  make	  it	  easy	  for	  mosquitoes	  to	  
breed,	  aiding	  the	  spread	  of	  malaria.	  	  
	  
Life	  cycle	  of	  malaria	  
	   The	  life	  cycle	  of	  malaria	  (figure	  2)	  is	  complex,	  involving	  vertebrate	  and	  
mosquito	  hosts	  and	  spanning	  three	  stages.	  The	  life	  cycle	  of	  P.	  falciparum	  is	  described	  
below;	  the	  cycles	  of	  rodent	  malaria	  parasites	  are	  qualitatively	  similar	  but	  differ	  in	  
terms	  of	  the	  time	  frames	  and	  cell	  numbers.	  Infection	  begins	  when	  infected	  female	  
mosquitoes	  feed	  on	  the	  blood	  from	  the	  host,	  depositing	  the	  parasites	  in	  its	  motile	  
sporozoite	  form	  in	  the	  skin.	  Up	  to	  100	  sporozoites	  are	  transmitted	  into	  the	  skin,	  
where	  they	  can	  stay	  for	  as	  long	  as	  4	  days	  (11).	  These	  motile	  parasites	  burrow	  their	  
way	  into	  the	  bloodstream	  and	  travel	  to	  the	  liver,	  where	  they	  traverse	  multiple	  
Figure	  2:	  Life	  cycle	  of	  the	  Plasmodium	  parasite.	  See	  the	  main	  text	  for	  details.	  
Diagram	  reproduced	  from	  (10).	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hepatocytes	  before	  finally	  residing	  and	  developing	  within	  one	  (12,	  13).	  Each	  
sporozoite	  then	  develops	  into	  an	  exo-­‐erythrocytic	  form,	  wherein	  replication	  and	  
differentiation	  of	  as	  many	  as	  40,000	  asexual	  forms	  (termed	  merozoites)	  occurs	  in	  a	  
week’s	  time.	  At	  this	  point,	  infected	  hepatocytes	  develop	  merosomes,	  vesicles	  that	  
are	  filled	  with	  merozoites,	  and	  these	  bud	  off	  from	  the	  dying	  hepatocyte.	  The	  lack	  of	  
phosphatidylserine	  expression	  on	  the	  surface	  of	  merosomes	  prevents	  phagocytosis	  
by	  Kupffer	  cells,	  ensuring	  their	  successful	  release	  into	  the	  bloodstream	  (14).	  These	  
merosomes	  travel	  to	  the	  lung	  microvasculature	  where	  they	  disintegrate,	  releasing	  
the	  merozoite	  cargo	  into	  the	  blood	  (15).	  Each	  merozoite	  then	  proceeds	  to	  make	  
contact	  with	  an	  erythrocyte,	  realigning	  itself	  with	  its	  apical	  end	  interacting	  with	  the	  
erythrocyte	  membrane	  (16).	  Localized	  secretory	  granules	  (micronemes,	  rhoptries	  
and	  dense	  granules)	  at	  the	  apical	  end	  of	  the	  merozoite	  then	  unload	  their	  contents	  at	  
the	  site	  of	  contact,	  forming	  interactions	  with	  receptors	  on	  the	  erythrocyte	  
membrane	  (17-­‐19).	  These	  are	  then	  translocated	  across	  the	  merozoite	  surface,	  
mediated	  by	  the	  actin-­‐myosin	  motor	  complex	  in	  the	  parasite’s	  inner	  membrane	  
complex	  (20,	  21),	  pulling	  the	  erythrocyte’s	  membrane	  to	  form	  an	  envelope	  around	  
the	  merozoite.	  Eventually,	  the	  membrane	  traverses	  the	  whole	  parasite	  and	  fuses	  
together,	  enclosing	  it	  in	  a	  parasitophorous	  vacuole	  (PVM)	  within	  the	  erythrocyte,	  
completing	  the	  invasion	  process.	  This	  whole	  process	  of	  erythrocyte	  invasion	  happens	  
rapidly,	  averaging	  less	  than	  two	  minutes	  (22,	  23).	  The	  nascent	  ring	  stage	  parasite	  
then	  develops	  into	  a	  tropozoite,	  actively	  feeding	  on	  the	  host	  cell’s	  hemoglobin,	  
before	  replicating	  and	  undergoing	  schizogony	  to	  form	  up	  to	  32	  merozoites	  in	  each	  
infected	  erythrocyte.	  Schizonts	  then	  rupture,	  releasing	  new	  merozoites	  to	  continue	  
the	  asexual	  blood	  stage	  cycle.	  Some	  of	  the	  infected	  erythrocytes	  will	  exit	  this	  cycle	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and	  develop	  into	  sexual	  gametocytes,	  which	  remain	  circulating	  in	  the	  host	  until	  
taken	  up	  by	  a	  mosquito	  during	  a	  blood	  meal.	  Gametogenesis	  occurs	  inside	  the	  
midgut,	  and	  flagellated	  male	  gametes	  swim	  and	  fertilize	  female	  gametes	  to	  form	  
ookinetes,	  which	  invade	  the	  gut	  epithelium	  and	  develop	  into	  oocysts	  at	  the	  basal	  
membrane	  (24).	  After	  about	  15	  days,	  oocysts	  mature	  and	  release	  sporozoites	  into	  
the	  hemolymph,	  where	  they	  traverse	  and	  invade	  into	  the	  salivary	  glands	  (24),	  ready	  
to	  restart	  the	  life	  cycle	  when	  the	  mosquito	  takes	  a	  blood	  meal	  again.	  
	  
Drug	  treatments	  and	  resistance	  in	  malaria	  
	  
Treatments	  for	  malaria	  existed	  in	  antiquity,	  with	  the	  use	  of	  chinchona	  bark	  in	  
the	  West	  and	  sweet	  wormwood	  in	  the	  East	  for	  hundreds	  of	  years	  (25).	  The	  
respective	  key	  ingredients,	  quinine	  and	  artemisinin,	  were	  isolated	  and	  discovered	  
only	  in	  the	  19th	  and	  20th	  century.	  Though	  there	  are	  a	  number	  of	  antimalarial	  drugs	  
available	  on	  the	  market,	  most	  drugs	  were	  rendered	  obsolete,	  mainly	  due	  to	  the	  
parasites	  having	  acquired	  resistance	  to	  them.	  Two	  antimalarial	  drugs,	  chloroquine	  
and	  artesunate,	  stand	  out	  among	  the	  others.	  	  
	  
After	  its	  implementation	  in	  1947	  as	  a	  treatment	  against	  malaria,	  chloroquine	  
became	  the	  most	  widely	  used	  antimalarial	  drug	  due	  to	  its	  affordability,	  effectiveness	  
and	  good	  tolerance	  in	  humans.	  Its	  mechanism	  of	  action	  is	  through	  formation	  of	  
complexes	  with	  ferriprotoporphyrin	  IX,	  a	  toxic	  intermediate	  that	  is	  produced	  from	  
the	  digestion	  of	  hemoglobin	  by	  the	  parasite	  for	  energy	  and	  growth	  (26).	  This	  
prevents	  further	  modification	  of	  the	  toxic	  product	  into	  non-­‐toxic	  hemozoin,	  causing	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the	  parasite	  to	  be	  killed	  by	  its	  own	  metabolite.	  Overuse	  of	  chloroquine	  led	  to	  the	  
emergence	  and	  spread	  of	  resistant	  strains,	  with	  the	  first	  reports	  of	  chloroquine-­‐
resistant	  P.	  falciparum	  infections	  came	  from	  Thailand	  and	  Colombia	  in	  1957,	  just	  12	  
years	  after	  it	  was	  adopted	  as	  the	  drug	  of	  choice	  (27,	  28).	  Chloroquine	  resistance	  then	  
spread	  outwards	  from	  these	  two	  regions	  in	  Asia	  and	  South	  America,	  and	  taking	  hold	  
in	  Africa	  within	  20	  years	  (29).	  This	  sparked	  development	  and	  eventual	  deployment	  of	  
other	  anti-­‐malarial	  drugs	  in	  order	  to	  combat	  drug	  resistance.	  Unfortunately,	  all	  these	  
drugs	  also	  met	  the	  same	  fate,	  with	  drug-­‐resistant	  strains	  appearing	  at	  alarming	  rates	  
of	  5	  years	  or	  less	  (28).	  A	  number	  of	  reasons	  were	  put	  forth	  to	  explain	  the	  emergence	  
of	  these	  resistant	  parasites.	  The	  earlier	  attempts	  to	  eradicate	  malaria	  through	  mass	  
distribution	  of	  table	  salt	  mixed	  with	  anti-­‐malarial	  drugs	  to	  endemic	  areas	  were	  often	  
poorly	  controlled,	  leading	  to	  inconsistent	  and	  sub-­‐therapeutic	  dosing	  (25,	  29).	  The	  
continued	  and	  presumptive	  use	  of	  drugs,	  especially	  chloroquine,	  in	  areas	  with	  
resistant	  parasites	  also	  contributed	  to	  its	  spread	  (29).	  Chloroquine	  still	  remains	  
effective	  in	  treating	  P.	  vivax,	  P.	  malariae	  and	  P.	  ovale	  infections.	  However,	  resistance	  
in	  P.	  vivax	  has	  been	  observed	  in	  Southeast	  and	  South	  Asia	  and	  South	  America	  (30).	  
	  
Artemisinins,	  employed	  in	  traditional	  Chinese	  medicine	  in	  treating	  malaria,	  
emerged	  as	  the	  last	  line	  of	  defence	  against	  drug-­‐resistant	  malaria.	  The	  fastest-­‐acting	  
among	  all	  antimalarial	  drugs,	  artemisinin	  affects	  both	  early	  and	  late	  stages	  of	  blood	  
infection,	  reducting	  parasite	  mass	  by	  10	  000–fold	  in	  48	  hours	  (31,	  32).	  Its	  mechanism	  
of	  action	  is	  not	  completely	  understood.	  It	  has	  a	  short	  half-­‐life	  of	  40	  to	  60	  minutes	  in	  
the	  body	  (26,	  33),	  thus	  necessitating	  the	  combination	  with	  other	  antimalarial	  drugs	  
as	  artemisinin-­‐based	  combination	  therapies.	  This	  extends	  the	  duration	  of	  drug	  cover	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against	  parasites	  and	  minimizes	  the	  risk	  of	  parasites	  developing	  resistance.	  
Alarmingly,	  artemisinin	  resistance	  has	  emerged	  recently	  in	  Southeast	  Asia	  (34-­‐36).	  
The	  inevitable	  spread	  of	  malaria	  that	  will	  occur	  if	  artemisinin	  loses	  its	  efficacy	  frames	  




Individuals	  living	  in	  endemic	  areas	  could	  acquire	  natural	  immunity	  from	  
severe	  forms	  of	  malaria	  disease	  during	  childhood,	  though	  these	  wanes	  in	  the	  
absence	  of	  continued	  exposure	  (37).	  Researchers	  have	  been	  working	  to	  stimulate	  
protective	  immunity	  for	  decades,	  but	  thus	  far,	  no	  effective	  malaria	  vaccine	  has	  been	  
licensed.	  Vaccine	  candidates	  can	  be	  categorized	  into	  whole	  organism	  vaccines	  and	  
subunit	  vaccines.	  The	  approaches	  that	  have	  been	  explored	  under	  whole	  organism	  
vaccines	  include	  irradiated	  sporozoites	  (38,	  39),	  genetically-­‐attenuated	  parasites	  (40,	  
41),	  and	  the	  use	  of	  chloroquine	  as	  a	  prophylaxis	  while	  inoculating	  with	  live	  
sporozoites	  (42).	  In	  all	  three	  approaches,	  rechallenge	  with	  live	  infectious	  sporozoites	  
did	  not	  establish	  blood	  stage	  infections,	  conferring	  clinical	  immunity	  to	  the	  
volunteers.	  The	  protective	  mechanism	  remains	  incompletely	  understood,	  but	  it	  is	  
thought	  that	  the	  T	  cell-­‐mediated	  immune	  responses	  generated	  against	  liver	  stage	  
parasites	  were	  similar	  in	  all	  three	  approaches	  (42,	  43).	  The	  need	  for	  cryopreservation	  
of	  live	  parasites	  and	  establishment	  of	  reliable	  cold	  chain	  management,	  especially	  in	  
resource-­‐poor	  nations	  where	  malaria	  is	  endemic,	  prevents	  adoption	  and	  deployment	  
of	  whole	  organism	  vaccines	  in	  the	  field.	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Many	  antigen	  subunits	  from	  the	  parasite	  have	  been	  tested	  as	  vaccine	  
candidates	  and	  most	  of	  them	  ended	  in	  failure.	  The	  RTS,S	  vaccine,	  based	  on	  the	  
circumsporozoite	  protein,	  is	  the	  only	  frontrunner	  to	  reach	  phase	  3	  clinical	  trials	  (44,	  
45).	  Immunization	  with	  RTS,S	  vaccine	  resulted	  in	  30-­‐50%	  protection	  in	  both	  adults	  
and	  children,	  and	  this	  protection	  lasted	  only	  a	  few	  months	  (46-­‐50).	  The	  correlates	  of	  
protection	  could	  not	  be	  reliably	  pinpointed,	  with	  varying	  degrees	  of	  T	  cell	  and	  
antibody	  responses	  across	  the	  protected	  individuals	  (51-­‐53).	  
	  
Symptoms	  of	  malaria	  infection	  
	  
The	  clinical	  symptoms	  of	  malaria	  infection	  are	  attributed	  only	  to	  the	  
erythrocytic	  stage,	  while	  liver	  stage	  infection	  is	  asymptomatic.	  In	  uncomplicated	  
malaria	  episodes,	  the	  intermittent	  fevers	  (once	  every	  2	  days	  for	  falciparum,	  vivax	  
and	  ovale	  malaria,	  3	  days	  for	  malariae	  malaria)	  coincide	  with	  the	  release	  of	  
merozoites	  and	  metabolic	  wastes	  from	  ruptured	  schizonts.	  Chills,	  sweating,	  nausea,	  
headaches	  and	  malaise	  also	  accompany	  uncomplicated	  malaria	  infection,	  which	  can	  
easily	  be	  confused	  with	  other	  illnesses	  such	  as	  influenza	  (54).	  However,	  some	  
patients,	  especially	  those	  that	  are	  naïve	  to	  malaria	  infections,	  may	  progress	  to	  
develop	  severe	  complications,	  such	  as	  acute	  renal	  failure,	  acute	  respiratory	  distress,	  
severe	  anemia	  and	  cerebral	  malaria	  (54,	  55).	  
	  
Cerebral	  malaria	  in	  humans	  (HCM)	  is	  defined	  by	  the	  exhibition	  of	  unrousable	  
coma	  in	  patients	  with	  falciparum	  malaria,	  with	  a	  score	  of	  <11	  on	  the	  Glasgow	  coma	  
scale.	  Symptoms	  that	  often	  precede	  coma	  include	  ataxia,	  seizures	  or	  prostration	  (54,	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55).	  This	  complication	  is	  almost	  always	  fatal	  if	  left	  untreated	  and	  is	  responsible	  for	  
most	  of	  the	  P.	  falciparum	  deaths.	  With	  prompt	  treatment,	  mortality	  decreases	  to	  15	  
–	  20%	  (54,	  56).	  Survivors	  of	  cerebral	  malaria	  may	  display	  neurological	  sequalae,	  such	  
as	  cognitive	  impairments,	  epilepsy,	  language	  and	  motor	  disorders	  (56-­‐62).	  Post-­‐
mortem	  pathological	  studies	  reveal	  massive	  sequestration	  of	  infected	  erythrocytes	  
in	  the	  microvasculature	  of	  the	  brain,	  especially	  at	  the	  perivascular	  region	  (63-­‐65).	  
Such	  sequestration	  occurs	  only	  in	  falciparum	  malaria	  and	  extremely	  rarely	  in	  vivax	  
malaria	  (66).	  Petechial	  hemorrhages	  are	  found	  at	  the	  sites	  of	  sequestration,	  with	  
evidence	  of	  accompanying	  edema	  (64,	  67,	  68).	  In	  addition	  to	  infected	  erythrocytes,	  
leukocytes	  may	  also	  be	  found	  at	  the	  occlusion	  sites	  (65,	  68-­‐70).	  
	  
Mouse	  models	  for	  HCM	  
	  
Pre-­‐mortem	  studies	  on	  HCM	  cannot	  be	  ethically	  performed	  and	  post-­‐mortem	  
analysis	  does	  not	  allow	  the	  progression	  of	  HCM	  to	  be	  observed	  or	  firm	  conclusions	  
to	  be	  drawn	  (71).	  A	  mouse	  model	  is	  attractive	  because	  the	  ready	  availability	  of	  mice	  
of	  defined	  genetic	  background	  and	  the	  ability	  to	  conduct	  experiments	  on	  whole	  
organs	  in	  a	  defined	  setting	  facilitates	  uncovering	  the	  mechanisms	  of	  this	  neuro-­‐
complication.	  In	  the	  malaria	  research	  community,	  the	  widely	  recognized	  model	  is	  the	  
infection	  of	  C57BL/6J	  mice	  with	  the	  rodent	  parasite	  P.	  berghei	  ANKA	  (PbA).	  CBA/Ca	  
and	  129,B6	  mice	  are	  also	  susceptible	  but	  they	  are	  not	  as	  widely	  used	  as	  the	  C57BL/6J	  
mice.	  In	  this	  model,	  infected	  mice	  develop	  neurological	  signs	  that	  closely	  mimic	  
symptoms	  in	  human	  patients	  suffering	  from	  HCM:	  ataxia,	  paralysis,	  convulsions	  and	  
coma	  (71).	  This	  syndrome,	  termed	  experimental	  cerebral	  malaria	  (ECM),	  appears	  6-­‐
	   10	  
12	  days	  post-­‐infection	  and	  is	  often	  fatal	  with	  <10%	  parasitaemia	  in	  the	  blood.	  In	  the	  
brains	  of	  mice	  with	  ECM,	  sequestration	  of	  leukocytes	  in	  the	  microvasculature	  was	  
observed,	  corroborating	  with	  the	  findings	  in	  HCM.	  However,	  sequestration	  of	  
infected	  red	  blood	  cells	  (iRBCs)	  occurs	  to	  a	  lesser	  extent	  (72),	  which	  remains	  a	  bone	  
of	  contention	  as	  to	  whether	  the	  ECM	  mouse	  model	  is	  relevant	  to	  HCM	  (73).	  
Nevertheless,	  with	  a	  lack	  of	  better	  models	  or	  methods	  to	  analyze	  HCM,	  this	  mouse	  
model	  with	  many	  similarities	  to	  HCM	  (74)	  remains	  popular	  is	  studied	  with	  the	  hope	  
that	  any	  findings	  can	  be	  extrapolated	  to	  HCM	  (71,	  75,	  76).	  	  
	  
There	  are	  other	  rodent	  Plasmodium	  parasites	  that	  are	  employed	  as	  separate	  
mouse	  models	  for	  non-­‐neurological	  pathologies	  that	  are	  associated	  with	  malaria.	  P.	  
berghei	  NK65	  (PbNK65)	  parasites,	  when	  inoculated	  into	  C57BL/6J	  mice,	  causes	  mice	  
to	  develop	  experimental	  acute	  respiratory	  distress	  syndrome	  instead	  of	  ECM	  (77).	  P.	  
yoelii	  yoelii	  17X	  clone	  1.1	  (Py17X)	  is	  an	  avirulent	  parasite	  that	  results	  in	  acute,	  but	  
self-­‐resolving,	  malaria	  in	  mice	  (78).	  It	  is	  often	  studied	  together	  with	  the	  virulent	  P.	  
yoelii	  yoelii	  YM	  strain,	  to	  investigate	  immune	  mechanisms	  that	  contribute	  to	  lethality	  




The	  blood-­‐brain	  barrier	  (BBB,	  figure	  3A)	  is	  one	  of	  a	  trio	  of	  barriers	  that	  
separate	  the	  brain	  contents	  from	  the	  rest	  of	  the	  circulation,	  with	  the	  other	  two	  
being	  the	  blood-­‐cerebrospinal	  fluid	  barrier	  at	  the	  choroid	  plexus	  (figure	  3B)	  and	  the	  
arachnoid	  epithelium	  (figure	  3C)	  [reviewed	  in	  (79,	  80)].	  Of	  these,	  the	  BBB	  is	  widely	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regarded	  as	  the	  most	  important	  of	  the	  three,	  accounting	  for	  the	  largest	  surface	  area	  
where	  exchange	  of	  molecules	  takes	  place	  (between	  12	  to	  18	  m2)	  in	  the	  brain.	  
Furthermore,	  the	  close	  proximity	  of	  all	  cells	  in	  the	  brain	  to	  a	  nearby	  blood	  vessel	  
(about	  25	  µm	  or	  less)	  makes	  it	  an	  important	  route	  for	  nutrient	  acquisition	  and	  waste	  
removal.	  At	  the	  cellular	  level,	  the	  BBB	  (figure	  4)	  comprises	  of	  endothelial	  cells	  that	  
form	  tight	  junctions	  in	  between	  them,	  surrounded	  partially	  by	  pericytes.	  This	  is	  
embedded	  in	  the	  basal	  lamina,	  with	  astrocyte	  feets	  forming	  a	  complex	  web	  that	  
encloses	  the	  whole	  capillary.	  
Figure	  3:	  Diagram	  of	  the	  human	  brain,	  showing	  the	  3	  barriers	  that	  separate	  the	  
brain	  and	  cerebrospinal	  fluid	  from	  the	  blood	  circulation.	  Diagram	  reproduced	  
from	  (79).	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The	  BBB	  plays	  important	  roles	  in	  regulating	  the	  transport	  of	  ions	  and	  other	  
small	  molecules	  into	  the	  brain	  parenchyma.	  Many	  of	  these,	  such	  as	  sodium,	  
potassium	  ions	  and	  glutamate,	  must	  be	  maintained	  at	  constant	  levels	  in	  the	  brain,	  
regardless	  of	  changes	  in	  ion	  levels	  in	  the	  blood	  circulation	  following	  exercise	  or	  
meals	  (81,	  82).	  Otherwise,	  neuronal	  damage	  and	  short	  circuitry	  of	  neurotransmission	  
can	  occur,	  since	  glutamate	  is	  one	  of	  the	  neurotransmitters	  secreted	  by	  neurons.	  
Other	  macromolecules	  in	  the	  blood	  are	  notably	  absent	  in	  the	  brain,	  where	  they	  
could	  initiate	  immune	  activation,	  damage	  and	  apoptosis	  of	  the	  neurons	  if	  they	  are	  
allowed	  access	  (83-­‐85).	  Regulation	  of	  solutes	  across	  the	  BBB	  is	  made	  possible	  
through	  transporters,	  carriers	  and	  receptors	  that	  are	  found	  on	  the	  apical	  surfaces	  of	  
the	  endothelial	  cells.	  
	  
	   	  
Figure	  4:	  Structure	  of	  BBB.	  The	  
endothelial	  cells	  in	  the	  brain	  capillaries	  
establish	  tight	  junctions	  with	  adjacent	  
neighbours,	  forming	  an	  impermeable	  
barrier	  between	  the	  brain	  parenchyma	  
and	  the	  blood.	  Pericytes	  surround	  the	  
endothelial	  cells	  partially,	  and	  both	  
cells	  are	  enclosed	  within	  the	  basal	  
lamina.	  Astrocytes	  form	  networks	  that	  
surround	  the	  brain	  capillaries	  with	  
their	  endfoot	  processes,	  maintaining	  
the	  integrity	  of	  the	  vessels.	  Microglia	  
are	  found	  next	  to	  the	  vessels,	  ready	  to	  
react	  to	  any	  pathogens	  that	  breach	  the	  
BBB.	  	  Diagram	  reproduced	  from	  (79).	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Immune	  subsets	  involved	  in	  ECM	  
	  
The	  observation	  that	  leukocytes	  are	  found	  sequestered	  in	  the	  brain	  
microvasculature	  of	  both	  HCM	  and	  ECM	  prompted	  the	  dissection	  of	  immune	  cell	  
types	  that	  are	  involved	  in	  the	  latter.	  The	  situation	  was	  revealed	  to	  be	  complex,	  with	  
many	  different	  cell	  types	  involved.	  Macrophages	  are	  found	  to	  be	  present	  in	  areas	  
where	  breakdown	  of	  vasculature	  occurs	  in	  mice	  (86).	  Their	  depletion	  at	  the	  time	  of	  
inoculation	  but	  not	  later	  in	  infection	  led	  to	  protection	  against	  ECM,	  suggesting	  that	  
they	  are	  only	  involved	  in	  the	  induction	  process	  (87,	  88).	  Neutrophils	  are	  also	  
observed	  in	  the	  brains	  of	  CBA/Ca	  mice	  during	  ECM	  and	  they	  were	  shown	  to	  be	  
essential	  for	  ECM	  development	  (89).	  However,	  depletion	  in	  the	  129,B6	  mouse	  model	  
could	  not	  protect	  them	  from	  ECM	  (87),	  suggesting	  that	  neutrophils	  have	  different	  
roles	  to	  play	  during	  infection	  in	  different	  mice.	  Natural	  killer	  (NK)	  cells	  were	  reported	  
to	  be	  essential	  for	  ECM	  development,	  as	  mice	  depleted	  of	  these	  cells	  with	  anti-­‐asialo	  
GM1	  antibodies	  did	  not	  develop	  pathology	  (90).	  Mice	  devoid	  of	  B	  cells	  can	  still	  
develop	  ECM,	  suggesting	  that	  these	  cells	  play	  minimal	  roles	  in	  the	  disease	  
progression	  (91).	  T	  cells,	  on	  the	  other	  hand,	  are	  implicated	  heavily.	  Numbers	  of	  the	  
two	  main	  types	  of	  T	  cells,	  CD4+	  and	  CD8+,	  increased	  in	  the	  brain	  of	  mice	  during	  ECM	  
(87),	  and	  mice	  that	  are	  deficient	  for	  T	  cells,	  either	  through	  depletion	  or	  knockout	  
mice	  [such	  as	  β2-­‐microglobulin	  (β2m)-­‐	  or	  RAG-­‐KO	  mice],	  do	  not	  develop	  ECM	  (91).	  
These	  cells	  influence	  ECM	  development	  at	  different	  stages.	  CD4+	  T	  cells	  are	  shown	  to	  
be	  important	  during	  the	  initial	  days	  of	  parasite	  infection,	  but	  are	  dispensable	  later	  in	  
the	  infection	  when	  ECM	  is	  expected	  to	  develop	  (87,	  91,	  92).	  On	  the	  other	  hand,	  ECM	  
prevention	  can	  be	  achieved	  with	  late	  depletion	  of	  CD8+	  T	  cells	  at	  day	  6,	  one	  day	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before	  ECM	  is	  expected	  to	  manifest,	  implicating	  these	  cells	  as	  the	  effector	  
population	  (87).	  In	  the	  spleen,	  conventional	  dendritic	  cells	  (DC)	  that	  express	  
CD11chigh	  were	  reported	  to	  be	  essential	  for	  ECM,	  through	  depletion	  of	  these	  cells	  in	  
CD11c-­‐DTR	  (diphtheria	  toxin	  receptor)	  mice	  (93).	  Subsequently,	  the	  CD8α+	  subset	  of	  
the	  CD11chigh	  DCs	  was	  identified	  as	  the	  ones	  most	  effective	  in	  cross-­‐presenting	  
parasite	  antigens	  to	  CD8+	  T	  cells	  (94),	  though	  this	  is	  restricted	  to	  days	  2-­‐3	  post-­‐
infection	  (95).	  Separately,	  other	  groups	  used	  Clec9A-­‐DTR	  (96)	  and	  Langerin-­‐DTR	  mice	  
(97)	  to	  target	  CD8α+	  DC	  depletion	  and	  confirmed	  its	  role,	  as	  these	  mice	  were	  totally	  
or	  partially	  protected	  when	  infected	  with	  PbA,	  respectively.	  In	  the	  former	  study,	  
CD4+	  and	  CD8+	  T	  cell	  accumulation	  in	  the	  brains	  were	  reduced	  following	  DC	  
depletion.	  	  
	  
Cytotoxic	  (CD8+)	  T	  cells	  
	  
Cytotoxic	  T	  cells	  are	  a	  subset	  of	  T	  lymphocytes	  that	  form	  one	  half	  of	  the	  
classical	  adaptive	  immune	  system.	  Precursors	  of	  T	  lymphocytes	  originate	  from	  
hematopoietic	  stem	  cells	  in	  the	  bone	  marrow.	  These	  then	  exit	  into	  the	  blood	  
circulation	  and	  travel	  to	  the	  thymus,	  where	  they	  undergo	  a	  complex	  process	  to	  
differentiate	  into	  CD4+	  and	  CD8+	  single-­‐positive	  T	  cells.	  During	  this	  process,	  T	  cells	  
with	  a	  T	  cell	  receptor	  (TCR)	  that	  can	  interact	  with	  self-­‐major	  histocompatibility	  
complex	  (MHC)	  with	  intermediate	  avidity	  will	  survive.	  If	  the	  recognition	  is	  to	  MHC	  
class	  I,	  the	  T	  cell	  will	  eventually	  become	  CD8+	  T	  cell,	  whereas	  those	  recognizing	  MHC	  
class	  II	  become	  CD4+	  T	  cells.	  At	  the	  medulla,	  all	  CD8+	  T	  cells	  undergo	  a	  negative	  
process,	  where	  they	  interact	  with	  MHC	  class	  I	  molecules	  presented	  by	  medullary	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thymic	  epithelial	  cells.	  These	  cells	  present	  self-­‐antigens	  that	  are	  normally	  found	  
elsewhere	  in	  the	  body,	  through	  expression	  of	  the	  transcription	  factor	  AutoImmune	  
Regulator.	  CD8+	  T	  cells	  that	  interact	  too	  strongly	  with	  these	  self-­‐peptide-­‐MHC	  
complexes	  are	  eliminated,	  preventing	  them	  from	  mounting	  an	  immune	  response	  
against	  host	  cells	  (central	  tolerance).	  Thus,	  only	  those	  that	  interact	  weakly	  are	  
allowed	  to	  survive	  and	  leave	  the	  thymus	  as	  naïve	  CD8+	  T	  cells.	  These	  cells	  travel	  to	  
peripheral	  lymphoid	  organs	  to	  interact	  with	  professional	  antigen	  presenting	  cells	  
(APC).	  
	  
The	  APCs	  in	  the	  lymphoid	  organs	  may	  have	  travelled	  from	  an	  infection	  site	  
after	  capturing	  foreign	  antigens	  and	  becoming	  activated.	  Naïve	  CD8+	  T	  cells	  having	  
the	  corresponding	  TCRs	  will	  be	  activated,	  mainly	  through	  two	  main	  interactions.	  The	  
interaction	  between	  the	  TCR	  and	  its	  cognate	  epitope	  bound	  to	  MHC	  class	  I,	  with	  CD8	  
as	  a	  co-­‐receptor,	  constitutes	  the	  first	  signal	  for	  activation	  (figure	  5).	  If	  the	  T	  cell	  
receives	  only	  this	  first	  signal,	  it	  will	  become	  anergic,	  rendering	  it	  unable	  to	  mount	  an	  
effective	  immune	  response	  against	  target	  cells	  (98).	  The	  second	  signal	  required	  for	  
activation	  comes	  from	  co-­‐stimulatory	  molecules,	  which	  is	  often	  in	  the	  form	  of	  
interaction	  between	  CD28	  on	  the	  T	  cells,	  and	  CD80	  or	  CD86	  on	  the	  activated	  APCs.	  
Other	  co-­‐stimulatory	  molecules	  on	  the	  T	  cells	  that	  can	  also	  lead	  to	  its	  activation	  
include	  CD134,	  CD137,	  and	  CD278	  (Inducible	  T-­‐cell	  COStimulator),	  which	  are	  
expressed	  after	  T	  cells	  recognize	  antigen,	  unlike	  CD28	  that	  is	  expressed	  
constitutively.	  The	  third	  signal	  for	  CD8+	  T	  cell	  activation	  is	  cytokine	  stimulation,	  most	  
often	  by	  interleukin-­‐2	  (IL2).	  Its	  binding	  to	  IL2	  receptors	  on	  T	  cells	  can	  lead	  to	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intracellular	  signaling	  that	  augments	  or	  even	  replaces	  the	  second	  signal	  to	  push	  T	  
cells	  to	  activation.	  
	  
The	  main	  effector	  function	  of	  activated	  CD8+	  T	  cells	  is	  cytolysis	  of	  host	  cells	  
presenting	  cognate	  peptide-­‐MHC	  (pMHC)	  complexes.	  The	  CD8+	  T	  cells	  form	  
immunological	  synapses	  with	  the	  target	  cells,	  mediated	  mainly	  by	  the	  TCR-­‐pMHC	  
and	  CD11a-­‐ICAM-­‐1	  (intracellular	  adhesion	  molecule	  1)	  interactions.	  From	  here,	  
target	  cells	  can	  be	  killed	  in	  two	  ways.	  Firstly,	  secretory	  granules	  that	  contains	  
Figure	  5:	  Different	  signals	  that	  drive	  activation	  of	  CD8+	  T	  cells.	  Interaction	  
between	  pMHC	  and	  TCR	  provides	  the	  first	  signal	  for	  activation.	  Further	  signals	  
come	  from	  the	  interactions	  between	  co-­‐stimulatory	  receptors	  on	  CD8+	  T	  cells	  
and	  their	  respective	  ligands,	  or	  from	  binding	  of	  cytokines	  to	  the	  corresponding	  
receptors.	  Diagram	  reproduced	  from	  (99).	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granzymes	  and	  perforins	  are	  released	  within	  the	  immunological	  synapse	  in	  the	  
direction	  of	  the	  target	  cells	  (100).	  Perforin	  forms	  pores	  in	  the	  target	  cell	  membrane,	  
allowing	  granzymes	  to	  enter	  the	  cell	  interior	  and	  initiate	  apoptosis	  through	  the	  
caspase-­‐dependent	  pathway	  (101).	  The	  alternative	  route	  by	  which	  CD8+	  T	  cells	  kill	  
target	  cells	  is	  expressing	  Fas	  ligand	  that	  interacts	  with	  Fas	  receptors	  (CD95)	  on	  the	  
target	  cells.	  This	  forms	  a	  death-­‐inducing	  signaling	  complex	  in	  the	  cytoplasm,	  which	  
then	  triggers	  a	  signaling	  cascade	  that	  ultimately	  leads	  to	  apoptosis	  through	  the	  same	  
caspase-­‐dependent	  pathway	  as	  the	  first	  approach	  (102).	  In	  addition	  to	  cytolysis,	  
CD8+	  T	  cells	  can	  exert	  their	  effectors	  by	  secreting	  interferon	  γ	  (IFNγ)	  and	  tumor	  
necrosis	  factor	  α	  (TNFα),	  cytokines	  with	  antiviral	  and	  antitumoral	  effects.	  
	  
Major	  histocompatibility	  complex	  (MHC)	  class	  I	  	  
	  
The	  MHC	  class	  I	  molecule	  comprises	  the	  α	  chain	  with	  a	  peptide-­‐binding	  
groove	  and	  beta-­‐2	  microglobulin	  (β2m),	  and	  is	  expressed	  on	  the	  cell	  surfaces	  of	  all	  
nucleated	  cells	  in	  vertebrates.	  Through	  interacting	  with	  TCRs	  on	  CD8+	  T	  cells,	  they	  
allow	  the	  immune	  system	  to	  determine	  if	  the	  cells	  are	  healthy.	  During	  infection	  by	  
intracellular	  pathogens	  or	  transformation	  into	  cancerous	  cells,	  epitopes	  from	  
pathogen	  proteins	  or	  cancer	  antigens	  are	  presented	  on	  MHC	  class	  I	  molecules.	  CD8+	  
T	  cells	  with	  TCRs	  that	  can	  bind	  these	  foreign	  pMHCs	  become	  activated	  by	  APCs	  and	  
mount	  a	  cytotoxic	  response	  to	  eliminate	  these	  abnormal	  target	  cells.	  MHC	  class	  I	  
molecules	  complexed	  with	  self-­‐epitopes	  will	  not	  be	  targeted	  as	  self-­‐reactive	  CD8+	  T	  
cells	  were	  eliminated	  in	  the	  thymus	  prior	  to	  maturation	  through	  negative	  selection.	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Where	  do	  the	  peptides	  that	  bind	  MHC	  class	  I	  molecules	  come	  from?	  A	  
portion	  of	  every	  protein	  that	  is	  synthesized	  in	  the	  cell	  is	  sent	  to	  the	  proteasomes	  to	  
be	  digested	  into	  small	  fragments,	  which	  are	  transported	  into	  the	  endoplasmic	  
reticulum	  (ER)	  by	  transporter	  associated	  with	  antigen	  processing	  (TAP).	  In	  the	  ER,	  
nascent	  MHC	  class	  I	  molecules	  without	  peptides	  are	  first	  stabilized	  by	  an	  array	  of	  
chaperone	  proteins	  (figure	  6)	  that	  include	  tapasin,	  calnexin,	  calreticulin	  and	  ERp57	  
(103).	  Calnexin	  first	  dissociates	  from	  the	  complex	  upon	  binding	  of	  β2m	  to	  the	  α	  
chain,	  and	  following	  successful	  loading	  of	  a	  high-­‐affinity	  peptide	  into	  the	  binding	  
groove,	  the	  rest	  of	  the	  stabilizing	  chaperones	  dissociate,	  allowing	  the	  complete	  
pMHC	  to	  be	  exported	  to	  the	  surface	  of	  host	  cells	  (103,	  104).	  
Figure	  6:	  Stabilization	  of	  nascent	  MHC	  class	  I	  molecules.	  Prior	  to	  peptide	  
loading,	  nascent	  MHC	  class	  I	  molecules	  interact	  with	  multiple	  chaperone	  
proteins	  (tapasin,	  calreticulin	  and	  ERp57)	  in	  the	  ER.	  This	  stabilizes	  the	  complex	  
until	  MHC	  class	  I	  epitopes	  get	  transported	  by	  TAP	  into	  the	  ER	  and	  load	  onto	  the	  
MHC	  class	  I,	  leading	  to	  dissociation	  of	  the	  chaperone	  proteins.	  Diagram	  
reproduced	  from	  (103).	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MHC	  class	  I	  molecules,	  in	  general,	  present	  peptides	  from	  cytosolic	  sources.	  
However,	  MHC	  class	  I	  molecules	  can	  also	  present	  epitopes	  from	  extracellular	  
sources,	  a	  process	  termed	  cross-­‐presentation	  (106).	  The	  mechanism	  of	  cross-­‐
presentation	  is	  not	  completely	  elucidated,	  and	  a	  number	  of	  models	  were	  proposed,	  
shown	  in	  figure	  7	  (reviewed	  in	  (105)].	  The	  canonical	  model	  (a)	  involves	  
Figure	  7:	  Proposed	  models	  of	  cross-­‐presentation.	  Exogenous	  antigens	  are	  
endocytosed	  into	  the	  cell,	  and	  from	  here	  three	  different	  models	  were	  
hypothesized.	  The	  antigen	  is	  transported	  into	  the	  cytosol	  (a)	  and	  is	  degraded	  by	  
proteasomes.	  The	  resulting	  peptides	  are	  translocated	  into	  the	  ER	  by	  TAP,	  loaded	  
onto	  nascent	  MHC	  class	  I	  molecules	  and	  then	  exported	  to	  the	  cell	  surface.	  In	  
(b),	  the	  antigen	  is	  transported	  back	  to	  the	  ER	  and	  gains	  access	  to	  the	  cytosol	  
through	  an	  ER-­‐associated	  protein	  degradation	  pathway,	  possibly	  by	  Sec61.	  In	  
(c),	  fusion	  of	  phagosomes	  containing	  the	  antigen	  with	  ER	  occurs,	  providing	  
another	  route	  for	  the	  antigen	  to	  translocate	  into	  the	  cytosol	  through	  Sec61	  
transporter.	  Diagram	  reproduced	  from	  (105).	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transportation	  of	  endocytosed	  antigens	  into	  the	  cytosol,	  where	  proteasomes	  
generate	  the	  peptides	  that	  are	  then	  exported	  into	  the	  ER	  or	  ER-­‐phagosome	  fusion	  
for	  loading	  onto	  MHC	  class	  I	  molecules	  (107,	  108).	  An	  alternative	  model	  (b)	  proposes	  
that	  transport	  of	  endocytosed	  antigens	  from	  the	  endosomes	  back	  to	  the	  ER	  can	  
occur,	  from	  which	  the	  antigens	  access	  the	  cytosol	  through	  the	  ER-­‐associated	  protein	  
degradation	  pathway,	  possibly	  through	  Sec61	  protein	  translocater	  (109).	  Antigen	  
fragments	  are	  then	  transported	  back	  to	  ER	  as	  per	  the	  canonical	  model.	  A	  third	  model	  
hypothesizes	  that	  phagosomes	  containing	  foreign	  antigens	  fuse	  directly	  with	  the	  ER,	  
providing	  another	  route	  for	  antigens	  to	  access	  the	  cytosol	  (107,	  110).	  However,	  this	  
model	  was	  not	  well	  accepted,	  with	  others	  showing	  data	  to	  question	  this	  hypothesis	  
(111-­‐114).	  Cross-­‐presentation	  is	  a	  critical	  process	  by	  which	  professional	  APCs	  induce	  
CD8+	  T	  cell-­‐mediated	  immunity	  against	  tumours	  and	  viruses	  that	  infect	  other	  cell	  
types.	  These	  APCs	  have	  the	  ability	  to	  ingest	  dying	  cells,	  thus	  acquiring	  the	  foreign	  
antigens	  for	  MHC	  class	  I	  presentation.	  In	  addition,	  they	  can	  also	  capture	  cellular	  
antigens	  from	  intact	  cells,	  a	  process	  termed	  ‘nibbling’	  (115).	  	  
	  
MHC	  multimers	  	  
	  
In	  a	  watershed	  work	  by	  Altman	  and	  colleagues,	  they	  created	  fluorescent	  
MHC	  tetramers	  through	  refolding	  biotin-­‐tagged	  MHC	  class	  I	  α	  chain	  with	  β2m	  and	  
peptides	  of	  interest,	  biotinylating	  the	  resulting	  MHC	  class	  I	  complex,	  followed	  by	  
tetramerization	  with	  fluorescent	  streptavidin	  conjugates	  (117).	  The	  MHC	  multimers	  
bind	  to	  multiple	  cognate	  TCRs	  on	  CD8+	  T	  cells	  at	  the	  same	  time,	  allowing	  them	  to	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stabilize	  this	  weak	  interaction	  through	  avidity	  (figure	  8).	  This,	  in	  turn,	  gives	  
researchers	  the	  ability	  to	  identify	  antigen-­‐specific	  CD8+	  T	  cells	  and	  evaluate	  their	  
functions,	  thereby	  paving	  the	  way	  for	  better	  understanding	  of	  the	  role	  of	  specific	  
CD8+	  T	  cells	  in	  pathogenic	  and	  protective	  settings.	  Apart	  from	  tetravalency,	  other	  
forms	  of	  MHC	  multimers	  exist,	  where	  more	  pMHC	  complexes	  available	  for	  binding	  to	  
T	  cells	  facilitates	  the	  labeling	  of	  rare	  antigen-­‐specific	  CD8+	  T	  cells	  or	  those	  with	  TCRs	  
of	  a	  lower	  affinity	  to	  cognate	  pMHC	  complexes	  (118).	  One	  difficulty	  of	  producing	  
pMHC	  multimers	  is	  the	  laborious	  need	  to	  refold	  the	  MHC	  chains	  with	  each	  peptide	  
of	  interest.	  Other	  researchers	  improved	  on	  this	  technology	  by	  synthesizing	  unique	  
peptides	  with	  a	  photo-­‐labile	  (2-­‐nitro)phenyl	  side	  chain	  moiety	  (119-­‐121).	  These	  form	  
complexes	  with	  MHC	  class	  I	  molecules	  during	  refolding.	  Irradiation	  with	  UV	  light	  will	  
Figure	  8:	  MHC	  
tetramers	  enable	  the	  labeling	  
of	  antigen-­‐specific	  T	  cells.	  
The	  interaction	  between	  TCRs	  
and	  pMHC	  complex	  has	  a	  very	  
short	  half-­‐life	  averaging	  a	  few	  
seconds,	  leading	  to	  rapid	  
dissociation	  of	  pMHC	  
monomers	  (a).	  However,	  
pMHC	  tetramers	  bind	  to	  
multiple	  TCRs	  on	  the	  same	  
cell	  more	  strongly	  through	  
increased	  avidity,	  allowing	  
specific	  T	  cells	  to	  be	  labeled	  
and	  analyzed.	  Diagram	  
reproduced	  from	  (116).	  
	  
	   22	  
induce	  self-­‐cleavage	  of	  the	  peptide	  in	  the	  resulting	  pMHC	  complex.	  Addition	  of	  a	  
suitable	  peptide	  of	  interest	  during	  irradiation	  causes	  it	  to	  replace	  the	  cleaved	  
peptide	  in	  the	  peptide-­‐binding	  groove	  of	  the	  MHC	  α	  chain.	  This	  method	  enables	  the	  
generation	  of	  tetramers	  with	  different	  specificities	  in	  a	  rapid	  fashion.	  	  
	  
CD8+	  T	  cells	  are	  involved	  in	  ECM	  pathogenesis	  
	  
In	  the	  mouse	  model,	  a	  number	  of	  studies	  demonstrated	  that	  CD8+	  T	  cells	  are	  
the	  effector	  cells	  that	  mediate	  ECM	  (87,	  92,	  122-­‐125).	  These	  cells	  do	  not	  recognize	  
self-­‐antigens,	  as	  transfer	  of	  CD8+	  T	  cells	  from	  PbA-­‐infected,	  ECM-­‐susceptible	  mice	  
into	  recipient	  mice	  only	  causes	  neurological	  signs	  only	  if	  the	  latter	  are	  also	  infected	  
(126).	  When	  wild-­‐type	  mice	  were	  adoptively	  transferred	  with	  chicken	  ovalbumin	  
(OVA)-­‐specific	  CD8+	  T	  cell	  and	  infected	  with	  transgenic	  parasites	  carrying	  the	  OVA	  
epitope	  (SIINFEKL),	  the	  specific	  CD8+	  T	  cells	  were	  activated,	  proliferated,	  trafficked	  to	  
the	  brain	  and	  exhibited	  epitope-­‐specific	  cytotoxicity	  (94,	  127).	  In	  other	  studies,	  
analyzing	  the	  TCR	  repertoire	  of	  CD8+	  T	  cells	  in	  the	  brains	  of	  mice	  succumbing	  from	  
ECM	  revealed	  that	  some	  TCRβ	  segments,	  especially	  Vβ8.1,	  were	  found	  more	  often,	  
as	  compared	  to	  uninfected	  controls	  (87,	  128).	  Depletion	  of	  CD8+	  T	  cells	  carrying	  
these	  subsets	  resulted	  in	  a	  delay	  in	  ECM	  onset	  (128).	  All	  these	  suggest	  that	  the	  CD8+	  
T	  cells	  that	  were	  found	  in	  the	  brains	  of	  mice	  during	  ECM	  were	  specific	  for	  parasite	  
antigens.	  Characterizations	  of	  total	  (or	  OVA-­‐specific)	  CD8+	  T	  cells	  in	  the	  ECM	  mouse	  
model	  revealed	  an	  activated	  phenotype,	  and	  the	  types	  of	  markers	  they	  exhibit	  are	  
summarized	  in	  table	  1.	  The	  expression	  of	  perforin	  and	  granzyme	  B	  by	  CD8+	  T	  cells,	  
but	  not	  IFNγ,	  was	  demonstrated	  to	  be	  vital	  for	  ECM	  pathogenesis	  (122,	  123).	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Table	  1:	  Biomarkers	  expressed	  by	  CD8+	  T	  cells	  sequestered	  in	  the	  brains	  of	  mice	  
during	  ECM.	  Reproduced	  from	  (129).	  
Markers	   Expression	   Reference	  
CD	  markers	   	   	  
CD11a	  (LFA-­‐1)	   High	   (128,	  130,	  131)	  
CD44	   High	   (123,	  127,	  128)	  
CD54	  (ICAM-­‐1)	   High	   (128)	  
CD62L	   Low	   (123,	  127,	  128)	  
CD69	   High	   (127,	  128)	  
Cytokines	   	   	  
IFNγ	   Majority	   (128,	  131,	  132)	  
TNFα	   Subset	   (128)	  
IL4	   None	   (128)	  
IL10	   Minority	   (128)	  
Chemokine	  receptors	   	   	  
CCR2	   Upregulated	   (123,	  133)	  
CCR5	   Upregulated	   (123,	  131,	  134)	  
CXCR3	   Upregulated	   (90,	  123,	  131,	  135)	  
Cytolytic	  granules	   	   	  
Granzyme	  B	   Majority	   (122,	  127,	  130-­‐132)	  
Perforin	   Majority	   (123)	  
	  
Migration	  of	  CD8+	  T	  cells	  to	  the	  brain	  
	  
Analysis	  of	  chemokine	  receptor	  expression	  on	  brain-­‐sequestered	  CD8+	  T	  cells	  
in	  the	  ECM	  mouse	  model	  showed	  that	  chemokine	  receptors	  CCR2,	  CCR5,	  CXCR3	  and	  
CXCR4	  were	  over-­‐expressed	  as	  compared	  to	  naïve	  CD8+	  T	  cells,	  suggesting	  that	  these	  
receptors	  mediate	  trafficking	  of	  parasite-­‐specific	  CD8+	  T	  cells	  to	  the	  brain.	  However,	  
CCR2	  was	  eventually	  shown	  to	  be	  nonessential,	  as	  CCR2	  knockout	  mice	  remain	  
susceptible	  to	  ECM	  (133).	  CCR5	  involvement	  varies	  in	  different	  laboratories.	  Mice	  
lacking	  CCR5	  were	  either	  largely	  protected	  against	  ECM	  (134),	  or	  simply	  had	  a	  delay	  
in	  ECM	  occurrence	  (123).	  Those	  that	  did	  succumb	  to	  ECM	  had	  similar	  numbers	  of	  
CD8+	  T	  cells	  in	  the	  brains	  as	  that	  of	  wild-­‐type	  mice	  with	  ECM.	  In	  the	  case	  of	  CXCR3,	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the	  majority	  of	  lymphocytes	  sequestered	  in	  the	  brains	  of	  mice	  during	  ECM	  express	  
this	  receptor	  (90).	  CXCR3-­‐deficient	  mice	  were	  mostly	  protected	  against	  ECM,	  
concomitant	  with	  a	  decrease	  in	  the	  number	  of	  CD8+	  T	  cells	  found	  in	  the	  brains	  (135,	  
136).	  This	  protection	  was	  abolished	  when	  CD8+	  T	  cells	  from	  wild-­‐type	  mice	  were	  
adoptively	  transferred	  into	  the	  CXCR3-­‐deficient	  mice	  (135,	  136).	  A	  redundancy	  of	  the	  
pathogenic	  roles	  of	  CCR5	  and	  CXCR3	  may	  exist	  during	  ECM	  pathogenesis,	  with	  CCR2	  
being	  excluded.	  The	  role	  of	  CXCR4	  in	  ECM	  remains	  to	  be	  studied.	  
	  
The	  chemokines	  CXCL4,	  CXCL9,	  CXCL10	  and	  CXCL11	  are	  the	  ligands	  for	  CXCR3;	  	  
the	  former	  three	  have	  been	  investigated	  in	  ECM	  development.	  CXCL11	  was	  omitted	  
as	  C57BL/6	  mice	  are	  unable	  to	  express	  this	  due	  to	  a	  point	  mutation	  (136).	  CXCL9-­‐	  or	  
CXCL10-­‐deficient	  mice	  were	  partially	  protected	  from	  ECM	  in	  one	  study	  (136),	  while	  
researchers	  from	  another	  lab	  showed	  almost	  complete	  protection	  in	  the	  latter	  mice,	  
with	  T	  cells	  being	  trapped	  in	  the	  spleen	  during	  infection	  (137).	  The	  endothelial	  cells	  
in	  the	  brain	  were	  pinpointed	  as	  one	  of	  the	  sources	  of	  CXCL9	  and	  CXCL10	  in	  the	  brain	  
(135,	  136),	  but	  other	  conflicting	  reports	  have	  implicated	  microglia	  for	  CXCL9,	  
astrocytes	  for	  CXCL10	  (135)	  and	  neurons	  for	  CXCL10	  expression	  (136).	  CXCL4	  
knockout	  mice	  conferred	  some	  protection	  against	  ECM,	  associated	  with	  less	  T	  cell	  
trafficking	  to	  the	  brain	  (138).	  The	  ligands	  for	  CCR5,	  namely	  CCL3,	  CCL4	  and	  CCL5,	  
were	  also	  over-­‐expressed	  during	  infection	  (136,	  139-­‐142),	  but	  their	  involvement	  in	  
ECM	  pathogenesis	  remains	  unclear.	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Effects	  exerted	  by	  pro-­‐inflammatory	  cytokines	  during	  ECM	  
	  
Following	  PbA	  infection,	  sequestration	  of	  iRBC	  in	  the	  brain	  vasculature	  (143)	  
lead	  to	  production	  of	  pro-­‐inflammatory	  cytokines	  in	  the	  brain,	  including	  IFNγ	  (124,	  
144).	  The	  expression	  of	  ICAM-­‐1	  on	  the	  surfaces	  of	  these	  cells	  is	  also	  increased	  (145),	  
allowing	  them	  to	  interact	  with	  activated	  T	  cells,	  which	  express	  the	  cognate	  receptor	  
lymphocyte	  function	  –associated	  1	  or	  LFA-­‐1,	  a	  heterodimer	  of	  CD11a	  and	  CD18.	  
Blocking	  this	  interaction	  with	  antibodies	  prevented	  ECM	  (145),	  demonstrating	  that	  
this	  interaction	  is	  essential	  for	  leukocytes	  to	  sequester	  in	  the	  brain	  microvasculature.	  
TNFα	  production	  was	  elevated	  in	  the	  brains	  of	  mice	  after	  PbA	  infection	  (146,	  147),	  
but	  it	  was	  lymphotoxin	  alpha	  (LTα),	  not	  TNFα,	  that	  was	  indispensable	  for	  ECM	  
development	  (148).	  The	  mechanism	  of	  LTα	  involvement	  in	  ECM	  is	  not	  clearly	  
demonstrated,	  but	  it	  is	  thought	  to	  be	  similar	  to	  that	  of	  IFNγ	  (149).	  
	  
Though	  expression	  of	  IFNγ	  by	  CD8+	  T	  cells	  is	  not	  critical	  for	  ECM,	  mice	  
deficient	  in	  IFNγ	  or	  IFNγ	  receptor	  remain	  resistant	  to	  ECM	  (91,	  150,	  151),	  showing	  
that	  expression	  of	  this	  cytokine	  from	  other	  cellular	  sources	  is	  essential	  for	  
development	  of	  pathology.	  The	  diverse	  roles	  IFNγ	  play	  in	  causing	  ECM	  has	  been	  
reviewed	  (152)	  and	  include	  the	  regulation	  of	  CD8+	  T	  cell	  trafficking	  to	  the	  brain	  (142,	  
151,	  153)	  and	  parasite	  sequestration	  in	  the	  organs	  (124).	  Expression	  of	  chemokines	  
CCL3,	  CCL4,	  CCL5,	  CXCL9	  and	  CXCL10	  in	  the	  brain	  was	  attenuated	  during	  PbA	  
infection	  in	  IFNγ-­‐	  or	  IFNγ	  receptor-­‐knockout	  mice	  (142,	  151).	  In	  NK-­‐depleted	  mice,	  
adoptive	  transfer	  of	  NK	  cells	  from	  wild-­‐type,	  but	  not	  IFNγ-­‐knockout	  mice,	  was	  able	  
to	  restore	  T	  cell	  trafficking	  to	  the	  brain	  (90).	  In	  a	  study	  involving	  IFNγ	  reporter	  mice,	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Villegas-­‐Mendez	  and	  colleagues	  found	  that	  in	  the	  brain	  NK	  cells	  form	  the	  bulk	  of	  
IFNγ-­‐producing	  cells	  early	  in	  the	  infection,	  but	  CD4+	  and	  CD8+	  T	  cells	  eventually	  
became	  the	  major	  producers	  over	  the	  course	  of	  infection	  (153).	  Moreover,	  IFNγ-­‐
knockout	  mice	  that	  received	  wild-­‐type	  CD4+	  T	  cells,	  but	  not	  CD8+	  T	  cells,	  became	  
susceptible	  to	  ECM	  (153).	  These	  suggest	  that	  NK	  and	  CD4+	  T	  cells	  form	  the	  primary	  
producers	  of	  IFNγ	  in	  the	  brain,	  in	  the	  context	  of	  ECM	  pathogenesis.	  
	  
Brain	  endothelial	  cells	  as	  the	  targets	  in	  ECM.	  
	  
The	  pathological	  changes	  in	  the	  BBB	  are	  the	  hallmark	  of	  ECM	  [reviewed	  in	  
(154)],	  and	  the	  cause	  of	  this	  breakdown	  is	  speculated	  to	  lie	  in	  the	  destruction	  of	  
endothelial	  cells	  (87,	  123,	  126,	  155).	  In	  certain	  scenarios,	  such	  as	  an	  inflammatory	  
milieu	  (156),	  these	  cells	  acquire	  the	  ability	  to	  become	  APCs	  and	  become	  efficient	  in	  
antigen	  presentation	  [reviewed	  in	  (157)].	  In	  support	  of	  this,	  an	  increase	  in	  expression	  
of	  MHC	  class	  I	  and	  II	  molecules,	  β2m,	  and	  TAP	  were	  observed	  in	  PbA-­‐infected	  
C57BL/6	  mice	  (158).	  Mice	  lacking	  both	  H-­‐2Kb	  and	  H-­‐2Db	  MHC	  class	  I	  molecules,	  as	  
well	  as	  β2m,	  were	  resistant	  to	  ECM	  (128).	  Coupled	  with	  the	  requirement	  of	  granzyme	  
B	  and	  perforin	  for	  ECM	  to	  develop	  (122,	  123),	  these	  paint	  a	  picture	  that	  endothelial	  
cells	  cross-­‐present	  parasite	  epitopes	  on	  their	  MHC	  class	  I	  molecules	  during	  ECM,	  and	  
subsequent	  recognition	  by	  activated	  parasite-­‐specific	  CD8+	  T	  cells	  lead	  to	  endothelial	  
cell	  death	  due	  to	  pro-­‐apoptotic	  actions	  of	  granzyme	  B	  and	  perforin.	  However,	  no	  
evidence	  of	  such	  cross-­‐presentation	  had	  been	  uncovered	  at	  the	  outset	  of	  this	  work.	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Much	  research	  into	  ECM	  mouse	  models	  have	  led	  to	  the	  proposed	  mechanism	  
of	  ECM	  pathogenesis	  by	  Rénia	  et	  al	  in	  figure	  9	  (126,	  129).	  In	  this	  model,	  infection	  of	  
C57BL/6J	  mice	  with	  PbA	  leads	  to	  priming	  of	  malaria-­‐specific	  CD4+	  and	  CD8+	  T	  cells	  in	  
lymphoid	  organs	  by	  CD8+	  Clec9A+	  dendritic	  cells.	  In	  the	  brain	  microvasculature,	  
sequestration	  of	  iRBC	  and	  subsequent	  rupture	  releases	  cell	  debris	  and	  inflammatory	  
molecules,	  activating	  cells	  in	  the	  brain	  endothelium	  and	  attracting	  leukocytes	  to	  the	  
brain.	  These	  form	  a	  positive	  feedback	  loop	  that	  further	  intensifies	  the	  
proinflammatory	  microenvironment,	  eventually	  recruiting	  activated	  malaria-­‐specific	  
CD8+	  T	  cells	  to	  the	  brain	  through	  secretion	  of	  chemokines.	  Activated	  cells	  in	  the	  brain	  
endothelium	  phagocytose	  parasite	  antigens,	  then	  cross-­‐present	  malaria	  epitopes	  on	  
their	  MHC	  class	  I	  molecules.	  These	  are	  recognized	  by	  specific	  CD8+	  T	  cells,	  leading	  to	  
secretion	  of	  perforin	  and	  granzymes	  to	  destroy	  presenting	  cells,	  ultimately	  breaching	  
the	  BBB.	  Edema	  and	  hemorrhage	  follow,	  cumulating	  into	  the	  neurological	  symptoms	  
seen	  in	  ECM.	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At	  the	  beginning	  of	  this	  project,	  no	  epitopes	  that	  are	  recognized	  by	  parasite-­‐
specific	  CD8+	  T	  cells	  during	  ECM	  had	  been	  identified.	  The	  lack	  of	  known	  epitopes	  
severely	  limited	  characterization	  of	  the	  parasite-­‐specific	  CD8+	  T	  cell	  response	  and	  
how	  it	  leads	  to	  pathogenesis.	  This	  project	  thus	  set	  out	  to	  address	  this	  deficiency,	  
with	  the	  following	  main	  and	  sub-­‐objectives:	  
	  
1) Construct	  a	  PbA	  complementary	  DNA	  (cDNA)	  library	  and	  express	  it	  in	  EL4	  cells	  
(which	  share	  the	  same	  MHC	  haplotype	  as	  C57BL/6J	  mice).	  	  
2) Identify	  the	  cognate	  epitopes	  essential	  in	  ECM.	  This	  is	  done	  in	  two	  steps.	  
a) Construct	  T	  reporter	  cell	  lines	  bearing	  TCRαβ	  chains	  from	  brain-­‐sequestered	  
CD8+	  T	  cells	  from	  mice	  with	  ECM,	  and	  screen	  the	  EL4	  PbA	  cDNA	  library	  to	  
identify	  cognate	  antigens.	  
Figure	  9:	  Proposed	  mechanism	  for	  ECM	  pathogenesis.	  Refer	  to	  text	  for	  details.	  
The	  work	  in	  this	  thesis	  helped	  to	  refine	  this	  model.	  Diagram	  reproduced	  from	  
(129).	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b) Utilize	  MHC	  tetramer	  technology	  to	  identify	  the	  cognate	  epitope	  from	  the	  
antigens	  discovered	  in	  2a.	  
3) With	  the	  tetramers	  and	  T	  reporter	  cells,	  investigate	  the	  epitope-­‐specific	  CD8+	  T	  
cell	  responses	  in	  the	  PbA	  mouse	  model.	  
a) Incidence	  and	  characterization	  of	  epitope-­‐specific	  CD8+	  T	  cells	  in	  mice	  
infected	  with	  PbA,	  Py17X	  and	  PbNK65.	  
b) Incidence	  and	  extent	  of	  cross-­‐presentation	  of	  parasite	  epitopes	  in	  the	  brain	  
microvasculature	  of	  mice	  infected	  with	  PbA,	  Py17X	  and	  PbNK65.	  
c) Demonstration	  of	  BBB	  damage	  by	  epitope-­‐specific	  CD8+	  T	  cells	  in	  PbA	  mouse	  
model	  
d) Investigate	  the	  effects	  of	  tolerizing	  CD8+	  T	  cells	  of	  known	  specificites.	  
	  
The	  research	  that	  addresses	  the	  objectives	  listed	  will	  be	  described	  in	  the	  
following	  3	  chapters	  in	  this	  thesis.	  
	  
	   	  
	   30	  




In	  general,	  three	  approaches	  can	  be	  adopted	  to	  search	  for	  unknown	  CD8+	  T	  
cell	  epitopes.	  Firstly,	  if	  the	  pathogen	  genome	  (or	  even	  better,	  the	  pathogen	  
proteome)	  is	  known,	  epitopes	  that	  can	  bind	  to	  MHC	  class	  I	  molecules	  can	  be	  
predicted.	  Examples	  of	  online	  databases	  that	  provide	  such	  functions	  include	  
SYFPEITHI	  (http://www.syfpeithi.de/)	  and	  IEDB	  (http://www.iedb.org/).	  A	  prediction	  
program	  that	  generates	  a	  combined	  score	  from	  different	  prediction	  algorithms	  is	  
also	  available	  (121).	  The	  output	  of	  predicted	  epitopes	  can	  be	  tested	  experimentally	  
to	  identify	  those	  that	  can	  bind	  and	  stabilize	  MHC	  class	  I	  molecules,	  or	  those	  that	  can	  
stimulate	  CD8+	  T	  cells.	  Secondly,	  APCs	  from	  the	  infected	  host	  can	  be	  isolated,	  and	  
peptides	  in	  the	  binding	  grooves	  of	  their	  MHC	  class	  I	  molecules	  can	  be	  eluted	  and	  
analyzed	  by	  mass	  spectrometry	  (159,	  160).	  Thirdly,	  activated	  CD8+	  T	  cells	  that	  have	  
experienced	  clonal	  expansion	  following	  infection	  can	  be	  isolated	  and	  screened	  
against	  a	  library	  of	  pathogen	  epitopes	  presented	  by	  APCs	  on	  their	  MHC	  class	  I	  
molecules.	  To	  preserve	  the	  TCR	  α	  and	  β	  chains,	  these	  CD8+	  T	  cells	  can	  be	  fused	  
together	  with	  the	  T	  cell	  fusion	  partner	  BWZ.36	  created	  by	  Professor	  Nilabh	  Shastri	  
(UC	  Berkeley)	  (161).	  Engagement	  of	  TCR	  on	  the	  fused	  hybridoma	  leads	  to	  a	  signaling	  
cascade	  that	  triggers	  nuclear	  import	  of	  the	  transcription	  factor	  nuclear	  factor	  of	  
activated	  T-­‐cells	  (NFAT),	  leading	  to	  activation	  of	  Shastri’s	  NFAT-­‐LacZ	  cassette,	  which	  
can	  be	  visualized	  by	  X-­‐gal	  staining.	  	  
	  
	   31	  
To	  screen	  for	  the	  malaria	  CD8+	  T	  cell	  epitopes	  recognized	  by	  the	  generated	  T	  
reporter	  cells,	  a	  PbA	  cDNA	  library	  had	  to	  be	  created	  and	  expressed	  in	  relevant	  APCs	  
(such	  as	  EL4	  cell	  line)	  that	  share	  the	  same	  haplotype	  as	  C57Bl/6J	  mice.	  In	  our	  case,	  
we	  chose	  to	  work	  with	  EL4,	  a	  mouse	  thymoma	  suspension	  cell	  line,	  because	  of	  its	  
ease	  in	  growing	  them	  in	  cultures	  and	  its	  histocompatibility	  with	  C57BL/6J	  mice.	  A	  
common	  method	  of	  making	  the	  cDNA	  library	  is	  through	  the	  use	  of	  oligo-­‐dT	  primers	  
to	  purify	  mRNA	  and	  synthesize	  full-­‐length	  cDNAs,	  but	  we	  reasoned	  that	  a	  shorter	  
cDNA	  library	  constructed	  with	  random	  hexamer	  primers	  may	  be	  better	  in	  our	  
context.	  With	  the	  AT-­‐rich	  nature	  of	  the	  malaria	  genome,	  reverse	  transcriptase	  
starting	  from	  the	  mRNA	  polyA	  tail	  may	  often	  fail	  to	  reach	  the	  5’	  end	  of	  mRNA,	  
leading	  to	  poorer	  coverage	  at	  that	  end.	  Shorter	  cDNAs	  are	  also	  less	  likely	  to	  be	  lost	  
or	  expressed	  poorly	  in	  mammalian	  cell	  lines.	  However,	  expression	  of	  random-­‐primed	  
cDNA	  libraries	  was	  typically	  inefficient,	  with	  an	  estimated	  8%	  of	  clones	  harbouring	  
inserts	  in	  open	  reading	  frame	  (ORF)	  (162).	  Furthermore,	  the	  addition	  of	  overhangs	  to	  
cDNA	  primed	  with	  random	  hexamers	  (in	  order	  to	  facilitate	  cloning	  into	  vectors)	  is	  
difficult	  (163).	  The	  reason	  is	  speculated	  to	  arise	  from	  the	  exonuclease	  activity	  of	  E.	  
coli	  DNA	  polymerase,	  which	  snips	  off	  unpaired	  DNA	  strands	  from	  the	  5’	  to	  3’	  end	  
(162,	  164).	  To	  address	  these	  shortcomings,	  a	  number	  of	  modifications	  were	  
employed	  during	  the	  library	  construction	  in	  this	  chapter.	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C57BL/6J	  mice	  from	  6	  to	  8	  weeks	  old	  were	  used	  throughout	  the	  experiments,	  
unless	  otherwise	  stated.	  	  These	  mice	  were	  bred	  under	  specific	  pathogen-­‐free	  
conditions	  in	  the	  Biological	  Resource	  Centre,	  Singapore.	  All	  animal	  experiments	  and	  
procedures	  were	  approved	  by	  the	  Institutional	  Animal	  Care	  And	  Use	  Committee	  and	  
complied	  with	  the	  guidelines	  of	  the	  Agri-­‐Food	  and	  Veterinary	  Authority	  and	  National	  




PbA	  iRBC	  were	  passaged	  by	  intraperitoneal	  injection	  (i.p.)	  in	  C57BL/6J	  mice,	  
harvested	  and	  stored	  in	  Alsever’s	  solution	  in	  liquid	  nitrogen.	  	  For	  PbA	  infection,	  mice	  
were	  injected	  i.p.	  with	  0.3	  to	  1.0	  x	  106	  iRBC,	  with	  the	  dose	  adjusted	  for	  each	  batch	  so	  
that	  most	  mice	  develop	  neurological	  signs	  at	  7	  days	  post-­‐infection.	  Parasitaemia	  was	  
checked	  by	  examination	  of	  thin	  blood	  smears	  stained	  with	  Giemsa,	  or	  by	  flow	  
cytometry	  (165).	  
	  
Messenger	  RNA	  isolation	  
	  
Mice	  were	  exsanguinated	  under	  ketamine/xylazine	  anesthesia	  through	  the	  
retro-­‐orbital	  route	  or	  cardiac	  puncture.	  Blood	  from	  5	  mice	  was	  collected	  in	  10	  mL	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PBS	  with	  50U/mL	  heparin	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  with	  frequent	  swirling	  of	  
the	  mixture	  throughout	  to	  minimize	  blood	  clotting.	  The	  harvested	  blood	  was	  passed	  
through	  a	  Plasmodipur	  filter	  (EuroProxima,	  Arnhem,	  Netherlands)	  twice	  to	  remove	  
leukocytes.	  Erythrocytes	  were	  centrifuged	  at	  500	  g	  for	  5	  min,	  aspirated	  and	  re-­‐
dissolved	  in	  15	  pellet	  volumes	  of	  Trizol	  (Life	  Technologies,	  Grand	  Island,	  NY)	  at	  37˚C	  
for	  5	  min.	  Chloroform	  (Merck,	  Darmstadt,	  Germany)	  was	  added	  to	  the	  mixture	  at	  a	  
ratio	  of	  1	  part	  to	  5	  parts	  Trizol,	  mixed	  thoroughly	  and	  spun	  in	  30	  mL	  Oak	  Ridge	  
centrifuge	  tubes	  at	  12	  000	  g,	  4˚C	  for	  30	  min.	  The	  aqueous	  phase	  was	  collected	  and	  
mixed	  with	  100%	  molecular-­‐biology	  grade	  isopropanol	  (PanReac	  Applichem,	  
Darmstadt,	  Germany)	  at	  a	  ratio	  of	  10:7,	  incubated	  at	  -­‐20˚C	  for	  at	  least	  2	  hours,	  and	  
passed	  through	  0.7	  µm	  Target	  glass	  microfiber	  filter	  (National	  Scientific	  Company,	  
Rockwood,	  TN).	  The	  RNA	  in	  the	  filter	  was	  washed	  first	  with	  70%,	  followed	  by	  100%	  
ethanol,	  dried	  and	  eluted	  with	  10	  mM	  Tris-­‐HCl,	  pH	  8.0.	  Messenger	  RNA	  was	  treated	  
with	  DNA-­‐free	  DNA	  removal	  kit	  (Ambion,	  Life	  Technologies),	  followed	  by	  isolation	  
with	  PolyATtract	  mRNA	  Isolation	  System	  III	  kit	  (Promega,	  Madison,	  WA),	  both	  
according	  to	  the	  manufacturer’s	  instructions.	  
	  
PbA	  cDNA	  synthesis	  
	  
The	  purified	  mRNA	  (for	  every	  1	  µg)	  was	  reverse	  transcribed	  with	  20	  pmol	  IFb-­‐
17PS-­‐X6	  primer	  and	  SuperScript	  II	  reverse	  transcriptase	  (Life	  Technologies)	  according	  
to	  manufacturer’s	  instructions,	  with	  addition	  of	  100	  µg/mL	  bovine	  serum	  albumin	  
(BSA,	  New	  England	  Biolabs,	  Ipswich,	  MA)	  to	  improve	  yields.	  For	  each	  10	  µL	  of	  the	  
first	  strand	  synthesis	  product,	  the	  following	  reagents	  were	  added	  to	  a	  reaction	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volume	  of	  50	  µL:	  1X	  second	  strand	  buffer,	  0.2	  mM	  dNTP	  (both	  from	  Life	  
Technologies),	  0.02	  U/µL	  RNase	  H,	  0.4	  U/µL	  E.	  coli	  DNA	  polymerase,	  0.1	  U/µL	  E.	  coli	  
DNA	  ligase	  (all	  three	  enzymes	  from	  New	  England	  Biolabs)	  and	  100	  µg/mL	  BSA,	  
followed	  by	  incubation	  at	  16˚C	  for	  2	  hours,	  inactivation	  at	  70˚C	  for	  10	  min.	  T4	  DNA	  
Polymerase	  (New	  England	  Biolabs)	  was	  added	  at	  10	  U/µL	  and	  incubated	  at	  12˚C	  for	  
15	  min,	  followed	  by	  termination	  of	  all	  reactions	  by	  addition	  of	  10	  mM	  EDTA,	  70˚C	  for	  
20	  min.	  The	  cDNA	  was	  purified	  with	  QIAquick	  MInElute	  spin	  columns	  (QIAgen,	  
Hilden,	  Germany),	  following	  manufacturer’s	  instructions.	  
	  
Annealing	  of	  DNA	  adaptor	  	  
	  
The	  DNA	  adaptors	  Acc-­‐ins	  and	  IFLink-­‐b3	  were	  created	  by	  mixing	  equimolar	  
amounts	  of	  primer	  pairs	  (Acc-­‐ins1	  and	  Acc-­‐ins2;	  IFLink-­‐a	  and	  IFlink-­‐b3,	  respectively)	  
in	  1X	  T4	  DNA	  ligase	  buffer	  (New	  England	  Biolabs)	  and	  heated	  at	  95˚C	  for	  5	  min,	  
followed	  by	  stepwise	  decrease	  of	  temperature	  at	  1˚C	  per	  min	  until	  reaction	  reached	  




To	  create	  the	  pScrAn-­‐Int	  vector,	  modpGEX	  vector	  (created	  by	  Dr	  Shanshan	  
Howland,	  derived	  from	  pGEX-­‐2T	  vector)	  was	  digested	  with	  SwaI	  and	  EcoRI	  to	  clone	  in	  
the	  kanamycin	  resistance	  gene	  (KanR).	  Immediately	  upstream	  of	  the	  KanR	  gene,	  an	  
11	  bp	  DNA	  sequence	  that	  contains	  3	  stop	  codons	  in	  3	  different	  reading	  frames	  was	  
introduced.	  This	  was	  transformed	  into	  OneShot	  TOP10	  chemically	  competent	  cells	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(Life	  Technologies),	  and	  positive	  transformants	  were	  identified	  with	  3StopKanR	  and	  
pGEX-­‐2Tr	  primers	  by	  colony	  PCR.	  
	  
Dr	  Shanshan	  Howland	  modified	  the	  pWPXL	  lentivector,	  a	  kind	  gift	  from	  Didier	  
Trono	  (Addgene	  plasmid	  #12257)	  to	  pScrAn1	  vector	  by	  fusing	  a	  self-­‐cleaving	  T2A	  
sequence	  to	  the	  distal	  region	  of	  enhanced	  green	  fluorescent	  protein	  (EGFP).	  From	  
here,	  pScrAn1	  was	  linearized	  with	  restriction	  enzymes	  XmaI	  and	  NdeI,	  purified	  with	  
QIAquick	  MinElute	  spin	  columns	  and	  ligated	  with	  Acc-­‐ins	  DNA	  adaptor	  with	  Quick	  T4	  
DNA	  Ligase	  to	  create	  pScrAn-­‐Acc,	  followed	  by	  transformation	  into	  OneShot	  Stbl3	  
chemically	  competent	  cells	  (Life	  Technologies).	  Positive	  transformants	  were	  
identified	  by	  colony	  PCR	  with	  preGFP	  and	  Acc-­‐ins2	  primers.	  
	  
Amplification	  and	  cloning	  of	  PbA	  cDNA	  
	  
The	  IFLink-­‐b3	  DNA	  adaptors	  at	  0.18	  µmol	  were	  ligated	  to	  every	  1	  µg	  PbA	  
cDNA	  at	  the	  5’	  end	  by	  Quick	  T4	  DNA	  ligase	  in	  the	  presence	  of	  100	  µg/mL	  BSA	  
through	  temperature-­‐cycle	  ligation	  (166)	  as	  depicted	  in	  table	  2.	  Excess	  DNA	  adaptors	  
were	  removed	  by	  QIAquick	  MinElute	  spin	  column	  purification,	  and	  the	  PbA	  cDNA	  
was	  amplified	  in	  1X	  High-­‐Fidelity	  PCR	  buffer	  with	  0.5	  µM	  IFLink-­‐a	  and	  IF21	  primers,	  
0.2	  mM	  dNTP,	  Phusion	  II	  DNA	  polymerase	  (Life	  Technologies)	  with	  the	  conditions	  set	  
out	  in	  table	  3,	  followed	  by	  spin	  column	  purification.	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Table	  2:	  Condition	  for	  ligating	  IFLink-­‐b3	  DNA	  adaptors	  to	  PbA	  cDNA	  by	  temperature-­‐
cycle	  ligation	  
Step	   Temperature	  (˚C)	   Duration	  (sec)	  
1	   10	   30	  
2	   30	   30	  
3	   Repeat	  steps	  1	  to	  2	  for	  a	  total	  of	  480	  cycles	  
4	   65	   1200	  
6	   20	   60	  
	  
Table	  3:	  PCR	  cycling	  conditions	  for	  amplification	  of	  PbA	  cDNA	  library.	  
Step	   Temperature	  (˚C)	   Duration	  (sec)	  
1	   98	   30	  
2	   98	   10	  
3	   38	   20	  
4	   72	   60	  
5	   Repeat	  steps	  2	  to	  4	  for	  a	  total	  of	  14	  cycles	  
6	   72	   600	  
	  
For	  In-­‐fusion	  cloning	  into	  pScrAn-­‐Int	  vector,	  the	  vector	  was	  cut	  with	  
restriction	  enzymes	  NsiI	  and	  SwaI,	  run	  on	  1%	  TAE	  gel	  and	  purified	  from	  the	  182	  bp	  
fragment	  by	  gel	  extraction	  with	  QIAquick	  MinElute	  spin	  columns.	  This	  was	  mixed	  
with	  PbA	  cDNA	  library	  amplicons	  at	  vector	  to	  insert	  ratio	  of	  6.67:1,	  together	  with	  In-­‐
Fusion	  enzyme	  (Clontech,	  Mountain	  View,	  CA)	  and	  performed	  according	  to	  
manufacturer’s	  instructions.	  Reaction	  mix	  was	  purified	  by	  QIAquick	  MinElute	  spin	  
columns,	  transformed	  into	  ElectroMax	  Stbl4	  competent	  cells	  (Life	  Technologies),	  
plated	  on	  LB	  agar	  plates	  supplemented	  with	  50	  µg/mL	  kanamycin	  (Merck)	  and	  0.02	  
mM	  isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG,	  Life	  Technologies),	  and	  incubated	  
at	  37˚C	  for	  16	  hours.	  Clones	  were	  harvested	  by	  adding	  1	  mL	  LB	  media	  to	  each	  plate	  
and	  scraped	  with	  a	  spreader.	  Cell	  suspensions	  were	  pooled,	  pelleted	  at	  4000	  g	  for	  5	  
min,	  and	  pScrAn-­‐Int-­‐PbA	  cDNA	  plasmids	  purified	  with	  Nucleospin	  plasmid	  miniprep	  
kit	  (Macherey-­‐Nagel,	  Düren,	  Germany).	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To	  clone	  into	  lentivector	  pScrAn-­‐Acc,	  the	  PbA	  cDNA	  insert	  in	  pScrAn-­‐Int	  
vector	  was	  excised	  out	  with	  EagI	  restriction	  enzyme,	  separated	  from	  the	  vector	  by	  
gel	  electrophoresis	  in	  1%	  TAE	  and	  the	  resulting	  smear	  purified	  by	  gel	  extraction.	  The	  
pScrAn-­‐Acc	  vector	  was	  cut	  with	  restriction	  enzymes	  BstBI	  and	  AsiSI	  and	  spin-­‐column	  
purified.	  Both	  the	  PbA	  cDNA	  insert	  and	  linearized	  pScrAn-­‐Acc	  was	  incubated	  
together	  with	  In-­‐Fusion	  enzyme,	  electroporated	  into	  ElectroMax	  Stbl4	  cells	  and	  
plated	  on	  LB	  plates	  supplemented	  with	  100	  µg/mL	  ampicillin	  (Merck).	  Clones	  were	  
harvested	  in	  the	  same	  fashion	  as	  described	  earlier	  and	  the	  vectors	  purified	  with	  




Plasmodium	  yoelii	  UIS4	  (PyUIS4)	  gene	  that	  was	  cloned	  into	  a	  lentivector	  by	  Dr	  
Shanshan	  Howland	  was	  amplified	  with	  0.5	  µM	  forward	  primer	  IF-­‐PyUIS4f	  and	  0.5	  µM	  
of	  either	  of	  the	  reverse	  primers	  IF15-­‐PyUIS4r	  or	  IF15PS-­‐PyUIS4r,	  in	  the	  presence	  1X	  
PCR	  buffer	  containing	  1.5	  mM	  or	  3	  mM	  MgCl2,	  0.2	  mM	  dNTP,	  0.02	  U/µL	  AmpliTaq	  
Gold	  DNA	  polymerase	  (Life	  Technologies).	  Amplicons	  were	  analyzed	  in	  1%	  TAE	  gel,	  
gel-­‐purified	  with	  QIAquick	  MinElute	  kit,	  cloned	  into	  NsiI,	  SwaI-­‐treated	  pScrAn-­‐Int	  
vector,	  transformed	  into	  OneShot	  TOP10	  competent	  cells	  and	  grown	  on	  LB	  agar	  
plates	  with	  100	  µg/mL	  ampicillin.	  In	  separate	  experiments,	  PCR	  amplicons	  were	  used	  
as	  templates	  for	  a	  new	  round	  of	  amplification	  with	  0.5	  µM	  IFLink-­‐a	  and	  IF21	  primers	  
in	  1X	  High-­‐Fidelity	  PCR	  buffer	  containing	  1.5	  mM	  MgCl2,	  0,2	  mM	  dNTP,	  0.02	  U/µL	  
Phusion	  II	  DNA	  polymerase.	  Presence	  of	  PCR	  product	  was	  analyzed	  in	  1%	  TAE	  gel.	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Sequencing	  
	  
The	  PbA	  cDNA	  inserts	  in	  pScrAn-­‐Int	  vector	  from	  individual	  clones	  were	  picked	  
and	  sent	  to	  a	  commercial	  company	  (Suprenom,	  Singapore)	  for	  sequencing	  with	  
pScrAn-­‐IntF	  primer.	  Results	  were	  analyzed	  by	  BLAST	  against	  PlasmoDB	  database	  
(www.plasmodb.org).	  
	  
EL4	  transduction	  with	  pScrAn-­‐Acc-­‐PbA	  cDNA	  lentivector	  
	  
HEK293T	  cells	  were	  cultured	  at	  37˚C,	  5%	  CO2	  in	  four	  100	  mm	  tissue	  culture	  
dishes	  to	  ~50%	  confluency	  in	  DMEM	  media	  supplemented	  with	  10%	  FBS	  (without	  
antibiotics).	  For	  every	  dish,	  2.5	  µg	  pScrAn-­‐Acc	  PbA	  cDNA	  library	  lentivector	  were	  
mixed	  with	  0.875	  µg	  pMD2.G	  envelope	  vector	  and	  1.625	  µg	  psPAX2	  packaging	  vector	  
(kind	  gifts	  from	  Didier	  Trono,	  Addgene	  plasmids	  #12259	  and	  #12260	  respectively)	  in	  
200	  µL	  OptiMEM	  serum-­‐free	  media	  (Life	  Technologies).	  This	  was	  mixed	  dropwise	  to	  
another	  tube	  with	  200	  µL	  OptiMEM	  serum-­‐free	  media	  and	  15	  µL	  EndoFectin	  Lenti	  
(GeneCopoeia,	  Rockville,	  MD)	  while	  vortexing,	  followed	  by	  adding	  the	  whole	  mixture	  
dropwise	  into	  the	  HEK293T	  cells.	  After	  overnight	  incubation,	  the	  DMEM	  media	  was	  
replaced	  with	  3	  mL	  fresh	  media	  and	  cells	  were	  allowed	  to	  incubate	  for	  2	  more	  days.	  
Media	  containing	  lentiviral	  particles	  were	  harvested,	  centrifuged	  at	  500	  g	  for	  5	  min	  
to	  remove	  cell	  debris,	  aliquoted	  and	  stored	  at	  -­‐80˚C.	  	  
	  
EL4	  cells	  were	  seeded	  in	  eighteen	  6-­‐well	  plates	  at	  3	  x	  105	  cells	  per	  well	  with	  
RPMI	  complete	  media,	  followed	  by	  addition	  of	  20	  µL	  pScrAn-­‐Acc	  PbA	  cDNA	  library	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lentiviral	  particles	  in	  3	  µg/mL	  hexadimethrine	  bromide	  (Sigma-­‐Aldrich).	  The	  plates	  
were	  centrifuged	  at	  1200	  g	  for	  1	  hour	  at	  30˚C,	  and	  then	  incubated	  at	  37˚C,	  5%	  CO2	  
overnight.	  The	  media	  was	  replaced	  with	  fresh	  ones,	  and	  cells	  were	  allowed	  to	  
culture	  for	  one	  more	  day	  before	  sorted	  for	  live	  EGFP+	  transductants.	  Sorted	  cells	  
were	  grown,	  aliquoted	  and	  frozen	  in	  liquid	  nitrogen.	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Results	  
	  
Generation	  of	  pScrAn-­‐Int	  vector	  
	  
We	  designed	  and	  constructed	  the	  pScrAn-­‐Int	  vector	  (Screen	  antigen	  –	  
intermediate,	  figure	  10A)	  for	  cloning	  the	  PbA	  cDNA	  fragments	  and	  performing	  ORF	  
enrichment	  in	  bacteria.	  Excision	  of	  pScrAn-­‐Int	  with	  NsiI	  and	  SwaI	  restriction	  enzymes	  
leaves	  homologous	  ends	  that	  allow	  PbA	  cDNA	  fragments	  to	  be	  inserted	  by	  In-­‐Fusion	  
cloning	  (figure	  10B).	  In	  this	  design,	  PbA	  cDNA	  in	  pScrAn-­‐Int	  will	  be	  under	  the	  control	  
of	  a	  tac	  promoter,	  inducible	  by	  IPTG,	  and	  translation	  is	  made	  possible	  by	  the	  Shine-­‐
Dalgarno	  (SD)	  ribosomal	  binding	  site.	  The	  3	  stop	  codons	  at	  the	  end	  of	  cDNA	  
(highlighted	  in	  gray)	  will	  allow	  mRNA	  translation	  to	  terminate	  regardless	  of	  the	  
reading	  frame.	  The	  KanR	  expression	  cassette	  constructed	  in	  very	  close	  proximity	  to	  
the	  stop	  codons	  (in	  fact,	  it	  overlaps	  with	  the	  stop	  codon	  in	  the	  +3	  frame).	  If	  the	  cDNA	  
Figure	  10:	  Creation	  of	  pScrAn-­‐Int	  vector	  for	  selecting	  PbA	  cDNA	  clones	  with	  
full	  ORF.	  The	  pScrAn-­‐Int	  vector	  (A)	  contains	  a	  SD	  sequence	  at	  the	  proximal	  end	  
and	  a	  kanamycin	  resistance	  gene	  (KanR)	  at	  the	  distal	  end.	  Upon	  excision	  of	  
pScrAn-­‐Int	  with	  NsiI	  and	  SwaI	  and	  cloning	  of	  PbA	  cDNA	  fragments	  to	  this	  site	  
(B),	  the	  SD	  and	  start	  codon	  upstream	  of	  PbA	  cDNA	  enables	  its	  translation,	  while	  
the	  unique	  11	  bp	  sequence	  (in	  gray)	  allows	  stoppage	  of	  in-­‐frame	  ORF	  fragments	  
at	  one	  of	  the	  3	  forward	  frames.	  Only	  when	  this	  occurs	  will	  translation	  of	  KanR	  be	  
initiated	  through	  translational	  coupling.	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is	  in	  frame	  with	  the	  vector’s	  start	  codon	  and	  there	  are	  no	  intervening	  stop	  codons,	  
the	  ribosome	  can	  re-­‐initiate	  translation	  of	  KanR	  after	  it	  reaches	  the	  three	  overlapping	  
stop	  codons,	  a	  process	  termed	  translational	  coupling	  (167).	  Thus,	  only	  clones	  with	  
intact	  ORFs	  will	  be	  able	  to	  grow	  in	  the	  presence	  of	  kanamycin.	  After	  selecting	  for	  
PbA	  cDNA	  fragments	  cloned	  in	  ORF,	  the	  flanking	  EagI	  sites	  enable	  them	  to	  be	  excised	  
for	  sub-­‐cloning	  into	  a	  mammalian	  expression	  vector.	  
	  
Phosphorothioate	  (PS)	  bonds	  mildly	  affects	  PCR	  but	  severely	  hinders	  In-­‐Fusion	  cloning	  
	  
	  
Efficient,	  directional	  cloning	  of	  gene	  fragments	  with	  undefined	  sequences	  
requires	  the	  addition	  of	  exogenous	  sequences	  that	  are	  compatible	  with	  the	  ends	  of	  
the	  linearized	  vector.	  In	  In-­‐Fusion	  cloning,	  the	  vector	  and	  insert	  sequences	  are	  joined	  
Figure	  11:	  PCR	  amplification	  of	  PyUIS4	  with	  PO-­‐	  or	  PS-­‐	  primers.	  (A)	  IF15-­‐PyUIS4r	  
(-­‐)	  or	  IF15PS-­‐PyUIS4r	  (+)	  reverse	  primers	  homologous	  to	  3’	  end	  of	  PyUIS4	  were	  
used	  to	  amplify	  the	  gene	  and	  analyzed	  by	  gel	  electrophoresis.	  (B)	  IF15PS-­‐PyUIS4r	  
primer	  was	  used	  in	  amplifying	  PyUIS4	  in	  3	  mM	  MgCl2.	  (C)	  PyUIS4	  PCR	  products	  
from	  (B)	  were	  amplified	  with	  IFLink-­‐a	  and	  IF21	  primers	  in	  different	  annealing	  
temperatures	  and	  the	  mixture	  analyzed	  by	  gel	  electrophoresis.	  In	  all	  figures,	  
GeneRuler	  1kb	  DNA	  ladder	  was	  used	  throughout,	  and	  PyUIS4	  PCR	  products	  
appear	  as	  bands	  at	  582	  bp	  region.	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through	  homologous	  sequences	  of	  at	  least	  15	  bp	  at	  their	  ends.	  No	  restriction	  digest	  
of	  DNA	  is	  necessary,	  which	  is	  advantageous	  as	  these	  restriction	  sites	  could	  be	  
present	  in	  some	  cDNAs.	  However,	  simply	  adding	  a	  15	  bp	  tail	  to	  the	  random	  hexamer	  
primers	  used	  for	  cDNA	  synthesis	  will	  not	  work	  as	  the	  tail	  is	  vulnerable	  to	  the	  5’	  to	  3’	  
exonuclease	  activity	  of	  E.	  coli	  DNA	  polymerase.	  This	  activity,	  however,	  is	  reported	  to	  
not	  work	  on	  nucleotides	  joined	  by	  PS	  linkages	  (168,	  169).	  We	  envisioned	  that	  
incorporating	  this	  type	  of	  linkage	  into	  the	  primers	  would	  protect	  them	  from	  excision	  
and	  allow	  subsequent	  downstream	  cloning.	  First	  we	  wanted	  to	  see	  how	  the	  
presence	  of	  PS	  tails	  on	  primers	  would	  affect	  priming,	  PCR	  amplification	  and	  In-­‐Fusion	  
cloning.	  To	  test	  this,	  PyUIS4	  gene	  was	  amplified	  with	  forward	  primer	  IF-­‐PyUIS4f	  and	  
either	  IF15-­‐PyUIS4r	  or	  IF15PS-­‐PyUIS4r	  reverse	  primers.	  	  In	  a	  typical	  PCR	  reaction	  of	  
1.5	  mM	  MgCl2,	  PyUIS4	  amplification	  with	  IF15-­‐PyUIS4r	  yielded	  more	  products	  than	  
with	  IF15PS-­‐PyUIS4r	  (figure	  11A).	  By	  increasing	  the	  amount	  of	  MgCl2	  to	  3	  mM,	  
IF15PS-­‐PyUIS4r	  can	  then	  efficiently	  amplify	  the	  same	  gene	  (figure	  11B).	  These	  PCR	  
products	  were	  purified,	  cloned	  into	  pScrAn-­‐Int	  linearized	  with	  NsiI	  and	  SwaI,	  
transformed	  into	  competent	  cells	  and	  selected	  for	  positive	  transformants.	  Colonies	  
with	  phosphodiester	  (PO)-­‐linked	  3’	  ends	  yielded	  about	  10	  times	  more	  colonies	  than	  
that	  with	  PS-­‐linked	  3’	  ends	  (table	  4),	  highlighting	  the	  incompatibility	  between	  In-­‐
Fusion	  cloning	  with	  PS-­‐bonded	  homologous	  ends.	  	  
	  
Table	  4:	  Transformation	  efficiencies	  of	  pScrAn-­‐Int-­‐PyUIS4	  synthesized	  by	  PO-­‐	  or	  PS-­‐
linked	  primers	  through	  In-­‐Fusion	  cloning.	  
	   Colonies	  (CFU/µg)	  
pScrAn-­‐Int-­‐IF15-­‐PyUIS4	   5.2	  x	  103	  
pScrAn-­‐Int-­‐IF15PS-­‐PyUIS4	   5.8	  x	  102	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As	  inserts	  with	  PS-­‐linked	  tails	  were	  shown	  to	  be	  incompatible	  with	  In-­‐Fusion	  
cloning,	  the	  possibility	  of	  replacing	  the	  PS	  tails	  with	  normal	  PO	  tails	  through	  PCR	  is	  
investigated.	  PyUIS4	  PCR	  products	  with	  PS-­‐linked	  distal	  tails	  were	  used	  as	  templates	  
for	  regular	  PCR	  amplification	  with	  PO-­‐linked	  IFLink-­‐a	  and	  IF21	  primers.	  This	  was	  also	  
performed	  over	  a	  range	  of	  annealing	  temperatures,	  in	  anticipation	  that	  hybridization	  
between	  PO-­‐	  and	  PS-­‐linked	  DNA	  sequences	  might	  be	  less	  than	  optimal	  because	  of	  
slight	  differences	  in	  the	  DNA	  backbone	  structure	  (170).	  Unexpectedly,	  amplification	  
was	  shown	  to	  be	  efficient	  with	  the	  tested	  annealing	  temperatures,	  between	  35˚C	  to	  
55˚C	  (figure	  11C),	  indicating	  that	  the	  “conversion”	  from	  PS	  linkage	  to	  PO	  linkage	  can	  
be	  achieved	  with	  ease.	  
	  
The	  use	  of	  PS	  primers	  during	  library	  synthesis	  yielded	  more	  colonies	  
	  
To	  test	  the	  usage	  of	  PS-­‐linked	  primers	  in	  cDNA	  library	  synthesis,	  1	  µg	  total	  RNA	  was	  
reverse	  transcribed	  with	  IFb-­‐15PS-­‐X6	  or	  IF-­‐15-­‐X6	  primers,	  followed	  by	  second	  strand	  
synthesis	  and	  subsequent	  downstream	  steps	  in	  figure	  12A.	  Primers	  with	  
phosphorothioate	  (PS)	  linkages	  were	  used	  to	  synthesize	  cDNA	  from	  mRNA	  with	  
reverse	  transcriptase,	  and	  second	  strand	  synthesis	  performed	  with	  the	  enzymes	  
RNaseH	  (to	  degrade	  mRNA),	  E.	  coli	  DNA	  polymerase	  (to	  use	  mRNA	  fragments	  as	  
primers	  for	  amplification)	  and	  E.	  coli	  DNA	  ligase	  (to	  join	  Okazaki	  fragments	  together	  
to	  form	  one	  continuous	  strand).	  T4	  DNA	  polymerase	  was	  used	  to	  fill	  up	  the	  5’	  ends	  
of	  cDNA	  fragments	  that	  were	  vacated	  by	  the	  degraded	  mRNA,	  resulting	  in	  a	  
phosphate	  group	  at	  that	  end.	  DNA	  adaptors	  homologous	  to	  the	  3’	  end	  of	  linearized	  
pScrAn-­‐Int	  would	  be	  attached	  to	  the	  5’	  end	  of	  cDNA	  by	  T4	  DNA	  ligase	  through	  this	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phosphate	  group.	  The	  cDNA	  would	  be	  expanded	  by	  PCR	  amplification	  with	  PO	  or	  PS	  
primers,	  cloned	  into	  pScrAn-­‐Int	  vectors	  through	  In-­‐Fusion	  cloning,	  transformed	  into	  
ElectroMax	  competent	  cells	  and	  selected	  by	  IPTG	  induction	  and	  kanamycin	  
resistance.	  
	   	  
Figure	  12:	  Schematics	  of	  generating	  PbA	  cDNA	  and	  cloning	  into	  pScrAn-­‐Int	  
vector.	  (A)	  Random	  hexamers,	  with	  a	  5’	  PS-­‐bonded	  (denoted	  with	  ^)	  overhang	  tail	  
(in	  blue),	  were	  hybridized	  to	  PbA	  mRNA	  (gray),	  followed	  by	  1st	  strand	  cDNA	  
synthesis	  by	  reverse	  transcriptase.	  The	  mRNA	  was	  degraded	  by	  RNaseH,	  and	  E.	  
coli	  DNA	  polymerase	  (in	  green)	  used	  mRNA	  fragments	  to	  synthesize	  
complementary	  cDNA	  strands,	  with	  E.	  coli	  DNA	  ligase	  joining	  cDNA	  fragments	  
together	  after	  synthesis.	  T4	  DNA	  polymerase	  would	  fill	  up	  5’	  overhangs	  to	  make	  
cDNA	  fragments	  blunt-­‐ended,	  of	  which	  the	  free	  phosphate	  group	  (yellow	  circle)	  
created	  would	  allow	  adaptor	  sequences	  (in	  red)	  to	  be	  attached	  to	  by	  T4	  DNA	  
ligase.	  Primers	  (PO-­‐	  or	  PS-­‐based)	  complementary	  to	  the	  ends	  of	  cDNA	  were	  used	  
for	  amplification,	  followed	  by	  cloning	  into	  NsiI-­‐SwaI-­‐linearized	  pScrAn-­‐Int	  vector.	  
(B)	  The	  use	  of	  random	  hexamers	  with	  PO-­‐bonded	  overhang	  tail	  at	  5’	  end	  would	  
result	  in	  excision	  of	  the	  tail	  by	  E.	  coli	  DNA	  polymerase.	  The	  exposed	  phosphate	  
group	  would	  enable	  ligation	  of	  adaptors	  to	  both	  ends,	  which	  blocks	  cloning	  into	  
pScrAn-­‐Int	  vector.	  	  Diagram	  reproduced	  from	  (171).	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The	  PCR	  products	  were	  cloned	  into	  linearized	  pScrAn-­‐Int	  vector	  and	  
transformed	  into	  competent	  bacteria.	  As	  shown	  in	  table	  5,	  cDNA	  inserts	  synthesized	  
with	  IFb-­‐15PS-­‐X6	  primers	  resulted	  in	  more	  colonies	  obtained	  after	  In-­‐Fusion	  cloning	  
and	  transformation,	  more	  than	  7	  times	  than	  that	  with	  IF-­‐15-­‐X6	  primers.	  Cloning	  the	  
cDNA	  product	  directly	  into	  the	  vector	  gave	  very	  few	  colonies,	  demonstrating	  that	  
amplification	  of	  cDNA	  was	  necessary	  as	  part	  of	  the	  strategy	  to	  construct	  PbA	  cDNA	  
library.	  Figure	  12B	  depicts	  a	  model	  explaining	  the	  low	  numbers	  of	  colonies	  obtained	  
with	  the	  unmodified	  primer.	  The	  5’	  overhangs	  in	  PO-­‐linked	  primers	  were	  targeted	  by	  
the	  3’	  to	  5’	  exonuclease	  activity	  of	  E.	  coli	  DNA	  polymerase,	  leaving	  behind	  a	  
phosphate	  group	  at	  the	  5’	  end	  of	  the	  partial	  downstream	  homologous	  sequence,	  to	  
which	  a	  DNA	  adaptor	  can	  be	  subsequently	  ligated.	  Only	  a	  minority	  of	  inserts	  
retaining	  sufficiently	  long	  portions	  of	  the	  downstream	  homologous	  sequence	  were	  
successfully	  cloned	  into	  pScrAn-­‐Int	  vector.	  	  
	  
Table	  5:	  Transformation	  efficiency	  of	  cDNA	  inserts	  obtained	  with	  PO-­‐	  or	  PS-­‐linked	  
primers.	  
Reverse	  transcription	  primer	   PCR	  performed	  after	  adaptor	  ligation	  
	   –	   +	  
IF-­‐15-­‐X6	   26	   269	  
IFb-­‐15PS-­‐X6	   19	   1993	  
Linearized	  vector	  control	   12	   NA	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Generation	  of	  PbA	  cDNA	  library	  fragments	  
	  
	  
Encouraged	  by	  the	  tests,	  the	  actual	  library	  synthesis	  work	  was	  performed	  to	  
convert	  PbA	  mRNA	  to	  cDNA	  with	  IFb-­‐15PS-­‐X6	  primers.	  The	  cDNA	  was	  cloned	  into	  
pScrAn-­‐Int	  vector	  in	  a	  series	  of	  steps	  as	  described	  earlier	  and	  the	  transformed	  
bacteria	  clones	  selected	  for	  resistance	  to	  kanamycin.	  An	  estimated	  total	  of	  1.2	  x	  105	  
pScrAn-­‐Int	  clones	  were	  obtained	  from	  the	  compilation	  of	  3	  rounds	  of	  library	  
generation.	  A	  handful	  of	  clones	  were	  picked	  and	  sequenced	  to	  assess	  the	  quality	  of	  
PbA	  cDNA	  inserts.	  As	  shown	  in	  figure	  13,	  a	  range	  of	  cDNA	  lengths	  was	  obtained	  in	  
the	  library,	  with	  the	  majority	  at	  less	  than	  400	  bp.	  More	  importantly,	  only	  1	  out	  of	  48	  
clones	  had	  an	  insert	  not	  originating	  from	  PbA,	  and	  18	  (38.3%)	  of	  these	  clones	  carried	  
Figure	  13:	  Breadth	  of	  PbA	  cDNA	  insert	  sizes	  and	  the	  frequency	  of	  those	  with	  
full-­‐length	  ORFs	  in	  pScrAn-­‐Int	  library.	  A	  sample	  of	  47	  clones	  from	  pScrAn-­‐Int-­‐
PbA	  cDNA	  library	  were	  sequenced	  and	  the	  length	  of	  PbA	  cDNA	  inserts	  were	  
tabulated.	  The	  frequency	  of	  clones	  with	  full-­‐length	  ORFs	  amounted	  to	  38.3%.	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the	  PbA	  inserts	  in	  ORF.	  The	  high	  percentage	  of	  clones	  with	  PbA	  inserts	  in	  frame	  
validated	  the	  strategy	  of	  cDNA	  library	  synthesis	  outlined	  here.	  
	  
Cloning	  PbA	  cDNA	  inserts	  into	  lentivector	  pScrAn-­‐Acc	  
	  
	  
The	  pScrAn-­‐Int	  vector	  was	  created	  as	  a	  means	  to	  select	  for	  PbA	  cDNA	  inserts	  
that	  could	  be	  expressed	  in	  ORF.	  To	  express	  these	  cDNA	  inserts	  within	  EL4	  cell	  line,	  
they	  need	  to	  be	  excised	  out	  of	  pScrAn-­‐Int	  and	  cloned	  into	  a	  lentivector,	  packaged	  
into	  lentiviral	  particles	  and	  introduced	  to	  EL4	  cells.	  A	  lentivector	  plasmid	  was	  thus	  
designed	  to	  accept	  the	  screened	  PbA	  antigenic	  inserts,	  hence	  the	  name	  pScrAn-­‐Acc	  
(figure	  14A).	  When	  linearized	  with	  BstBI	  and	  AsiSI,	  the	  ends	  of	  pScrAn-­‐Acc	  are	  
compatible	  for	  In-­‐Fusion	  cloning	  with	  cDNA	  excised	  from	  pScrAn-­‐Int	  with	  EagI.	  The	  
cDNA	  is	  then	  positioned	  downstream	  of	  EGFP,	  a	  T2A	  self-­‐cleaving	  peptide	  and	  a	  
glycine-­‐rich	  linker	  (figure	  14B).	  When	  transduced	  into	  mammalian	  cells,	  T2A	  peptide	  
Figure	  14:	  Creation	  of	  pScrAn-­‐Acc	  lentivector	  for	  accepting	  PbA	  cDNA	  clones	  
with	  full	  ORF	  from	  pScrAn-­‐Int.	  The	  pScrAn-­‐Acc	  lentivector	  (A)	  contains	  an	  EGFP	  
tag	  fused	  with	  self-­‐cleaving	  T2A	  peptide.	  Upon	  cutting	  with	  BstBI	  and	  AsiSI,	  PbA	  
cDNA	  excised	  from	  pScrAn-­‐Int	  with	  EagI	  can	  be	  cloned	  into	  pScrAn-­‐Acc	  by	  In-­‐
Fusion	  cloning	  (required	  overlapping	  regions	  in	  gray),	  giving	  rise	  to	  pScrAn-­‐Acc-­‐
PbA	  cDNA	  (B).	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ensures	  that	  EGFP	  and	  PbA	  cDNA	  fragment	  are	  produced	  separately	  even	  when	  
under	  the	  control	  of	  a	  single	  elongation	  factor	  1α	  (EF-­‐1α)	  promoter.	  EGFP	  allows	  
transduced	  mammalian	  cells	  to	  be	  identified	  and	  isolated	  from	  non-­‐transduced	  cells	  
through	  flow	  sorting.	  The	  pScrAn-­‐Acc-­‐PbA	  cDNA	  formed	  by	  In-­‐Fusion	  cloning	  (figure	  
14B)	  was	  then	  transformed	  into	  Stbl4	  competent	  cells	  and	  positive	  transformants	  
selected	  by	  ampicillin	  resistance,	  followed	  by	  pooling	  all	  the	  clones	  together	  to	  
harvest	  the	  plasmids.	  	  
	  
Generation	  of	  EL4	  PbA	  cDNA	  library	  
	  
The	  pScrAn-­‐Acc-­‐PbA	  cDNA	  lentiviral	  particles	  were	  produced	  in	  HEK	  293T	  
packaging	  cells	  and	  titrated	  against	  EL4	  cells	  in	  a	  small-­‐scale	  transduction	  
experiment.	  From	  a	  range	  of	  1-­‐100	  µL	  lentivector	  per	  1	  x	  105	  cells	  (figure	  15),	  we	  
chose	  the	  dose	  where	  we	  obtained	  between	  20-­‐30%	  transduction,	  as	  the	  risk	  of	  
generating	  cells	  with	  more	  than	  one	  insert	  becomes	  significant	  at	  higher	  
transduction	  efficiencies.	  Using	  this	  dose,	  a	  larger	  scale	  transduction	  was	  performed	  
to	  generate	  the	  EL4	  PbA	  cDNA	  library,	  ensuring	  that	  at	  least	  1.2	  x	  106	  EL4	  cells	  were	  
transduced	  to	  maintain	  library	  diversity.	  Transduced	  cells	  were	  sorted	  based	  on	  
EGFP	  expression,	  expanded	  and	  finally	  cryopreserved	  in	  aliquots.	  A	  summary	  of	  
statistics	  of	  our	  PbA	  cDNA	  library	  is	  detailed	  in	  table	  6.	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Table	  6:	  Summary	  of	  statistics	  of	  the	  PbA	  cDNA	  library	  created	  in	  this	  study	  
Number	  of	  clones	   1.2	  x	  105	  
Average	  insert	  length	  	   441	  bp	  
Size	  of	  PbA	  cDNA	  library	   5.21	  x	  107	  bp	  
Size	  of	  PbA	  transcriptome	   6.64	  x	  106	  bp	  (172)	  
Coverage	   7.9x	  
Percentages	  of	  clones	  in	  ORF	   38.3%	  
	  
	   	  
Figure	  15:	  Titration	  of	  PbA	  cDNA	  lentiviral	  particles	  in	  EL4	  cell	  line.	  PbA	  cDNA	  
lentiviral	  particles	  were	  incubated	  with	  1	  x	  105	  EL4	  cell	  line	  at	  different	  
amounts	  and	  the	  frequency	  of	  live	  cells	  expressing	  EGFP	  was	  quantified	  by	  
flow	  cytometry.	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Discussion	  
	  
The	  dearth	  of	  malaria	  CD8+	  T	  cell	  epitopes,	  despite	  that	  CD8+	  T	  cells	  were	  
shown	  to	  be	  responsible	  for	  ECM	  pathology	  much	  earlier	  (87,	  91,	  92),	  was	  the	  
motivation	  to	  conduct	  this	  study.	  In	  this	  chapter,	  PbA	  mRNA	  was	  isolated,	  converted	  
into	  cDNA	  and	  cloned	  into	  EL4	  cells.	  Within	  these	  cells,	  the	  cDNA	  fragments	  will	  be	  
translated	  into	  proteins	  and	  degraded	  by	  proteasomes	  into	  peptides.	  A	  portion	  of	  
these	  peptides	  will	  be	  loaded	  onto	  the	  MHC	  class	  I	  molecules	  and	  presented	  on	  the	  
EL4	  cell	  surface.	  These	  malarial	  pMHC	  complexes	  can	  be	  screened	  against	  malaria-­‐
specific	  TCRs	  of	  unknown	  specificities.	  The	  EL4	  clone	  that	  elicits	  a	  positive	  response	  
from	  such	  a	  screen	  can	  be	  analyzed	  to	  identify	  the	  transduced	  PbA	  cDNA	  fragment	  
and	  thus	  the	  antigens.	  
	  
Many	  decisions	  had	  to	  be	  made	  when	  planning	  the	  library	  construction,	  
starting	  with	  3	  main	  ones:	  the	  parasite	  genetic	  material,	  the	  choice	  of	  host	  cells	  for	  
the	  library	  and	  the	  method	  to	  introduce	  the	  former	  into	  the	  latter.	  As	  described	  
earlier,	  blood-­‐stage	  parasites	  are	  the	  ones	  responsible	  for	  the	  pathology	  associated	  
with	  patients	  suffering	  from	  malaria,	  including	  ECM.	  To	  maximize	  the	  chance	  of	  
identifying	  epitopes	  that	  are	  essential	  for	  ECM	  pathogenesis,	  mRNA	  of	  blood-­‐stage	  
parasites	  were	  isolated	  to	  create	  the	  library.	  This	  approach	  excluded	  the	  introns	  and	  
non-­‐coding	  regions	  that	  accompany	  the	  choice	  of	  using	  gDNA	  as	  the	  starting	  
material.	  The	  cell	  line	  that	  was	  chosen	  to	  be	  the	  host	  for	  the	  cDNA	  library,	  EL4,	  
originated	  from	  a	  lymphoma	  in	  a	  C57BL/6N	  mouse.	  It	  was	  chosen	  as	  a	  host	  for	  
expression	  of	  PbA	  cDNA	  library	  due	  to	  its	  fast	  and	  robust	  proliferation,	  suitability	  as	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a	  transfection	  host,	  and	  most	  importantly,	  having	  the	  same	  H-­‐2b	  MHC	  background	  as	  
C57BL/6J	  mice.	  Being	  a	  suspension	  cell	  line,	  cell	  transfer	  during	  high	  throughput	  
screening	  is	  easier	  than	  with	  adherent	  cells.	  To	  ensure	  stable	  expression	  of	  PbA	  
cDNA,	  lentiviral	  transduction	  was	  selected	  as	  it	  allows	  integration	  of	  exogenous	  
genetic	  material	  within	  the	  host	  chromosomes.	  In	  contrast,	  plasmid	  transfection	  and	  
non-­‐integrating	  viral	  transduction	  methods	  run	  a	  much	  higher	  risk	  of	  insert	  loss	  after	  
multiple	  rounds	  of	  cell	  division,	  even	  if	  selection	  pressure	  is	  applied.	  	  
	  
In	  the	  PbA	  cDNA	  library	  synthesis,	  choosing	  between	  random	  priming	  and	  
oligo-­‐dT	  priming	  to	  synthesize	  the	  cDNA	  was	  the	  biggest	  decision	  we	  faced.	  After	  
much	  thought,	  we	  rejected	  the	  latter	  as	  the	  AT-­‐rich	  PbA	  genome	  would	  result	  in	  a	  
library	  that	  is	  heavily	  biased	  against	  long	  genes,	  genes	  with	  more	  AT	  content,	  and	  
the	  5’	  ends	  of	  genes.	  However,	  a	  major	  disadvantage	  of	  random	  priming	  is	  that	  cDNA	  
libraries	  made	  without	  knowledge	  of	  correct	  frame	  or	  orientation	  are	  estimated	  to	  
have	  only	  8%	  of	  the	  clones	  in	  the	  correct	  frame	  (162).	  To	  circumvent	  this,	  Davis	  and	  
colleagues	  designed	  the	  pKE-­‐1	  vector	  such	  that	  only	  those	  transformants	  with	  gene	  
fragments	  in	  ORF	  that	  stopped	  right	  before	  a	  KanR	  gene	  can	  translate	  the	  latter	  and	  
become	  resistant	  to	  kanamycin	  selection.	  Similarly,	  a	  Japanese	  group	  introduced	  a	  
unique	  sequence	  that	  allows	  for	  full-­‐length	  ORFs	  in	  all	  three	  frames	  to	  be	  selected	  
for	  (167).	  The	  latter	  strategy	  was	  adopted	  in	  this	  study,	  resulting	  in	  38.3%	  of	  the	  
clones	  in	  the	  pScrAn-­‐Int	  library	  having	  PbA	  cDNA	  fragments	  in	  ORF,	  more	  than	  four	  
times	  compared	  to	  if	  no	  selection	  was	  used.	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The	  conventional	  method	  of	  cloning	  random-­‐primed	  cDNA	  is	  blunt-­‐end	  
ligation	  with	  the	  vector,	  which	  does	  not	  permit	  directional	  cloning.	  We	  also	  sought	  
to	  avoid	  the	  problem	  of	  inserts	  being	  cloned	  in	  the	  reverse	  orientation	  by	  adding	  a	  
tail	  to	  the	  random	  primers.	  This	  tail	  would	  also	  facilitate	  In-­‐Fusion	  cloning	  by	  being	  
homologous	  to	  one	  end	  of	  the	  pScrAn-­‐Int	  vector,	  fixing	  the	  insert	  orientation	  and	  
improving	  cloning	  efficiency.	  However,	  simply	  extending	  the	  random	  primer	  was	  
virtually	  unreported	  in	  the	  literature,	  and	  we	  suspect	  that	  excision	  of	  this	  tail	  by	  E.	  
coli	  DNA	  polymerase	  during	  cDNA	  synthesis	  was	  detrimental	  to	  cloning.	  We	  
hypothesized	  the	  PS	  linkages	  throughout	  the	  length	  of	  the	  overhang	  tail	  would	  offer	  
protection	  against	  5’	  to	  3’	  exonuclease	  cleavage.	  However,	  cDNA	  incorporating	  the	  
PS	  primer	  inhibited	  In-­‐Fusion	  cloning,	  as	  shown	  by	  the	  low	  number	  of	  clones	  
obtained	  in	  table	  4.	  The	  In-­‐Fusion	  enzyme	  is	  thought	  to	  remove	  DNA	  bases	  from	  
each	  strand	  in	  the	  3’	  to	  5’	  direction	  to	  generate	  5’	  overhangs,	  and	  it	  is	  possible	  that	  
the	  PS	  bonds	  prevent	  this.	  Fortunately,	  we	  were	  able	  to	  solve	  this	  by	  amplifying	  the	  
PS-­‐containing	  cDNA	  with	  unmodified	  primers	  before	  In-­‐Fusion	  cloning.	  Incorporating	  
both	  PS	  linkages	  in	  the	  primer	  tail	  and	  a	  PCR	  amplification	  step	  to	  “revert”	  to	  
unmodified	  DNA	  allowed	  random-­‐primed	  cDNA	  to	  be	  inserted	  by	  In-­‐Fusion	  cloning	  
into	  the	  vector	  in	  the	  correct	  orientation.	  This	  strategy	  may	  prove	  useful	  to	  other	  
researchers	  interested	  in	  constructing	  random-­‐primed	  cDNA	  libraries	  and	  has	  been	  
published	  (171).	  
	  
The	  PbA	  cDNA	  gene	  fragments	  in	  the	  pScrAn-­‐Acc	  lentivector	  were	  expressed	  
under	  the	  control	  of	  the	  constitutive	  EF-­‐1α	  promoter.	  Although	  this	  is	  weaker	  than	  
cytomegalovirus	  (CMV)	  promoter,	  high	  expression	  levels	  may	  be	  detrimental	  as	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many	  of	  the	  cDNA	  inserts	  may	  be	  toxic	  to	  EL4	  cells,	  which	  may	  inadvertently	  shrink	  
the	  diversity	  of	  the	  library.	  In	  addition,	  CMV	  promoter	  can	  be	  silenced	  by	  DNA	  
methylation	  over	  time	  (173,	  174).	  Silencing	  of	  EF-­‐1α	  promoter	  is	  rare,	  thus	  making	  it	  
more	  suitable	  for	  long-­‐term	  expression	  in	  mammalian	  cells.	  Due	  to	  the	  relatively	  
large	  size	  of	  pScrAn-­‐Acc	  lentivector	  (over	  10	  kilo	  base	  pairs),	  the	  length	  of	  PbA	  cDNA	  
gene	  fragments	  that	  was	  cloned	  in	  could	  not	  be	  too	  large,	  as	  this	  would	  impede	  
efficient	  transfection	  into	  HEK293T	  packaging	  cell	  line	  and	  viral	  packaging	  (175).	  This	  
was	  part	  of	  the	  reason	  cDNA	  was	  synthesized	  with	  random	  hexamers,	  because	  it	  
gives	  smaller	  fragments	  in	  contrast	  to	  full-­‐length	  cDNA.	  The	  EGFP	  in	  the	  lentivector,	  
occupying	  the	  EF-­‐1α	  promoter,	  was	  necessary	  for	  isolating	  positive	  transformants.	  
Cloning	  a	  separate	  promoter	  to	  express	  PbA	  cDNA	  inserts	  would	  greatly	  increase	  the	  
size	  of	  the	  vector.	  To	  circumvent	  this,	  the	  EGFP	  and	  PbA	  cDNA	  fragments	  were	  fused	  
together,	  separated	  by	  the	  short	  self-­‐cleaving	  T2A	  peptide	  sequence.	  This	  eliminated	  
the	  need	  for	  either	  another	  promoter	  to	  drive	  the	  expression	  of	  the	  cDNA	  gene	  
fragment	  or	  an	  internal	  ribosomal	  entry	  site.	  	  
	  
The	  size	  of	  the	  PbA	  cDNA	  library	  created	  here	  amounted	  to	  5.21	  x	  107	  bp	  
(table	  6),	  which	  is	  about	  7.9	  times	  the	  size	  of	  the	  PbA	  transcriptome.	  Note	  that	  genes	  
have	  different	  levels	  of	  expression	  even	  in	  a	  single	  cell,	  with	  some	  of	  them	  expressed	  
at	  extremely	  low	  levels.	  Assuming	  all	  mRNAs	  were	  successfully	  captured	  and	  
converted	  into	  cDNA,	  more	  abundant	  genes	  would	  be	  over-­‐represented	  in	  the	  
library,	  and	  vice	  versa,	  making	  detection	  of	  rare	  mRNAs	  in	  the	  library	  difficult.	  To	  
overcome	  this,	  some	  researchers	  have	  developed	  methods	  to	  create	  normalized	  
cDNA	  libraries	  (164,	  176,	  177).	  However,	  it	  is	  unclear	  whether	  normalizing	  our	  cDNA	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library	  will	  be	  beneficial	  for	  CD8+	  T	  cell	  epitope	  discovery,	  as	  generally	  speaking,	  rare	  
antigens	  are	  less	  likely	  to	  be	  immunogenic.	  To	  minimize	  losses	  of	  clones	  in	  the	  
subsequent	  conversion	  of	  the	  cDNA	  library	  from	  bacteria	  to	  EL4	  cells,	  we	  ensured	  
that	  the	  number	  of	  lentiviral	  particles	  and	  the	  number	  of	  transduced	  and	  sorted	  EL4	  
cells	  were	  at	  least	  ten	  times	  the	  library	  diversity	  (i.e.	  more	  than	  1.2	  x	  106).	  In	  the	  next	  
chapter,	  the	  screening	  of	  this	  EL4	  library	  with	  T	  reporter	  cells	  carrying	  TCRs	  found	  in	  
brains	  of	  mice	  during	  ECM	  will	  be	  described.	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With	  the	  construction	  of	  the	  PbA	  cDNA	  library	  described	  in	  the	  first	  chapter,	  
a	  method	  to	  screen	  the	  library	  for	  epitopes	  recognized	  by	  CD8+	  T	  cells	  during	  ECM	  is	  
needed.	  As	  described	  in	  chapter	  1,	  Professor	  Nilabh	  Shastri	  created	  the	  fusion	  
partner	  cell	  BWZ.36	  that	  expresses	  an	  NFAT-­‐LacZ	  cassette	  and	  can	  fuse	  with	  murine	  
T	  cells.	  The	  resulting	  hybridoma	  then	  expressed	  LacZ	  when	  its	  TCR	  binds	  to	  cognate	  
pMHC.	  Dr	  Howland	  in	  the	  lab	  experienced	  a	  low	  success	  rate	  of	  hybridoma	  
formation	  with	  CD8+	  T	  cells	  from	  PbA-­‐infected	  mouse	  brains	  and	  thus	  developed	  an	  
alternative	  approach.	  She	  sorted	  brain-­‐sequestered	  CD8+	  T	  cells	  from	  mice	  
succumbing	  to	  ECM	  and	  performed	  single	  cell	  sequencing	  of	  the	  TCRαβ	  chains	  so	  as	  
to	  identify	  pairs	  that	  appeared	  multiple	  times	  (131,	  132),	  indicating	  that	  they	  were	  
from	  parasite-­‐specific	  CD8+	  T	  cells	  that	  experienced	  clonal	  expansion	  (table	  7).	  A	  
BWX.36	  hybridoma	  that	  had	  lost	  TCR	  expression	  (termed	  LR-­‐null	  T	  reporter	  cells)	  
was	  selected	  as	  the	  host	  for	  transducing	  these	  TCRs	  in	  preparation	  for	  screening	  with	  
the	  EL4	  PbA	  cDNA	  library	  described	  in	  chapter	  1.	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Table	  7:	  TCRαβ	  pairs	  from	  brain-­‐sequestered	  CD8+	  T	  cells	  in	  mice	  with	  ECM	  were	  
isolated,	  sequenced	  and	  analyzed	  with	  IMGT/V-­‐QUEST.	  Pairs	  shown	  in	  this	  table	  
were	  found	  to	  be	  over-­‐represented	  were	  selected	  for	  transduction	  into	  LR-­‐null	  T	  
reporter	  cells.	  Adapted	  with	  permission	  from	  Dr	  Shanshan	  Howland.	  
Clone	   TRAV	   TRAJ	   TCRα	  Junction	   TRBV	   TRBD	   TRBJ	   TCRβ	  Junction	  
6.2	   16D	   57	   CAMSPQGGSAKLIF	   13-­‐3	   2-­‐5	   2	   CASSDWGNQDTQYF	  
8.4	   4D-­‐4	   52	   CAAEANTGANTGKLTF	   13-­‐3	   2-­‐1	   2	   CASSDWGAGAEQFF	  
10C6	   4-­‐2	   16	   CAVDPTSSGQKLVF	   13-­‐3	   2-­‐5	   1	   CASSPGQGTDTQYF	  
10C11	   6-­‐7	   50	   CALSDRSSSFSKLVF	   16	   1-­‐1	   1	   CASSSGTGNTEVFF	  
13.6	   9N-­‐2	   44	   CVLSRVGSGGKLTL	   12-­‐2	   1-­‐1	   1	   CASSLRGRDTEVFF	  
13.10	   7-­‐5	  or	  
7D-­‐5	  
23	   CAVSGYNQGKLIF	   26	   2-­‐1	   2	   CASSLGGRAEQFF	  
13.24	   12D-­‐3	  or	  
12N-­‐3	  
43	   CALRNNNNAPRF	   12-­‐1	   2-­‐3	   1	   CASSLPGGLETLYF	  
13.44	   7-­‐3	   40	   CAVIFTGNYKYVF	   3	   2-­‐5	   1	   CASSLGDTQYF	  
	  
The	  principle	  behind	  the	  epitope	  discovery	  screen	  is	  to	  divide	  the	  EL4	  PbA	  
cDNA	  library	  into	  many	  pools	  containing	  a	  limited	  number	  of	  clones,	  and	  each	  pool	  is	  
amplified	  and	  incubated	  overnight	  with	  a	  T	  reporter	  cell	  line	  in	  a	  96-­‐well	  plate.	  An	  
EL4	  clone	  containing	  a	  PbA	  cDNA	  fragment	  encoding	  the	  T	  reporter	  cell	  line’s	  
cognate	  epitope	  will	  present	  this	  peptide	  on	  its	  MHC	  class	  I	  molecules.	  This	  triggers	  
TCR	  ligation	  on	  nearby	  T	  reporter	  cells,	  leading	  to	  NFAT	  signaling	  and	  transcription	  
and	  translation	  of	  LacZ.	  These	  reporter	  cells	  are	  detected	  as	  blue	  spots	  when	  X-­‐gal	  
staining	  is	  performed.	  Allowing	  the	  pool	  or	  pools	  containing	  the	  target	  clone	  to	  be	  
identified.	  From	  this,	  the	  positive	  pool	  can	  be	  cloned	  for	  a	  second	  round	  of	  
screening,	  to	  isolate	  the	  incriminating	  EL4	  clone.	  The	  PbA	  cDNA	  fragment	  in	  the	  EL4	  
clone	  can	  be	  sequenced	  and	  identified	  by	  comparison	  with	  the	  published	  PbA	  
genome.	  	  
	  
To	  further	  narrow	  down	  the	  corresponding	  epitope	  that	  is	  recognized	  by	  the	  
cognate	  TCR,	  the	  PbA	  cDNA	  fragment	  can	  be	  analyzed	  with	  an	  epitope	  prediction	  
tool	  (121)	  to	  select	  candidate	  peptides	  for	  synthesizing	  pMHC	  tetramers.	  The	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traditional	  method	  of	  pMHC	  tetramer	  synthesis	  requires	  refolding	  of	  recombinant	  
MHC	  monomers	  in	  the	  presence	  of	  each	  peptide,	  a	  slow	  and	  laborious	  process	  that	  
cannot	  be	  multiplexed.	  Here,	  we	  take	  advantage	  of	  a	  UV-­‐mediated	  peptide	  exchange	  
strategy	  to	  quickly	  prepare	  multiple	  pMHC	  tetramers	  (121,	  178).	  Biotinylated	  MHC	  
class	  I	  heavy	  and	  light	  chains	  are	  first	  refolded	  with	  a	  photolabile	  peptide	  containing	  
a	  3-­‐amino-­‐3-­‐(2-­‐nitro)phenyl-­‐propanoic	  acid	  (Anp)	  residue.	  Small	  aliquots	  can	  then	  be	  
tetramerized	  with	  fluorescent	  streptavidin	  and	  UV-­‐irradiated	  in	  the	  presence	  of	  the	  
desired	  peptide.	  The	  Anp-­‐containing	  photolabile	  peptide	  cleaves	  and	  dissociates	  
from	  the	  MHC	  molecule	  to	  be	  replaced	  by	  the	  desired	  peptide.	  The	  candidate	  pMHC	  
tetramers	  are	  then	  screened	  for	  the	  ability	  to	  label	  the	  T	  reporter	  cell	  line.	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All	  peptides	  were	  synthesized	  and	  purchased	  from	  Genscript	  (Piscataway,	  
NJ),	  and	  were	  redissolved	  in	  100%	  dimethyl	  sulfoxide	  (Sigma-­‐Aldrich)	  at	  10	  or	  100	  
mg/mL.	  Peptides	  were	  diluted	  in	  RPMI	  complete	  media	  or	  PBS,	  whichever	  
applicable,	  to	  the	  desired	  concentrations	  prior	  to	  use	  in	  subsequent	  experiments.	  
	  
PbA	  cDNA	  library	  screening	  and	  identification	  of	  positive	  clones	  
	  
EL4	  cells	  containing	  transduced	  PbA	  cDNA	  inserts	  were	  cultured	  in	  96-­‐well	  
tissue-­‐culture	  plates	  in	  RPMI	  complete	  media	  at	  37˚C,	  5%	  CO2	  at	  initial	  density	  of	  250	  
cells	  per	  well.	  In	  separate	  96-­‐well	  filter	  plates	  (Pall	  8029,	  Pall	  Corportation,	  Port	  
Washington,	  NY),	  3	  x	  104	  of	  these	  cells	  per	  well	  were	  incubated	  together	  with	  equal	  
numbers	  of	  T	  reporter	  cell	  lines,	  LR-­‐BSL8.4a	  or	  LR-­‐BSL13.6b.	  Plates	  were	  drained	  the	  
next	  day	  by	  centrifugation	  and	  stained	  for	  LacZ	  activity	  with	  β-­‐gal	  staining	  kit	  (Life	  
Technologies).	  Blue	  spots	  were	  counted	  and	  analyzed	  on	  CTL	  Immunospot	  Analyzer.	  
The	  pools	  from	  which	  the	  positive	  wells	  were	  derived	  were	  sorted	  by	  FACS	  into	  
single	  cells	  in	  fresh	  96-­‐well	  tissue	  culture	  plates,	  grown	  up	  and	  re-­‐screened	  against	  
the	  T	  reporter	  cell	  lines	  again	  to	  identify	  positive	  clones.	  
	  
	   	  
	   59	  
Identification	  of	  positive	  PbA	  cDNA	  inserts	  
	  
Positive	  EL4	  clones	  were	  processed	  with	  DNeasy	  blood	  and	  Tissue	  kit	  
(QIAgen)	  to	  obtain	  purified	  genomic	  DNA.	  PbA	  cDNA	  inserts	  were	  amplified	  with	  the	  
primers	  T2AFor	  and	  WPRErev	  by	  PCR	  with	  Phusion	  II	  DNA	  polymerase	  and	  analyzed	  
on	  1%	  TAE	  gel.	  Where	  necessary,	  bands	  were	  excised	  from	  gels	  and	  purified	  with	  
QIAquick	  MinElute	  Gel	  Extraction	  kit	  (QIAgen),	  cloned	  into	  pCR®4-­‐TOPO®	  vector	  (Life	  
Technologies)	  and	  transformed	  into	  OneShot®TOP10	  competent	  cells	  (Life	  
Technologies).	  Sequencing	  of	  PbA	  cDNA	  inserts	  were	  outsourced	  to	  a	  commercial	  
company	  (AITBiotech,	  Singapore),	  with	  the	  primers	  M13F	  and	  T2AFor	  used	  for	  
inserts	  in	  TOPO	  vectors	  and	  EL4	  genomic	  DNA,	  respectively.	  Amino	  acid	  sequences	  
were	  analyzed	  and	  identified	  by	  performing	  an	  alignment	  search	  (BLAST	  –	  Basic	  Local	  
Alignment	  Search	  Tool)	  with	  the	  PlasmoDB	  database	  (http://plasmodb.org/plasmo/).	  
	  
Peptide-­‐MHC	  tetramer	  generation	  
	  
The	  production	  of	  recombinant	  caged	  MHC	  class	  I	  molecules	  were	  detailed	  
elsewhere	  (119,	  121,	  179).	  In	  brief,	  H-­‐2Kb	  or	  Db	  heavy	  chains	  with	  a	  biotinylation	  tag	  
at	  the	  C	  terminus	  (180)	  were	  refolded	  with	  β2m	  light	  chains	  and	  a	  photocleavable	  
peptide	  FAPGNY-­‐J-­‐AL,	  where	  J	  is	  3-­‐amiino-­‐3-­‐(2-­‐nitro)phenyl-­‐propanoic	  acid.	  Refolded	  
monomers	  were	  biotinylated,	  purified	  by	  size	  exclusion	  chromatography	  and	  mixed	  
with	  streptavidin	  R-­‐Phycoerythin	  conjugate	  (Molecular	  Probes,	  Life	  Technologies)	  or	  
streptavidin	  Brilliant	  Violet	  421	  (Biolegend,	  San	  Diego,	  CA)	  at	  4:1	  molar	  ratio	  
respectively.	  For	  peptide	  exchange,	  desired	  epitopes	  were	  added	  to	  the	  tetramers	  in	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vast	  excess	  and	  irradiated	  with	  365	  nm	  UV	  (UVP,	  Upland,	  CA)	  on	  ice	  for	  15	  min.	  




To	  identify	  the	  cognate	  epitopes,	  the	  peptide	  sequences	  obtained	  from	  
sequencing	  positive	  EL4	  clones	  were	  analyzed	  in	  silico	  for	  potential	  H-­‐2Kb	  and	  H-­‐2Db	  
epitopes	  (121),	  and	  the	  top	  3	  or	  5	  candidates	  for	  each	  category	  were	  synthesized.	  PE	  
tetramers	  were	  generated	  as	  described	  earlier.	  T	  reporter	  cell	  lines	  were	  stained	  
with	  LIVE/DEAD®	  Fixable	  Far	  Red	  stain	  (Life	  Technologies)	  at	  1:1000	  dilution	  in	  PBS	  
for	  30	  min	  at	  room	  temperature,	  followed	  by	  staining	  with	  PE	  tetramer	  of	  different	  
epitopes	  in	  separate	  tubes	  in	  FACs	  buffer,	  on	  ice	  for	  45	  min.	  Cells	  were	  washed	  with	  
FACs	  buffer,	  fixed	  with	  1%	  formaldehyde	  and	  analyzed	  by	  flow	  cytometry.	  
	  
Validation	  of	  malaria	  epitopes	  reported	  by	  others	  –	  Tetramer	  staining	  
	  
Five	  malaria	  epitopes	  reported	  by	  Lau	  et	  al	  (130)	  were	  synthesized	  and	  used	  
to	  generate	  PE	  tetramers	  as	  described	  above.	  5	  x	  106	  naïve	  or	  PbA-­‐infected	  
splenocytes	  were	  stained	  with	  LIVE/DEAD®	  Fixable	  Aqua	  stain	  (Life	  Technologies),	  
followed	  by	  desired	  PE	  tetramers	  as	  described	  above	  for	  15	  min	  on	  ice	  in	  the	  dark.	  
Anti-­‐mouse	  CD8a	  PerCP-­‐Cy5.5	  (clone	  53-­‐6.7,	  Biolegend)	  and	  anti-­‐mouse	  CD16/32	  
APC-­‐Cy7	  (clone	  93,	  Biolegend)	  were	  used	  to	  stain	  cells	  for	  an	  additional	  30	  min	  on	  
ice,	  away	  from	  light.	  Cells	  were	  washed,	  fixed	  as	  described	  before,	  and	  analyzed	  by	  
flow	  cytometry.	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Validation	  of	  malaria	  epitopes	  reported	  by	  others	  –	  IFNγ-­‐Enzyme-­‐linked	  Immunospot	  
(ELISpot)	  assay	  
	  
Anti-­‐mouse	  IFNγ	  (clone	  AN18;	  Mabtech,	  Nacka	  Strand,	  Sweden)	  were	  used	  to	  
coat	  96-­‐well	  MultiScreen	  HTS	  plates	  (MSIPS4510;	  Millipore,	  Billerica,	  MA)	  at	  750	  
ng/well,	  overnight	  at	  4˚C.	  Wells	  were	  washed	  thoroughly	  with	  H2O	  and	  blocked	  with	  
RPMI	  complete	  medium	  for	  at	  least	  2	  hours	  at	  37˚C,	  5%	  CO2	  until	  ready	  to	  use.	  
Splenocytes	  from	  infected	  mice	  were	  processed	  with	  CD8a	  T	  cell	  isolation	  kit	  II	  and	  
AutoMACS	  Pro	  Separator	  (both	  from	  Miltenyi	  Biotec,	  Auburn,	  CA).	  The	  isolated	  CD8+	  
T	  cells	  were	  left	  standing	  at	  room	  temperature	  for	  2	  hours	  to	  minimize	  background	  
staining.	  For	  each	  well,	  2.5	  x	  105	  naïve	  splenocytes	  and	  5	  x	  104	  isolated	  CD8+	  T	  cells	  
were	  incubated	  together	  with	  12	  U	  recombinant	  interleukin-­‐2	  (eBioscience,	  San	  
Diego,	  CA)	  and	  4	  µg	  peptides	  at	  37˚C,	  5%	  CO2	  overnight,	  after	  which	  cells	  were	  
discarded	  the	  following	  day.	  Wells	  were	  washed	  thoroughly	  with	  wash	  buffer	  (PBS	  +	  
0.05%	  Tween	  20	  [Sigma-­‐Aldrich])	  incubated	  with	  20	  ng/well	  biotinylated	  anti-­‐mouse	  
IFNγ	  (clone	  R4-­‐6A2,	  Mabtech)	  at	  37˚C	  for	  2	  hours,	  washed	  again,	  and	  incubated	  with	  
300	  ng/well	  ExtrAvidin-­‐alkaline	  phosphatase	  (Sigma-­‐Aldrich)	  at	  room	  temperature	  
for	  45	  min.	  After	  discarding	  the	  solution,	  wells	  were	  washed	  and	  developed	  with	  5-­‐
bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  phosphate-­‐nitroblue	  tetrazolium	  chloride	  (BCIP/NBT)	  
substrate	  (Sigma-­‐Aldrich).	  Spots	  were	  quantified	  with	  CTL	  ImmunoSpot	  analyzer.	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RMA/S	  stabilization	  assay	  
	  
RMA/S	  cells	  were	  grown	  in	  RPMI	  complete	  medium	  at	  37˚C,	  5%	  CO2,	  and	  
shifted	  to	  26˚C	  overnight	  one	  day	  prior	  to	  experiment.	  Cells	  (1	  x	  105)	  were	  seeded	  in	  
96-­‐well	  tissue-­‐culture	  plates	  and	  pulsed	  with	  varying	  concentrations	  of	  peptides	  
tested	  at	  26˚C	  for	  1	  hour,	  then	  moved	  back	  to	  37˚C	  for	  the	  same	  duration.	  Excess	  
peptides	  were	  washed	  and	  anti-­‐mouse	  H-­‐2Kb	  (clone	  AF6-­‐88.5,	  Biolegend)	  or	  anti-­‐
mouse	  H-­‐2Db	  (clone	  KH95,	  Biolegend)	  were	  used	  for	  staining,	  depending	  on	  MHC	  
restrictions	  of	  the	  peptides.	  Cells	  were	  washed,	  fixed	  in	  1%	  formaldehyde	  and	  
analyzed	  by	  flow	  cytometry.	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Results	  
	  
Identification	  of	  EL4	  library	  clones	  recognized	  by	  T	  reporter	  cell	  lines	  
	  
One	  important	  consideration	  for	  the	  screening	  was	  the	  number	  of	  initial	  EL4	  
library	  cell	  clones	  in	  each	  pool.	  Smaller	  pools	  make	  the	  assay	  more	  sensitive	  but	  
increase	  the	  number	  of	  plates	  that	  have	  to	  be	  screened	  to	  have	  a	  reasonable	  chance	  
of	  not	  omitting	  a	  potentially	  positive	  clone.	  Dr	  Howland’s	  prior	  work	  diluting	  OVA-­‐
transduced	  EL4	  cells	  with	  untransduced	  EL4	  cells	  demonstrated	  that	  OVA-­‐specific	  T	  
reporter	  cells	  could	  reliably	  detect	  the	  former	  at	  a	  ratio	  of	  1:243	  but	  only	  weakly	  at	  
1:729.	  Thus,	  the	  pool	  size	  was	  set	  at	  250	  clones.	  The	  workflow	  for	  the	  screening	  is	  
illustrated	  in	  figure	  16,	  where	  250	  EL4	  library	  cells	  were	  seeded	  in	  92	  wells	  of	  a	  96-­‐
well	  tissue	  culture	  plate	  and	  allowed	  to	  grow.	  From	  these	  master	  plates,	  3	  x	  104	  cells	  
per	  well	  were	  seeded	  in	  96-­‐well	  filter	  plates	  and	  incubated	  overnight	  with	  an	  equal	  
number	  of	  T	  reporter	  cells	  to	  be	  screened.	  Filter	  plates	  facilitate	  downstream	  X-­‐gal	  
staining	  by	  allowing	  the	  cells	  to	  be	  washed	  without	  losses	  and	  by	  providing	  a	  white	  
background	  for	  visualizing	  the	  blue	  spots.	  As	  stated	  in	  the	  earlier	  chapter,	  the	  library	  
construction	  yielded	  1.2	  x	  105	  clones	  at	  the	  initial	  stage.	  Assuming	  that	  there	  was	  a	  
clone	  that	  carried	  a	  cognate	  epitope,	  the	  probability	  of	  it	  being	  absent	  in	  the	  screen	  
would	  be	  (1	  –	  [1/1.2	  x	  105])n,	  where	  n	  is	  the	  number	  of	  cells	  to	  be	  screened.	  A	  
starting	  point	  of	  eleven	  96-­‐well	  plates	  (with	  the	  four	  corners	  omitted	  for	  negative	  
and	  positive	  controls	  for	  X-­‐gal	  staining),	  amounting	  to	  2.53	  x	  104	  EL4	  library	  cells	  was	  
chosen	  to	  be	  screened,	  corresponding	  to	  an	  11.8%	  probability	  that	  a	  particular	  clone	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would	  be	  missing.	  Eleven	  to	  sixteen	  plates	  of	  EL4	  library	  clones	  were	  screened	  for	  
each	  T	  reporter	  cell	  line.	  	  
	  
A	  histogram	  of	  the	  number	  of	  blue	  spots	  per	  well	  for	  screening	  the	  LR-­‐
BSL8.4a	  T	  reporter	  cell	  line	  against	  eleven	  96-­‐well	  plates	  of	  EL4	  PbA	  cDNA	  library	  
cells	  is	  shown	  in	  figure	  17.	  The	  vast	  majority	  (95%)	  of	  the	  wells	  contained	  between	  0	  
to	  6	  blue	  spots,	  which	  probably	  was	  due	  to	  the	  background	  expression	  of	  LacZ	  in	  the	  
absence	  of	  TCR	  activation.	  The	  well	  with	  the	  highest	  number	  of	  blue	  spots	  had	  22	  
spots,	  well	  above	  this	  
Figure	  16.	  Schematic	  of	  X-­‐gal	  screening	  of	  T	  reporter	  cell	  lines	  against	  EL4	  PbA	  
cDNA	  library	  cells.	  For	  internal	  positive	  and	  negative	  controls,	  equal	  numbers	  (3	  
x	  104)	  of	  T	  reporter	  cells	  and	  EL4	  cells	  were	  mixed	  in	  the	  remaining	  4	  wells	  per	  
plate,	  with	  3	  x	  104	  Dynabeads	  T-­‐activator	  CD3/CD28	  added	  to	  2	  of	  the	  wells	  per	  
plate.	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Figure	  17.	  Graph	  of	  number	  of	  blue	  spots	  per	  well	  against	  frequency	  of	  wells	  
during	  screening	  of	  LR-­‐BSL8.4a	  T	  reporter	  cells	  against	  EL4	  PbA	  cDNA	  library.	  
The	  number	  of	  blue	  spots	  and	  the	  frequency	  of	  wells	  with	  the	  corresponding	  
number	  of	  blue	  spots	  from	  1012	  wells	  were	  plotted	  (left	  Y-­‐axis)	  together	  with	  
the	  cumulative	  frequency	  on	  the	  right	  Y-­‐axis.	  The	  dotted	  line	  indicates	  the	  
cutoff	  where	  the	  top	  5%	  of	  wells	  with	  the	  most	  number	  of	  blue	  spots.	  
	  
Figure	  18.	  Identification	  of	  first	  antigen	  recognized	  by	  brain-­‐sequestered	  CD8+	  
T	  cells	  -­‐	  PbGAP50.	  The	  T	  reporter	  cell	  line	  LR-­‐BSL8.4a	  was	  incubated	  in	  1:1	  ratio	  
with	  EL4	  PbAcDNA	  library	  cells	  overnight.	  β-­‐gal	  staining	  was	  performed	  on	  the	  
cells	  the	  following	  day.	  (A)	  An	  image	  of	  a	  representative	  negative	  well.	  (B)	  The	  
image	  of	  the	  well	  with	  a	  sub-­‐library	  that	  contains	  GAP50	  fragment.	  The	  inset	  
shows	  blue	  spots	  that	  result	  from	  LacZ	  activation	  by	  LR-­‐BSL8.4a.	  (C)	  An	  image	  of	  
a	  well	  where	  single	  clones	  from	  (B)	  were	  sorted,	  grown	  and	  re-­‐incubated	  with	  
LR-­‐BSL8.4a.	  
	  
	  background.	  Wells	  of	  EL4	  PbA	  cDNA	  library	  cells	  corresponding	  to	  the	  top	  5%	  of	  blue	  
spots	  were	  subjected	  to	  repeat	  screenings.	  If	  the	  results	  remained	  consistently	  
positive,	  corresponding	  pools	  in	  the	  master	  plate	  would	  be	  expanded,	  sorted	  by	  




Figure	  19.	  Identification	  of	  second	  antigen	  recognized	  by	  brain-­‐sequestered	  
CD8+	  T	  cells	  –	  bergheilysin.	  The	  T	  reporter	  cell	  line	  LR-­‐BSL13.6b	  was	  treated	  as	  
described	  in	  Figure	  18.	  (A)	  A	  representative	  negative	  well.	  (B)	  A	  well	  with	  a	  sub-­‐
library	  that	  express	  bergheilysin	  gene	  fragment.	  Arrowheads	  in	  inset	  point	  to	  
faint	  positive	  blue	  spots.	  (C)	  A	  well	  where	  single	  clones	  from	  (B)	  were	  sorted,	  
grown	  and	  re-­‐screened	  with	  LR-­‐BSL13.6b.	  (D)	  The	  PbA	  cDNA	  gene	  fragment	  
from	  (C),	  which	  was	  found	  to	  be	  expressed	  out-­‐of-­‐frame,	  was	  corrected,	  
transduced	  into	  EL4	  cells	  and	  re-­‐screened	  with	  LR-­‐BSL13.6b	  cells.	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Out	  of	  eight	  T	  reporter	  cell	  lines,	  only	  two	  T	  reporter	  cell	  lines,	  LR-­‐BSL8.4a	  
(figure	  18)	  and	  LR-­‐BSL13.6b	  (figure	  19),	  elicited	  a	  consistently	  positive	  well	  during	  
the	  initial	  screens	  (figure	  18B	  and	  19B).	  These	  positive	  EL4	  library	  pools	  were	  cloned	  
and	  screened,	  leading	  to	  the	  identification	  of	  the	  positive	  clones	  shown	  in	  figures	  
18C	  and	  19C.	  The	  clone	  recognized	  by	  LR-­‐BSL8.4a	  gave	  a	  very	  convincing	  result	  with	  
deep,	  intense	  blue	  spots	  throughout	  the	  well.	  The	  clone	  recognized	  by	  LR-­‐BSL13.6b	  
showed	  fewer	  blue	  spots,	  but	  was	  clearly	  reproducible	  and	  far	  higher	  than	  the	  
background.	  
	  
Identification	  of	  positive	  PbA	  antigens	  and	  epitopes	  
	  
The	  EL4	  library	  clones	  that	  responded	  to	  T	  reporter	  cell	  lines	  LR-­‐BSL8.4a	  and	  
LR-­‐BSL13.6b	  were	  processed	  to	  harvest	  their	  gDNA.	  The	  region	  that	  contained	  the	  
transduced	  parasite	  genetic	  material	  was	  amplified	  by	  PCR	  with	  flanking	  primers	  and	  
analyzed	  by	  gel	  electrophoresis.	  In	  the	  EL4	  clone	  that	  triggered	  LR-­‐BSL8.4a,	  4	  
amplicons	  of	  different	  sizes	  were	  observed	  (figure	  20A),	  suggesting	  multiple	  
transduction	  events.	  The	  clone	  that	  elicited	  response	  in	  LR-­‐BSL13.6b	  only	  had	  one	  
amplicon	  (figure	  20B).	  Each	  amplicon	  was	  then	  gel-­‐extracted,	  cloned	  into	  
pCR®TOPO®	  vector	  and	  sequenced.	  Of	  the	  4	  PCR	  products	  in	  figure	  20A,	  only	  the	  
second	  band	  from	  the	  bottom	  contained	  a	  positive	  PbA	  gene	  fragment	  in	  frame:	  
glideosome-­‐associated	  protein	  50	  (GAP50,	  PlasmoDB	  gene	  ID:	  081900).	  To	  confirm	  
that	  this	  fragment	  was	  responsible,	  it	  was	  then	  cloned	  into	  pScrAn-­‐Acc	  and	  
transduced	  into	  EL4	  cells,	  giving	  a	  positive	  response	  when	  incubated	  with	  LR-­‐
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BSL8.4a	  cells.	  Sequencing	  of	  the	  lone	  gene	  fragment	  obtained	  from	  figure	  20B	  
identified	  bergheilysin	  (PlasmoDB	  gene	  ID:	  PBANKA_113700),	  but	  cloned	  in	  the	  +2	  
reading	  frame.	  This	  could	  explain	  why	  relatively	  few	  blue	  spots	  were	  present	  in	  
figure	  19C,	  as	  these	  spots	  were	  likely	  to	  be	  the	  result	  of	  baseline	  translation	  of	  
mRNA	  transcripts	  in	  the	  wrong	  frame	  (181,	  182).	  This	  gene	  fragment	  was	  re-­‐cloned	  
back	  into	  the	  correct	  frame	  by	  a	  deletion	  of	  one	  nucleotide	  at	  the	  start	  of	  the	  gene	  
fragment,	  transduced	  into	  EL4	  cells	  and	  screened	  against	  LR-­‐BSL13.6b.	  This	  yielded	  
more	  blue	  spots	  (figure	  19D),	  confirming	  that	  bergheilysin	  contains	  the	  cognate	  
epitope	  for	  LR-­‐BSL13.6b.	  The	  amino	  acid	  sequences	  of	  the	  GAP50	  and	  bergheilysin	  
fragments	  are	  shown	  in	  table	  8.	  
	  
Figure	  20.	  Identification	  of	  PbA	  cDNA	  gene	  fragments	  in	  EL4	  clones	  that	  
triggered	  LacZ	  response	  from	  T	  reporter	  cell	  lines.	  Genomic	  DNA	  from	  EL4	  
clones	  that	  elicited	  LacZ	  response	  in	  (A)	  LR-­‐BSL8.4a	  and	  (B)	  LR-­‐BSL13.6b	  T	  
reporter	  cell	  lines	  were	  purified,	  the	  PbA	  cDNA	  inserts	  amplified	  by	  PCR	  and	  
analyzed	  by	  gel	  electrophoresis.	  GeneRuler	  1kb	  DNA	  ladder	  was	  used	  in	  both	  
experiments.	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Table	  8:	  	  Gene	  fragment	  sequences	  of	  GAP50	  and	  bergheilysin	  that	  was	  identified	  
from	  figures	  18	  and	  19.	  
Gene	  fragment	   Sequence	  
Glideosome-­‐associated	  










To	  go	  further	  and	  identify	  the	  epitopes	  that	  elicited	  the	  LacZ	  activity,	  the	  
amino	  acid	  sequences	  in	  table	  8	  were	  analyzed	  with	  a	  computer	  algorithm	  (121)	  to	  
predict	  potential	  H-­‐2Kb	  and	  Db	  epitopes.	  Four	  different	  categories	  were	  predicted:	  H-­‐
2Kb	  MHC	  class	  I	  molecules	  bound	  with	  peptides	  of	  8	  and	  9	  amino	  acids	  long;	  and	  H-­‐
2Db	  MHC	  class	  I	  molecules	  bound	  with	  9-­‐	  and	  10-­‐mer	  peptides.	  The	  highest-­‐ranked	  
epitopes	  in	  each	  category	  were	  chosen	  (tables	  9	  and	  10)	  and	  synthesized.	  Each	  
Figure	  21.	  Identification	  of	  cognate	  epitopes	  SQLLNAKYL	  (Pb1)	  and	  IITDFENL	  
(Pb2)	  in	  GAP50	  and	  bergheilysin,	  respectively.	  Peptide-­‐MHC	  PE	  tetramers	  were	  
generated	  with	  predicted	  epitopes	  in	  tables	  9	  and	  10,	  and	  used	  to	  stain	  
corresponding	  T	  reporter	  cell	  lines.	  LR-­‐BSL8.4a	  and	  LR-­‐BSL3.6b	  were	  stained	  
positively	  by	  (A)	  H-­‐2Db-­‐SQLLNAKYL	  and	  (B)	  H-­‐2Kb-­‐IITDFENL,	  respectively	  (open	  
histograms).	  Grey,	  filled	  histograms	  are	  representatives	  of	  negative	  tetramer	  
stainings.	  
	   70	  
peptide	  was	  used	  to	  synthesize	  fluorescent	  pMHC	  tetramers	  by	  the	  photocleavable	  
peptide	  exchange	  strategy	  described	  earlier.	  These	  were	  then	  used	  to	  stain	  
corresponding	  T	  reporter	  cells	  to	  reveal	  the	  cognate	  epitope.	  For	  GAP50,	  the	  cognate	  
epitope	  is	  SQLLNAKYL	  (figure	  21A),	  spanning	  position	  38	  to	  46	  of	  the	  protein	  and	  is	  
H-­‐2Db-­‐restricted.	  For	  bergheilysin,	  it	  is	  H-­‐2Kb-­‐restrcted	  IITDFENL	  (figure	  21B),	  from	  
position	  592	  to	  599	  of	  the	  protein.	  Henceforth,	  these	  two	  novel	  epitopes	  will	  be	  
referred	  to	  as	  Pb1	  (SQLLNAKYL)	  and	  Pb2	  (IITDFENL).	  
	  
Table	  9:	  List	  of	  top-­‐ranked	  MHC	  class	  I-­‐binding	  candidate	  epitopes	  predicted	  from	  
GAP50	  in	  table	  8.	  
MHC	  restriction	   Peptide	  length	   Sequence	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Table	  10:	  List	  of	  top-­‐ranked	  MHC	  class	  I-­‐binding	  candidate	  epitopes	  predicted	  from	  
bergheilysin	  in	  table	  8.	  
MHC	  restriction	   Peptide	  length	   Sequence	  

















Analysis	  of	  other	  malaria	  CD8+	  T	  cell	  epitopes	  reported	  in	  the	  literature	  
	  
Partway	  through	  this	  project,	  Lau	  and	  colleagues	  took	  PbA	  proteins	  
expressed	  in	  the	  schizont	  stage	  and	  predicted	  H-­‐2Kb-­‐restricted	  peptides	  with	  
SYFPEITHI,	  an	  online	  MHC	  prediction	  tool.	  Out	  of	  the	  125	  candidates	  predicted,	  they	  
found	  5	  epitopes	  that	  were	  recognized	  by	  CD8+	  T	  cells	  in	  PbA-­‐infected	  mice.	  The	  
assays	  they	  used	  were	  intracellular	  IFNγ	  staining	  of	  peptide-­‐stimulated	  splenic	  CD8+	  
T	  cells	  from	  PbA-­‐infected	  mice,	  and	  for	  confirmation,	  cytolytic	  activity	  against	  
peptide-­‐pulsed	  donor	  cells	  in	  vivo	  (130).	  The	  sequence	  of	  these	  epitopes	  and	  the	  
antigens	  they	  came	  from	  are	  tabulated	  in	  table	  11.	  The	  authors	  reported	  that	  they	  
could	  not	  make	  tetramers	  for	  their	  epitopes	  to	  track	  the	  specific	  CD8+	  T	  cells	  in	  vivo	  
during	  infection.	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Table	  11:	  List	  of	  5	  H-­‐2Kb-­‐restricted	  PbA	  epitopes	  that	  were	  reported	  by	  Lau	  and	  
colleagues	  (130).	  
Epitope	   Sequence	   Antigen	   PlasmoDB	  Gene	  ID	  
A6	   LSGRYNDL	   Hypothetical	  protein	   PBANKA_133730	  
D5	   WGDEFEKL	   ribonucleoside-­‐diphosphate	  reductase,	  large	  
subunit	  
PBANKA_061160	  
F4	   EIYIFTNI	   replication	  factor	  A1,	  small	  fragment	   PBANKA_041660	  
F6	   LLPHFSIL	   replication	  factor	  C	  subunit	  1,	  putative	   PBANKA_031600	  






Figure	  22.	  Validation	  of	  5	  H-­‐
2Kb-­‐restricted	  PbA	  epitopes	  
reported	  in	  the	  literature.	  (A)	  
The	  previously	  reported	  
malaria	  epitopes	  A6,	  D5,	  F4,	  
F6	  and	  G4	  were	  used	  to	  
stimulate	  CD8+	  T	  cells	  isolated	  
from	  PbA-­‐infected	  
splenocytes,	  followed	  by	  IFNγ-­‐
ELISpot	  assay.	  They	  were	  also	  
used	  to	  synthesize	  PE	  
tetramers	  and	  stain	  PbA-­‐
infected	  splenocytes.	  Live	  
CD8+	  CD16/32+	  cells	  were	  
gated	  for	  tetramer-­‐specific	  
CD8+	  T	  cells	  as	  shown	  in	  (B).	  
The	  numbers	  of	  specific	  CD8+	  
T	  cells	  positive	  for	  PE	  tetramer	  
staining	  are	  shown	  in	  (C).	  The	  
naïve	  data	  is	  a	  representative	  
result	  of	  naïve	  splenocytes	  
stained	  with	  6	  different	  PE	  
tetramers.	  Bars	  in	  (A)	  and	  (C)	  
represent	  means	  and	  medians	  
respectively.	  *	  p	  <	  0.05,	  ***	  p	  
<	  0.001,	  ****	  p	  <	  0.0001,	  
One-­‐way	  ANOVA	  with	  
Dunnett’s	  post-­‐test.	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To	  validate	  the	  findings,	  CD8+	  T	  cells	  from	  PbA-­‐infected	  splenocytes	  were	  
stimulated	  with	  donor	  splenocytes	  pulsed	  with	  Pb1,	  Pb2	  or	  each	  of	  the	  5	  epitopes	  
and	  assayed	  for	  IFNγ	  production	  by	  IFNγ-­‐ELISpot	  (figure	  22A).	  Pb1	  epitope	  elicited	  
the	  strongest	  response	  out	  of	  the	  tested	  epitopes,	  while	  Pb2	  provoked	  a	  milder	  
response	  that	  is	  still	  significantly	  higher	  than	  the	  background.	  Unexpectedly,	  only	  A6	  
and	  F4	  epitopes	  elicited	  significant	  response	  after	  stimulation,	  whereas	  F6	  and	  G4	  
were	  negative.	  D5	  epitope	  seems	  to	  produce	  some	  IFNγ	  after	  stimulation,	  but	  this	  
did	  not	  attain	  significance.	  Using	  the	  caged	  MHC	  tetramer	  technology,	  H-­‐2Kb	  MHC	  
tetramers	  specific	  for	  each	  of	  the	  5	  epitopes	  were	  also	  created	  and	  used	  to	  stain	  
PbA-­‐infected	  splenocytes.	  The	  latter	  were	  also	  stained	  with	  antibodies	  against	  CD8a	  
and	  Fc	  receptors	  CD16/32,	  so	  that	  CD8+	  T	  cells	  can	  be	  discriminated	  from	  CD8α+	  
dendritic	  cells	  that	  also	  express	  CD16/32.	  Tetramer-­‐positive	  CD8+	  T	  cells	  were	  then	  
analyzed	  from	  total	  CD8+	  T	  cells	  gated	  (figure	  22B).	  Out	  of	  the	  5	  epitopes,	  only	  F4	  
tetramer	  showed	  positive	  staining	  towards	  its	  cognate	  CD8+	  T	  cells,	  while	  the	  rest	  
were	  negative	  for	  staining	  (figure	  22C).	  More	  detailed	  results	  for	  tetramer	  staining	  
for	  Pb1-­‐	  and	  Pb2-­‐specific	  CD8+	  T	  cells	  in	  infected	  mice	  are	  presented	  in	  the	  next	  
chapter.	  
	  
Affinity	  of	  Pb1,	  Pb2	  and	  F4	  epitopes	  to	  their	  corresponding	  MHC	  class	  I	  molecules	  
	  
The	  affinity	  of	  Pb1,	  Pb2	  and	  F4	  malaria	  peptides	  to	  their	  matching	  MHC	  class	  I	  
molecules	  was	  investigated	  by	  RMA/S	  binding	  assay.	  These	  cells	  are	  deficient	  in	  TAP,	  
a	  protein	  essential	  for	  loading	  MHC	  class	  I	  molecules	  with	  cytosolic	  peptides	  
generated	  by	  proteasomes.	  Without	  peptides	  in	  the	  binding	  groove,	  the	  MHC	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complex	  is	  unstable	  and	  dissociates	  rapidly	  at	  normal	  body	  temperature.	  When	  
exposed	  to	  a	  lower	  temperature	  (26˚C),	  expression	  of	  empty	  MHC	  class	  I	  complexes	  
on	  the	  cell	  surface	  became	  possible,	  allowing	  exogenous	  loading	  of	  peptides.	  By	  
bringing	  the	  temperature	  back	  to	  37˚C,	  MHC	  class	  I	  complexes	  bound	  to	  peptides	  of	  
sufficient	  affinity	  will	  stay	  on	  the	  surface,	  available	  for	  detection	  by	  antibody	  
staining.	  In	  this	  way,	  affinity	  of	  epitopes	  to	  the	  MHC	  class	  I	  molecules	  can	  be	  
assessed.	  Pb1	  epitope	  exhibits	  high	  affinity	  to	  H-­‐2Db	  MHC	  class	  I,	  as	  it	  has	  a	  similar	  
binding	  curve	  as	  that	  with	  the	  positive	  control	  influenza	  peptide	  NP366-­‐374	  as	  peptide	  
concentration	  increased	  (figure	  23A).	  The	  H-­‐2Kb	  epitopes	  Pb2	  and	  F4	  share	  similar	  
affinities	  to	  their	  cognate	  MHC	  class	  I	  molecule,	  but	  the	  slower	  rate	  of	  increase	  in	  
mean	  fluorescence	  intensity	  for	  H-­‐2Kb	  staining	  as	  peptide	  concentrations	  increase,	  as	  
compared	  to	  the	  positive	  control	  OVA,	  may	  hint	  that	  these	  2	  peptides	  have	  a	  weaker	  
affinity	  to	  H-­‐2Kb	  MHC	  as	  compared	  to	  the	  strong-­‐binder	  OVA	  (figure	  23B).	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Figure	  23.	  Pb1	  and	  Pb2	  malaria	  epitopes	  have	  good	  affinity	  to	  H-­‐2Db	  and	  H-­‐2Kb	  
MHC	  class	  I	  molecules	  respectively.	  RMA/S	  cells	  were	  pulsed	  with	  increasing	  
concentrations	  of	  corresponding	  peptides	  at	  25˚C,	  stained	  with	  anti-­‐H-­‐2Db	  or	  H-­‐
2Kb	  antibodies	  at	  37˚C	  and	  analyzed	  by	  flow	  cytometry.	  Binding	  curves	  of	  (A)	  Pb1,	  
(B)	  Pb2	  and	  F4	  malaria	  peptides	  to	  corresponding	  MHC	  class	  I	  molecules	  were	  
shown.	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Discussion	  
	  
The	  screening	  of	  the	  EL4	  PbA	  cDNA	  library	  created	  as	  described	  in	  chapter	  1	  
with	  the	  T	  reporter	  cell	  lines	  created	  by	  Dr	  Shanshan	  identified	  two	  positive	  leads.	  
The	  EL4	  library	  clones	  were	  isolated	  and	  PbA	  cDNA	  fragments	  were	  sequenced,	  
leading	  to	  the	  identification	  of	  GAP50	  and	  bergheilysin	  as	  the	  antigens	  that	  induced	  
specific	  CD8+	  T	  cell	  response.	  With	  the	  sequences	  of	  antigen	  fragments	  within	  GAP50	  
and	  bergheilysin	  identified,	  we	  made	  use	  of	  an	  epitope	  prediction	  tool	  developed	  by	  
Sette	  (183)	  and	  refined	  by	  Grotenbreg	  (121)	  to	  find	  putative	  candidates,	  use	  them	  to	  
synthesize	  MHC	  tetramers	  and	  validate	  the	  epitopes.	  In	  our	  study,	  only	  two	  out	  of	  
eight	  T	  reporter	  cell	  lines	  had	  TCRαβ	  pairs	  that	  recognize	  malaria	  epitopes	  in	  the	  
context	  of	  MHC	  class	  I	  molecules.	  It	  is	  unknown	  what	  the	  other	  six	  T	  reporter	  cells	  
recognize.	  Possible	  reasons	  could	  be	  that	  our	  library	  is	  not	  comprehensive	  enough,	  
or	  there	  are	  subtle	  differences	  in	  the	  epitope	  repertoire	  presentation	  between	  EL4	  
cells	  and	  dendritic	  cells	  in	  vivo.	  This	  may	  be	  especially	  so,	  since	  pro-­‐inflammatory	  
cytokines	  such	  as	  IFNg	  that	  is	  produced	  during	  infections	  can	  induce	  the	  formation	  of	  
immunoproteasomes,	  which	  breaks	  down	  and	  generates	  peptides	  with	  slightly	  
different	  repertoire	  as	  compared	  to	  normal	  proteasomes	  (184,	  185).	  	  
	  
GAP50	  and	  bergheilysin	  were	  the	  antigens	  that	  were	  discovered	  in	  this	  study	  
to	  be	  able	  to	  elicit	  CD8+	  T	  cell	  response.	  GAP50	  is	  part	  of	  a	  complex	  of	  proteins	  that	  
form	  the	  glideosome,	  a	  molecular	  motor	  employed	  by	  the	  parasite	  to	  move	  and	  
invade	  erythrocytes	  (20,	  186,	  187).	  Bergheilysin	  is	  the	  P.	  berghei	  orthologue	  of	  
falcilysin,	  an	  enzyme	  with	  dual	  function	  depending	  on	  the	  localization.	  It	  facilitates	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degradation	  of	  hemoglobin	  in	  the	  food	  vacuoles	  of	  parasites	  to	  obtain	  materials	  for	  
growth	  (188-­‐190).	  Elsewhere,	  bergheilysin	  is	  found	  in	  the	  apicoplast,	  where	  it	  is	  
speculated	  to	  degrade	  transit	  peptides,	  probably	  participating	  in	  directing	  protein	  
trafficking	  to	  other	  organelles.	  No	  multi-­‐gene	  families	  exist	  for	  both	  genes,	  and	  given	  
the	  vital	  functions	  they	  perform	  within	  the	  parasite,	  these	  two	  genes	  are	  potential	  
targets	  for	  CD8+-­‐mediated	  immune	  protection	  against	  liver	  stage	  infection.	  In	  
addition,	  the	  shared	  epitope	  sequences	  in	  both	  P.	  berghei,	  P.	  yoelii	  and	  P.	  chabaudi	  
present	  an	  opportunity	  to	  examine	  the	  induction	  and	  characterization	  of	  specific	  
CD8+	  T	  cells	  in	  non-­‐ECM	  and	  other	  mouse	  models.	  This	  is	  shown	  in	  the	  next	  chapter.	  
	  
It	  is	  noted	  that	  our	  analysis	  of	  the	  5	  epitopes	  reported	  by	  Lau	  et	  al	  did	  not	  
corroborate	  with	  their	  results,	  except	  for	  F4	  epitope	  (130).	  This	  could	  be	  due	  to	  the	  
different	  parasite	  clones	  or	  C57BL/6	  strains	  that	  were	  used,	  with	  subtle	  differences	  
that	  could	  have	  affected	  induction	  of	  CD8+	  T	  cell	  repertoire.	  For	  example,	  in	  another	  
mouse	  model	  to	  study	  protective	  immunity	  against	  malaria	  infection,	  infections	  with	  
different	  strains	  of	  P.	  chabaudi	  led	  to	  strain-­‐specific	  protective	  immunity	  that	  
accelerated	  clearance	  of	  homologous	  parasites	  (191).	  Beside	  F4	  epitope,	  we	  were	  
unable	  to	  demonstrate	  that	  CD8+	  T	  cells	  specific	  for	  A6,	  D5,	  F6	  and	  G4	  can	  be	  stained	  
with	  corresponding	  pMHC	  tetramers.	  For	  F6	  and	  G4	  that	  had	  negative	  ELISpot	  
results,	  it	  is	  likely	  that	  no	  specific	  CD8+	  T	  cells	  were	  induced.	  For	  A6	  and	  perhaps	  D5,	  
one	  possible	  explanation	  is	  that	  these	  peptides	  cannot	  bind	  to	  and	  stabilize	  empty	  
MHC	  class	  I	  complexes	  in	  vitro,	  following	  ablation	  of	  the	  caged	  photolabile	  peptide.	  
The	  presence	  of	  chaperones	  in	  vivo	  during	  peptide	  loading	  may	  significantly	  aid	  in	  
the	  loading	  of	  these	  peptides	  into	  MHC	  class	  I	  molecules.	  Another	  reason	  could	  be	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that	  the	  affinity	  of	  the	  peptide-­‐MHC	  interaction	  with	  cognate	  CD8+	  T	  cells	  is	  too	  low	  
to	  allow	  stable	  binding	  with	  MHC	  tetramers	  alone.	  In	  vivo,	  higher	  avidity	  is	  generated	  
by	  multiple	  pMHC-­‐TCR	  interactions	  between	  two	  cell	  surfaces	  stabilized	  with	  
adhesion	  molecules;	  these	  cannot	  be	  replicated	  with	  MHC	  tetramers.	  	  
	  
Despite	  the	  revelation	  that	  CD8+	  T	  cells	  are	  essential	  for	  ECM	  development,	  
studies	  of	  malaria-­‐specific	  CD8+	  T	  cells	  have	  not	  been	  performed	  due	  to	  the	  lack	  of	  
tools	  to	  identify	  these	  cells.	  Lau	  and	  colleagues,	  having	  failed	  to	  generate	  pMHC	  
tetramer,	  can	  only	  show	  that	  the	  5	  malaria	  epitopes	  are	  recognized	  during	  infection.	  
In	  this	  study,	  the	  ability	  to	  synthesize	  desired	  pMHC	  tetramers	  rapidly	  will	  allow	  us	  to	  
track	  antigen-­‐specific	  CD8+	  T	  cells	  during	  malaria	  infection.	  In	  addition,	  the	  T	  
reporter	  cells	  generated	  in	  this	  study	  can	  be	  useful	  in	  quantitating	  the	  presence	  of	  
malaria	  epitopes	  in	  the	  context	  of	  MHC	  class	  I	  molecules,	  potentially	  allowing	  the	  
antigen	  presentation	  in	  the	  organs	  to	  be	  detected	  and	  analyzed.	  These	  will	  be	  
further	  described	  in	  chapter	  3.	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Chapter	  3:	  Characterization	  of	  CD8+	  T	  cells	  recognizing	  novel	  malaria	  epitopes	  in	  




CD8+	  T	  cells	  were	  demonstrated	  to	  be	  the	  effector	  cause	  of	  ECM,	  as	  mice	  
lacking	  these	  cells	  do	  not	  exhibit	  this	  pathology	  (87).	  However,	  how	  this	  is	  achieved	  
is	  not	  fully	  understood	  because	  the	  paucity	  of	  malaria	  epitopes	  recognized	  by	  CD8+	  T	  
cells	  hindered	  further	  studies	  until	  recently.	  We	  described	  in	  the	  previous	  chapter	  
the	  discovery	  of	  two	  novel	  rodent	  malaria	  epitopes	  Pb1	  and	  Pb2,	  their	  corresponding	  
tetramers	  and	  T	  reporter	  cells.	  With	  these,	  we	  set	  out	  to	  track	  parasite-­‐specific	  CD8+	  
T	  cells	  in	  the	  spleens	  and	  brains	  in	  both	  ECM	  and	  non-­‐ECM	  models.	  In	  other	  studies,	  
many	  markers	  have	  been	  reported	  to	  be	  essential	  for	  ECM	  development.	  Of	  these,	  
those	  that	  can	  be	  associated	  to	  CD8+	  T	  cells	  include	  activation	  marker	  LFA-­‐1	  (145,	  
192),	  pro-­‐inflammatory	  cytokine	  IFNγ	  (151),	  granzyme	  B	  (122),	  and	  chemokine	  
receptors	  CCR5	  (134)	  and	  CXCR3	  (136,	  142).	  The	  expression	  of	  these	  markers	  by	  
parasite-­‐specific	  CD8+	  T	  cells	  were	  investigated	  to	  see	  if	  they	  correlate	  with	  earlier	  
findings.	  Through	  this	  characterization,	  we	  seek	  to	  demonstrate	  that	  parasite-­‐
specific	  CD8+	  T	  cells	  cause	  damage	  to	  the	  BBB	  during	  ECM	  development,	  and	  to	  
discover	  the	  mechanistic	  difference	  that	  separates	  PbA	  from	  non-­‐ECM	  causing	  
parasites.	  
	  
To	  gauge	  the	  breadth	  of	  the	  response	  and	  the	  relative	  contribution	  of	  the	  
known	  epitopes,	  and	  to	  investigate	  whether	  this	  could	  be	  a	  therapeutic	  modality,	  we	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took	  the	  approach	  of	  suppressing	  induction	  of	  parasite-­‐specific	  CD8+	  T	  cells	  through	  
high-­‐dose	  peptide	  tolerization,	  which	  has	  been	  used	  in	  a	  number	  of	  studies	  to	  study	  
the	  functions	  of	  specific	  CD8+	  T	  cells	  in	  different	  settings	  (193-­‐196).	  In	  this	  study,	  
mice	  were	  injected	  with	  peptides	  to	  suppress	  specific	  CD8+	  T	  cells	  during	  infection	  to	  
elucidate	  their	  effects	  on	  ECM	  development.	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C57BL/6J	  mice	  from	  6	  to	  8	  weeks	  old	  were	  used	  throughout	  the	  experiments,	  
unless	  otherwise	  stated.	  	  These	  mice	  were	  bred	  under	  specific	  pathogen-­‐free	  
conditions	  in	  the	  Biological	  Resource	  Centre,	  Singapore.	  All	  animal	  experiments	  and	  
procedures	  were	  approved	  by	  the	  Institutional	  Animal	  Care	  And	  Use	  Committee	  and	  
complied	  with	  the	  guidelines	  of	  the	  Agri-­‐Food	  and	  Veterinary	  Authority	  and	  National	  




The	  iRBC	  of	  the	  following	  species	  were	  used	  in	  the	  experiments:	  PbA,	  Py17X	  
(197),	  and	  PbNK65	  (198).	  These	  parasitized	  erythrocytes	  were	  passaged	  by	  i.p	  in	  
C57BL/6J	  mice,	  harvested	  and	  stored	  in	  Alsever’s	  solution	  in	  liquid	  nitrogen.	  	  For	  PbA	  
infection,	  mice	  were	  injected	  i.p.	  with	  0.3	  to	  1.0	  x	  106	  iRBC,	  with	  the	  dose	  adjusted	  
for	  each	  batch	  so	  that	  most	  mice	  develop	  neurological	  signs	  at	  7	  days	  post-­‐infection.	  
For	  Py17X	  and	  PbNK65	  infections,	  106	  iRBC	  were	  injected	  by	  i.p.	  Parasitaemia	  was	  
checked	  by	  examination	  of	  thin	  blood	  smears	  stained	  with	  Giemsa,	  or	  by	  flow	  
cytometry	  (165).	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Leukocyte	  isolation	  
	  
Mice	  were	  anesthetized	  by	  i.p.	  injection	  with	  ketamine/xylazine,	  followed	  by	  
exsanguination	  through	  retro-­‐orbital	  route.	  Brains	  were	  mashed	  in	  40	  µm	  cell	  
strainers	  (BD	  Biosciences,	  San	  Jose,	  CA)	  in	  10	  mL	  PBS	  with	  5	  mg	  collagenase	  type	  IV	  
(Worthington	  Biochemical,	  Lakewood,	  NJ)	  and	  100	  µg	  DNAse	  I	  (Roche,	  Quebec,	  
Canada)	  and	  mixed	  for	  30	  min	  at	  room	  temperature.	  The	  suspension	  was	  filtered	  
through	  the	  strainer	  into	  a	  50	  mL	  Falcon	  tube	  and	  centrifuged	  at	  500	  rpm	  for	  30	  sec	  
to	  pellet	  down	  cell	  debris.	  The	  supernatant	  was	  layered	  carefully	  on	  top	  of	  10	  mL	  
30%	  Percoll	  (Sigma-­‐Aldrich)	  and	  spun	  at	  1942	  g	  for	  10	  min	  without	  brakes.	  
Erythrocytes	  in	  the	  pellet	  were	  lysed	  with	  ACK	  lysis	  buffer	  (155	  mM	  NH4Cl,	  10	  mM	  
KHCO3,	  0.2	  mM	  EDTA,	  all	  chemicals	  from	  Sigma-­‐Aldrich)	  for	  a	  minute	  and	  washed	  
with	  RPMI	  complete	  medium	  supplemented	  with	  10%	  fetal	  bovine	  serum,	  100	  U/mL	  
pemicillin/streptomycin,	  1mM	  sodium	  pyruvate,	  55	  µM	  2-­‐mercaptoethanol	  (all	  from	  
Gibco,	  Life	  Technologies)	  and	  100	  µg/mL	  Primocin	  (Invivogen,	  San	  Diego,	  CA).	  
Spleens	  were	  mashed	  through	  40	  µm	  cell	  strainers	  into	  10	  mL	  RPMI	  complete	  
medium,	  spun	  down	  and	  the	  splenocyte	  pellets	  were	  treated	  with	  ACK	  lysis	  buffer	  as	  




Brain-­‐sequestered	  leukocytes	  (BSL)	  and	  splenocytes	  were	  stained	  with	  
LIVE/DEAD®	  Fixable	  Aqua	  stain	  (Molecular	  Probes)	  at	  1:1000	  dilution	  for	  30	  min	  at	  
room	  temperature,	  followed	  by	  centrifugation	  to	  remove	  supernatant.	  In	  separate	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experiments,	  the	  cells	  were	  added	  with	  H-­‐2Db-­‐Pb1	  PE	  tetramers	  only,	  or	  H-­‐2Kb-­‐Pb2	  
PE	  and	  H-­‐2Kb-­‐F4	  BV421	  tetramers	  (refer	  to	  Materials	  and	  Methods	  in	  chapter	  2	  for	  
tetramer	  synthesis)	  on	  ice	  for	  15	  min,	  away	  from	  light.	  The	  following	  antibodies	  were	  
used	  for	  staining:	  anti-­‐mouse	  CD8α	  BV605,	  PerCP-­‐Cy5.5	  (clone	  53-­‐6.7;	  Biolegend)	  or	  
APC	  (BD	  Biosciences);	  anti-­‐mouse	  CD16/32	  APC-­‐Cy7	  (clone	  93;	  Biolegend);	  anti-­‐
mouse	  CD11a	  FITC	  (clone	  M17/4;	  BD	  Biosciences);	  anti-­‐mouse	  CD183	  PerCP-­‐Cy5.5	  
(clone	  CXCR3-­‐173;	  eBioscience);	  anti-­‐mouse	  CCR5	  APC	  (clone	  MC-­‐68;	  a	  kind	  gift	  from	  
Dr	  Matthias	  Mack,	  University	  of	  Regensburg,	  Germany	  (199),	  conjugated	  with	  Lynx	  
APC	  conjugation	  kit	  from	  AbD	  Serotec,	  Kidlington,	  Oxford,	  United	  Kingdom).	  Cells	  
were	  washed,	  fixed	  with	  1%	  formaldehyde	  and	  acquired	  on	  LSRFortessa	  (BD	  
Biosciences).	  To	  protect	  the	  fluorophores	  against	  degradation	  for	  future	  acquisition	  
in	  some	  cases,	  the	  formaldehyde	  solution	  was	  spun	  down,	  discarded	  and	  replaced	  
with	  FACS	  buffer	  (PBS	  +	  0.5	  mg/mL	  bovine	  serum	  albumin	  [Sigma-­‐Aldrich]	  +	  2	  mM	  
EDTA).	  
	  
Intracellular	  cytokine	  staining	  
	  
BSL	  and	  splenocytes	  were	  incubated	  in	  RPMI	  complete	  medium	  with	  10	  
µg/mL	  Brefeldin	  A	  (eBioscience)	  at	  37˚C	  for	  2	  hours	  before	  proceeding	  with	  tetramer	  
staining.	  After	  fixing	  the	  samples	  in	  1%	  formaldehyde	  overnight	  at	  4˚C,	  cells	  were	  
permeabilized	  with	  0.5%	  (w/v)	  saponin	  (Sigma-­‐Aldrich)	  and	  stained	  with	  anti-­‐mouse	  
IFNγ	  FITC	  (clone	  XMG1.2;	  BD	  Biosciences)	  and	  anti-­‐mouse	  granzyme	  B	  PE-­‐Cy7	  (clone	  
NGZB;	  eBioscience).	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In	  vivo	  cytolysis	  assay	  
	  
Naïve	  splenocytes	  were	  pulsed	  with	  10	  µg/mL	  peptides	  at	  37˚C	  for	  1	  hour,	  
labeled	  with	  0.5	  µM	  carboxyfluorescein	  succinimidyl	  ester	  (CFSE,	  Molecular	  Probes)	  
and	  washed	  thoroughly	  with	  RPMI	  complete	  medium.	  Separately,	  unpulsed	  
splenocytes	  were	  labeled	  with	  5	  µM	  CFSE.	  Equal	  numbers	  of	  pulsed	  and	  unpulsed	  
splenocytes	  were	  mixed	  together	  and	  transferred	  into	  infected	  recipient	  mice	  at	  6	  
days	  post-­‐infection	  intravenously	  (i.v.),	  at	  a	  total	  of	  2	  x	  107	  cells	  per	  mouse.	  Twenty	  
hours	  later,	  recipient	  splenocytes	  were	  isolated,	  stained	  with	  100	  ng/µL	  4’,6-­‐
diamidino-­‐2-­‐phenylindole	  (DAPI,	  Molecular	  Probes)	  and	  CFSE-­‐labeled	  cells	  were	  
quantified	  by	  flow	  cytometry.	  The	  percentage	  of	  specific	  lytic	  activity	  is	  calculated	  as	  
follows:	  {1	  –	  [(CFSEhigh/CFSElow)naïve/(CFSEhigh/CFSElow)infected]}	  x	  100%	  
	  
Brain	  microvessel	  cross-­‐presentation	  assay	  
	  
The	  protocol	  for	  brain	  microvessel	  isolation	  was	  adapted	  from	  elsewhere	  in	  
the	  literature	  (200,	  201).	  Each	  mouse	  was	  anaesthetized,	  exsanguinated	  and	  the	  
brain	  (excluding	  the	  brain	  stem	  and	  meninges)	  was	  chopped	  in	  1	  mL	  RPMI	  complete	  
medium	  with	  a	  scalpel	  blade.	  The	  mixture	  was	  homogenized	  by	  forcing	  through	  a	  23-­‐
gauge	  needle	  5	  times,	  then	  mixed	  with	  an	  equal	  volume	  (approximately	  1.3	  mL)	  of	  
30%	  dextran	  (MW	  ~70,000;	  Sigma-­‐Aldrich)	  in	  PBS	  and	  spun	  at	  10,000	  g	  for	  15	  min	  at	  
4˚C.	  The	  pellet	  was	  resuspended	  in	  PBS,	  passed	  through	  40	  µm	  cell	  strainer	  and	  
backflushed	  with	  2	  mL	  PBS	  into	  a	  6-­‐well	  plate	  to	  collect	  the	  trapped	  brain	  
microvessels.	  Fetal	  bovine	  serum,	  collagenase	  type	  IV	  and	  DNAse	  I	  at	  2%,	  1	  mg/mL	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and	  10	  µg/mL	  respectively,	  were	  added	  to	  the	  microvessels	  and	  the	  mixture	  was	  
shaken	  at	  room	  temperature	  over	  an	  orbital	  shaker	  for	  90	  min.	  Treated	  microvessels	  
were	  topped	  with	  5	  mL	  RPMI	  complete	  medium,	  spun	  down	  at	  500	  g	  for	  5	  min,	  
resuspended	  in	  500	  µL	  RPMI	  complete	  medium	  and	  divided	  into	  5	  wells	  of	  a	  96-­‐well	  
filter	  plate	  (Pall	  8029,	  Pall	  Corportation).	  T	  reporter	  cell	  lines	  (3	  x	  104	  cells	  per	  well)	  
were	  added	  to	  a	  total	  of	  200	  µL/well	  and	  the	  plate	  was	  incubated	  at	  37˚C	  overnight.	  
X-­‐gal	  staining	  was	  performed	  the	  next	  day	  as	  described	  in	  Chapter	  1.	  
	  
Sequencing	  TCRαβ	  sequences	  from	  F4-­‐specific	  CD8+	  T	  cells	  
	  
PbA-­‐infected	  splenocytes	  were	  stained	  with	  tetramers	  and	  antibodies	  as	  
stated	  earlier.	  Single	  cell	  sorting	  was	  performed	  to	  sort	  live	  CD8a+	  CD16/32-­‐	  PE-­‐
tetramer+	  cells	  into	  separate	  PCR	  tubes	  coated	  with	  2	  µL	  of	  lysis	  buffer	  (final	  
concentrations:	  1X	  Superscript	  III	  RT	  First	  Strand	  buffer,	  10	  mM	  DTT,	  0.5	  mM	  dNTP,	  
0.8	  U/µL	  RNaseOUT	  [all	  from	  Life	  Technologies],	  0.25%	  Nonidet	  P-­‐40	  [Roche],	  0.1	  
mg/mL	  BSA	  [New	  England	  Biolabs],	  0.1	  µM	  mTCRaRT,	  0.1	  µM	  mTCRbRT)	  and	  stored	  
at	  -­‐80˚C.	  Tubes	  were	  thawed,	  reverse-­‐transcribed	  at	  55˚C	  for	  1	  hour	  with	  16	  U/µL	  
Superscript	  III	  RT	  enzyme	  (Life	  Technologies)	  in	  1X	  First	  Strand	  buffer,	  followed	  by	  
oligo-­‐dG	  tailing	  by	  terminal	  deoxynucleoside	  transferase	  (TdT)	  at	  37˚C	  for	  1	  hour	  in	  a	  
total	  volume	  of	  10	  µL	  reaction	  mix	  (final	  concentration:	  10	  mM	  Tris-­‐HCl	  [Sigma-­‐
Aldrich],	  10	  mM	  MgCl2,	  pH	  7.5,	  1	  mM	  DTT,	  2	  mM	  dGTP,	  0.75	  U/µL	  TdT	  [all	  from	  Life	  
Technologies]).	  	  Heat	  inactivation	  of	  the	  enzymes	  was	  performed	  at	  70˚C	  for	  10	  min.	  
Second	  strand	  synthesis	  was	  carried	  out	  in	  a	  total	  reaction	  mix	  of	  50	  µL	  (final	  
concentration:	  1X	  GC	  buffer,	  2	  U/µL	  Phusion	  II	  DNA	  polymerase	  [both	  from	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Finnzymes],	  0.2	  mM	  dNTP,	  0.5	  µM	  oligo-­‐dC-­‐adaptor)	  with	  the	  PCR	  cycle	  listed	  in	  
table	  12.	  	  The	  resulting	  cDNA	  transcripts	  (2	  µL)	  were	  used	  to	  amplify	  TCRα	  in	  a	  first	  
round	  of	  PCR	  in	  20	  µL	  reaction	  mix	  (final	  concentration:	  1X	  GC	  buffer,	  0.2	  mM	  dNTP,	  
0.5	  µM	  mTCRa1st	  primer,	  0.5	  µM	  AdaptorP1	  primer,	  0.02	  U/µL	  Phusion	  II	  DNA	  
polymerase)	  with	  the	  PCR	  cycle	  listed	  in	  table	  13.	  To	  amplify	  TCRβ,	  this	  step	  is	  
repeated	  with	  mTCRb1st	  and	  Adaptor	  P1	  primer	  pairs.	  From	  these,	  4	  µL	  of	  the	  
reaction	  mix	  was	  used	  to	  do	  a	  nested	  PCR	  with	  primer	  pairs	  mTCRaNest,	  AdaptorP2	  
for	  TCRα,	  and	  mTCRbNest,	  AdaptorP2	  for	  TCRβ,	  in	  the	  same	  conditions	  as	  that	  in	  the	  
first	  run.	  Amplicons	  were	  analyzed	  by	  gel	  electrophoresis	  on	  1%	  TAE	  gel,	  excised,	  
purified,	  cloned	  into	  pCR®4-­‐TOPO®	  vector	  and	  transformed	  into	  OneShot	  TOP10	  
competent	  cells.	  Positive	  transformants	  were	  miniprepped	  and	  sequenced.	  
	  
Table	  12:	  PCR	  cycling	  conditions	  for	  second	  strand	  synthesis	  of	  TCRαβ	  sequences.	  	  
Step	   Temperature	  (˚C)	   Duration	  (sec)	  
1	   98	   30	  
2	   98	   10	  
3	   60	   20	  
4	   72	   90	  
5	   Repeat	  steps	  2	  to	  4	  for	  a	  total	  of	  24	  cycles	  
6	   72	   300	  
	  
Table	  13:	  PCR	  cycling	  conditions	  for	  amplification	  of	  TCRαβ	  sequences.	  
Step	   Temperature	  (˚C)	   Duration	  (sec)	  
1	   98	   30	  
2	   98	   10	  
3	   64	   20	  
4	   72	   30	  
5	   Repeat	  steps	  2	  to	  4	  for	  a	  total	  of	  30	  cycles	  
6	   72	   300	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Cloning	  of	  F4-­‐specific	  TCRαβ	  sequences	  into	  lentivector	  
	  
TCR	  variable	  regions	  were	  assembled	  with	  constant	  regions	  and	  a	  T2A	  self-­‐
cleaving	  peptide	  into	  a	  single	  open-­‐reading	  frame	  with	  appropriate	  primers	  
(depicted	  in	  figure	  24)	  by	  overlap-­‐extension	  PCR.	  Adjoining	  fragments	  were	  
generated	  first,	  followed	  by	  combining	  all	  3	  of	  such	  fragments	  together	  in	  a	  separate	  
Figure	  24.	  Schematic	  of	  assembling	  F4-­‐specific	  TCRαβ	  sequences	  in	  one	  reading	  
frame.	  The	  TCRαβ	  sequences,	  with	  corresponding	  constant	  regions,	  from	  F4-­‐
specific	  CD8+	  T	  cells	  were	  amplified	  with	  different	  primer	  sets,	  and	  then	  
assembled	  together	  by	  PCR.	  A	  self-­‐cleaving	  T2A	  peptide	  were	  inserted	  between	  
the	  α	  and	  β	  chains	  to	  allow	  bicistronic	  expression.	  This	  was	  then	  cloned	  into	  the	  
MCS	  region	  of	  pW-­‐luc-­‐GFP.	  The	  templates	  needed	  were	  generated	  in	  the	  lab.	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PCR	  with	  BamHI-­‐TRAV13-­‐4	  and	  SpeI-­‐Cbeta2Rev	  primers.	  Reactions	  were	  analyzed	  by	  
gel	  electrophoresis	  in	  1%	  TAE	  buffer,	  excised,	  purified,	  cloned	  into	  BamHI-­‐,	  SpeI-­‐
digested	  pW-­‐luc-­‐GFP	  lentivector	  by	  using	  vector:insert	  molar	  ratio	  of	  1:3	  with	  Quick	  
Ligase	  (New	  England	  Biolabs),	  followed	  by	  transformation	  into	  OneShot	  Stbl3	  
chemically-­‐competent	  cells	  (Life	  Technologies).	  Positive	  clones	  were	  screened	  by	  
colony	  PCR	  with	  CbetaFor	  and	  WPRErev	  primers,	  miniprepped	  and	  stored	  at	  -­‐20˚C.	  
	  
Generation	  of	  lentiviral	  particles	  
	  
HEK293T	  cells	  were	  cultured	  at	  37˚C,	  5%	  CO2	  in	  a	  60	  mm	  tissue-­‐culture	  dish	  
to	  ~50%	  confluency	  in	  DMEM	  media	  supplemented	  with	  10%	  FBS.	  Lentivector	  
containing	  F4-­‐specific	  TCRαβ	  construct	  (1	  µg)	  were	  mixed	  with	  0.35	  µg	  pMD2.G	  
envelope	  vector	  and	  0.65	  µg	  psPAX2	  packaging	  vector	  (both	  from	  Trono	  lab,	  EPFL,	  
Switzerland)	  in	  80	  µL	  OptiMEM	  serum-­‐free	  media	  (Life	  Technologies).	  This	  was	  
mixed	  dropwise	  to	  another	  tube	  with	  80	  µL	  OptiMEM	  serum-­‐free	  media	  and	  6	  µL	  
EndoFectin	  Lenti	  (GeneCopoeia,	  Rockville,	  MD)	  while	  vortexing,	  incubated	  at	  room	  
temperature	  for	  15	  min,	  followed	  by	  adding	  the	  whole	  mixture	  dropwise	  into	  the	  
HEK293T	  cells.	  After	  overnight	  incubation,	  the	  DMEM	  media	  was	  replaced	  with	  3	  mL	  
fresh	  media	  and	  cells	  were	  allowed	  to	  incubate	  for	  2	  more	  days.	  Media	  containing	  
lentiviral	  particles	  were	  harvested,	  centrifuged	  at	  500	  g	  for	  5	  min	  to	  remove	  cell	  
debris,	  aliquoted	  and	  stored	  at	  -­‐80˚C.	  	  
	  
	   	  
	   89	  
Creation	  of	  LR-­‐WH3.4	  T	  reporter	  cell	  line	  
	  
LR-­‐null	  T	  reporter	  cells	  (132),	  which	  express	  TCR	  δ	  and	  ζ	  chains	  and	  NFAT-­‐
LacZ	  cassette,	  were	  seeded	  at	  105	  cells	  in	  a	  24-­‐well	  tissue-­‐culture	  plate	  with	  RPMI	  
complete	  media,	  transduced	  with	  100	  µL	  lentiviral	  particles	  obtained	  earlier	  and	  
incubated	  at	  37˚C,	  5%	  CO2.	  Change	  of	  media	  was	  done	  the	  next	  day,	  and	  cells	  were	  
incubated	  for	  2	  more	  days,	  before	  harvested	  and	  stained	  with	  anti-­‐mouse	  TCRβ	  PE	  at	  
1:1000	  dilution	  for	  30	  min	  on	  ice	  in	  FACs	  buffer.	  Cells	  were	  washed	  and	  resuspended	  
in	  FACs	  buffer	  with	  100	  ng/µL	  DAPI	  (Molecular	  Probes),	  followed	  by	  sorting	  for	  DAPI-­‐	  
PE+	  cells	  into	  a	  96-­‐well	  tissue	  culture	  plate	  filled	  with	  200	  µL	  RPMI	  complete	  media	  
per	  well,	  with	  one	  cell	  in	  each	  well.	  Cells	  were	  then	  cultured,	  and	  12	  wells	  with	  good	  
cell	  growth	  were	  tested	  by	  incubating	  3	  x	  104	  Dynabead	  Mouse	  T-­‐Activator	  
CD3/CD28	  (Life	  Technologies)	  with	  equal	  numbers	  of	  cells	  overnight,	  followed	  by	  
staining	  for	  LacZ	  activity	  as	  described	  earlier.	  
	  
Folic	  acid	  challenge	  
	  
To	  reduce	  parasite	  load	  rapidly	  before	  onset	  of	  ECM,	  PbA-­‐infected	  mice	  were	  
treated	  by	  i.p.	  injection	  with	  0.8	  mg	  chloroquine	  diphosphate	  (dissolved	  in	  H2O)	  
twice	  on	  days	  6	  and	  7,	  0.1	  mg	  artesunate	  (dissolved	  in	  5%	  sodium	  bicarbonate,	  then	  
added	  an	  equal	  amount	  of	  0.9%	  sodium	  chloride,	  all	  chemicals	  from	  Sigma-­‐Aldrich)	  
twice	  on	  the	  morning	  and	  evening	  of	  day	  6.	  Unless	  specified	  otherwise,	  100	  µg	  of	  
each	  peptide	  were	  introduced	  i.v.	  into	  each	  mouse	  thrice	  on	  day	  7,	  at	  4	  hours	  apart.	  
The	  next	  day,	  folic	  acid	  at	  pH	  7,	  0.25	  mg/g	  body	  weight	  (Sigma-­‐Aldrich)	  were	  injected	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i.v.	  twice	  at	  1	  hour	  apart,	  and	  monitored	  for	  90	  min	  after	  second	  injection.	  Mice	  that	  




Prior	  to	  PbA	  infection,	  mice	  were	  injected	  i.v.	  with	  300	  µg	  of	  each	  peptide	  at	  
day	  -­‐7,	  and	  100	  µg	  of	  each	  peptide	  on	  days	  -­‐4	  and	  -­‐1	  (196).	  Mouse	  survival	  was	  
monitored	  and	  tetramer	  staining	  on	  BSL	  and	  splenocytes	  were	  performed	  as	  




Flow	  cytometry	  data	  and	  all	  calculations	  were	  analyzed	  with	  Flowjo	  
(TreeStar,	  Ashland,	  OR)	  and	  Prism	  6	  (GraphPad,	  La	  Jolla,	  CA)	  respectively.	  The	  results	  
for	  staining	  of	  tetramer-­‐specific	  CD8+	  T	  cells	  were	  analyzed	  by	  Mann-­‐Whitney	  U	  test.	  
ELISpot	  readings	  were	  analyzed	  with	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  and	  
Dunnett’s	  post	  test	  with	  the	  unpulsed	  samples	  as	  the	  control	  group.	  The	  blue	  spots	  
counted	  in	  brain	  microvessel	  cross-­‐presentation	  assay	  were	  log	  transformed	  to	  
achieve	  homogeneity	  of	  variance	  and	  analyzed	  with	  one-­‐way	  ANOVA	  with	  
Bonferroni’s	  post	  test.	  Folic	  acid	  challenge	  and	  survival	  was	  analyzed	  with	  Fisher’s	  
exact	  test,	  while	  peptide	  tolerization	  and	  survival	  after	  PbA	  infection	  was	  analyzed	  
with	  log	  rank	  (Mantel	  Cox)	  test.	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Results	  
	  
Induction	  of	  CD8+	  T	  cells	  specific	  for	  malaria	  epitopes	  during	  Plasmodium	  infection	  
	  
With	  the	  identification	  of	  2	  novel	  Plasmodium	  epitopes	  and	  the	  description	  
of	  other	  epitopes	  in	  the	  literature	  in	  the	  previous	  chapter,	  we	  first	  asked	  if	  we	  can	  
detect	  the	  induction	  of	  these	  specific	  CD8+	  T	  cells	  in	  mice	  during	  ECM	  using	  pMHC	  
tetramers.	  Brains	  and	  spleens	  of	  PbA-­‐infected	  mice	  at	  day	  7	  post-­‐infection	  were	  
processed	  to	  isolate	  leukocytes	  and	  stained	  for	  live	  CD8+	  T	  cells,	  defined	  by	  CD8a+	  
and	  CD16/32-­‐	  expression	  (since	  T	  cells	  lack	  CD16	  and	  CD32	  Fc	  receptors).	  PE-­‐labeled	  
Pb1	  tetramer	  was	  used	  in	  one	  experiment,	  while	  in	  a	  separate	  experiment,	  PE-­‐
labeled	  Pb2	  tetramer	  and	  BV421-­‐labeled	  F4	  tetramer	  were	  used	  together	  (figure	  
25A).	  Clear	  populations	  of	  tetramer-­‐specific	  CD8+	  T	  cells	  were	  observed	  in	  the	  
spleens	  and	  brains	  of	  PbA-­‐infected	  mice	  and	  not	  in	  naïve	  mice	  (figure	  25B).	  This	  
demonstrates	  that	  CD8+	  T	  cells	  specific	  for	  natural	  malaria	  epitopes	  expanded	  and	  
migrated	  to	  the	  brains	  of	  mice	  during	  infection.	  
	  
As	  these	  epitopes	  are	  conserved	  in	  the	  non-­‐ECM	  causing	  parasites	  Py17X	  and	  
PbNK65	  (table	  14),	  one	  possibility	  is	  that	  malaria-­‐specific	  CD8+	  T	  cells	  are	  not	  
induced	  during	  infections	  with	  these	  parasites,	  thereby	  rendering	  the	  infected	  mice	  
ECM-­‐resistant.	  Tetramer	  staining	  revealed	  that	  they	  are	  also	  found	  in	  the	  brains	  and	  
spleens	  of	  mice	  infected	  with	  Py17X	  (figure	  26)	  and	  PbNK65	  (figure	  27).	  Of	  note,	  the	  
numbers	  of	  Pb1-­‐specific	  CD8+	  T	  cells	  in	  Py17X-­‐infected	  mice	  are	  2	  to	  10-­‐fold	  (in	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Figure	  25.	  Induction	  of	  malaria-­‐specific	  CD8+	  T	  cells	  during	  PbA	  infection.	  The	  
gating	  strategy	  to	  identify	  tetramer-­‐specific	  CD8+	  T	  cells	  in	  double	  tetramer	  staining	  
is	  shown	  in	  (A).	  In	  (B),	  the	  number	  of	  CD8+	  T	  cells	  specific	  for	  Pb1	  (top),	  Pb2	  
(middle)	  and	  F4	  (bottom)	  in	  the	  spleens	  and	  brains	  of	  infected	  mice	  are	  shown.	  Bars	  
represent	  medians.	  Results	  shown	  here	  are	  pooled	  from	  two	  independent	  
experiments.	  p	  <	  0.01	  for	  all	  results,	  Mann-­‐Whitney	  U	  test.	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Figure	  26.	  Induction	  of	  malaria-­‐specific	  CD8+	  T	  cells	  during	  Py17X	  infection.	  See	  
figure	  25b	  legends	  for	  description.	  p	  <	  0.01	  for	  all	  results,	  Mann-­‐Whitney	  U	  test.	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brains	  and	  spleens	  respectively)	  larger	  than	  in	  P.berghei-­‐infected	  mice.	  Therefore,	  
the	  mere	  presence	  of	  these	  specific	  CD8+	  T	  cells	  is	  not	  sufficient	  to	  cause	  ECM.	  
	  
Figure	  27.	  Induction	  of	  malaria-­‐specific	  CD8+	  T	  cells	  during	  PbNK65	  infection.	  See	  
figure	  25b	  legends	  for	  description.	  p	  <	  0.01	  for	  all	  results,	  Mann-­‐Whitney	  U	  test.	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Table	  14:	  Conservation	  of	  epitope	  sequences	  in	  different	  murine	  Plasmodium	  
parasites.	  The	  database	  PlasmoDB	  was	  used	  to	  search	  for	  conservation	  of	  epitopes	  
across	  different	  murine	  parasites,	  with	  sequences	  from	  P.	  berghei	  as	  the	  reference.	  
Sequence	  that	  differs	  from	  the	  reference	  is	  indicated.	  
	   	   	   Sequence	  conservation	  in:	  
MHC	  specificity	   Epitope	  Name	   Sequence	   P.	  yoelii	   P.	  chabaudi	  
H-­‐2Db	   Pb1	   SQLLNAKYL	   √	   √	  
H-­‐2Kb	   Pb2	   IITDFENL	   √	   IINDFENL	  





Figure	  28.	  Flow	  cytometric	  analysis	  of	  expression	  of	  cell	  surface	  markers	  on	  
malaria-­‐specific	  CD8+	  T	  cells	  during	  PbA	  infection.	  Tetramer-­‐specific	  CD8+	  T	  cells	  
from	  BSL	  and	  splenocytes	  of	  PbA-­‐infected	  mice	  were	  stained	  for	  LFA-­‐1,	  CXCR3	  and	  
CCR5.	  The	  histograms	  are	  the	  sums	  of	  data	  from	  3	  to	  7	  mice	  that	  were	  analyzed	  
separately	  (A),	  showing	  the	  expression	  of	  the	  tested	  markers	  on	  naïve	  (gray,	  filled)	  
and	  tetramer-­‐specific	  CD8+	  T	  cells	  (coloured	  lines)	  in	  the	  spleens	  and	  brains	  of	  
mice.	  The	  comparisons	  of	  MFI	  of	  CXCR3	  and	  CCR5	  between	  the	  different	  CD8+	  T	  
cells	  are	  depicted	  in	  (B)	  and	  (C)	  respectively.	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Characterization	  of	  malaria-­‐specific	  CD8+	  T	  cells	  	  
	  
The	  CD8+	  T	  cells	  specific	  for	  malaria-­‐epitopes	  during	  PbA	  infection	  were	  
analyzed	  for	  expression	  of	  surface	  markers	  by	  flow	  cytometry	  (figure	  28A).	  
Tetramer-­‐specific	  CD8+	  T	  cells	  in	  the	  spleens	  of	  infected	  mice	  were	  clearly	  positive	  
for	  LFA-­‐1,	  CXCR3	  and	  CCR5	  expression.	  In	  the	  brain,	  these	  cells	  still	  express	  LFA-­‐1	  but	  
CXCR3	  expression	  was	  downregulated	  (figure	  28B),	  while	  no	  obvious	  difference	  was	  
seen	  for	  CCR5	  expression	  (figure	  28C).
	  
	  
Figure	  29.	  Expression	  of	  intracellular	  IFNγ	  and	  granzyme	  B	  in	  malaria-­‐specific	  
CD8+	  T	  cells	  during	  PbA	  infection.	  Total	  CD8+	  T	  cells	  in	  naïve	  and	  PbA-­‐infected	  
mice	  were	  compared	  to	  determine	  the	  IFNγ+GrB+	  double-­‐positive	  gate	  (A),	  which	  
was	  then	  applied	  onto	  tetramer-­‐positive	  CD8+	  T	  cells.	  The	  frequencies	  of	  malaria-­‐
specific	  CD8+	  T	  cells	  that	  are	  IFNγ+GrB+	  in	  the	  (B)	  spleens	  and	  (C)	  brains	  of	  infected	  
mice	  were	  shown.	  Bars	  represent	  medians.	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Activated	  CD8+	  T	  cells	  express	  pro-­‐inflammatory	  cytokine	  IFNγ	  and	  cytolytic	  
granule	  granzyme	  B	  (GrB),	  and	  these	  are	  found	  to	  be	  indispensable	  for	  ECM	  (91,	  
122).	  To	  confirm	  if	  malaria-­‐specific	  CD8+	  T	  cells	  express	  these	  molecules,	  intracellular	  
cytokine	  staining	  was	  performed	  together	  with	  tetramer	  staining.	  The	  IFNγ+GrB+	  
double-­‐positive	  gate	  was	  drawn	  after	  comparison	  of	  total	  CD8+	  T	  cells	  between	  naïve	  
and	  infected	  mice,	  and	  this	  was	  used	  to	  gate	  on	  tetramer-­‐positive	  CD8+	  T	  cells	  (figure	  
29A).	  Indeed,	  a	  large	  population	  of	  these	  cells	  in	  the	  spleens	  (figure	  29B)	  and	  brains	  
(figure	  29C)	  of	  infected	  mice	  expresses	  both	  markers,	  indicating	  that	  they	  are	  
functional.	  To	  further	  demonstrate	  their	  cytolytic	  activity,	  an	  in	  vivo	  cytolysis	  assay	  
was	  performed.	  Differentially	  CFSE-­‐labeled	  donor	  splenocytes	  pulsed	  with	  or	  without	  
the	  target	  peptides	  were	  adoptively	  transferred	  into	  infected	  mice	  one	  day	  before	  
Figure	  30.	  In	  vivo	  cytotoxicity	  of	  malaria-­‐specific	  CD8+	  T	  cells	  in	  infected	  mice.	  
Unpulsed,	  CFSEhigh	  and	  peptide-­‐pulsed,	  CFSElow	  donor	  splenocytes	  were	  
transferred	  in	  equal	  numbers	  into	  infected	  mice	  at	  day	  6	  post-­‐infection.	  The	  next	  
day,	  frequencies	  of	  donor	  splenocytes	  in	  recipient	  spleens	  were	  gated	  (A).	  The	  
specific	  cytolytic	  activities	  of	  CD8+	  T	  cells	  of	  different	  specificities	  in	  (B)	  PbA-­‐,	  (C)	  
Py17X-­‐	  and	  (D)	  PbNK65-­‐infected	  mice	  were	  shown.	  Bars	  represent	  medians.	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ECM	  symptoms	  manifest.	  The	  mice	  were	  sacrificed	  the	  next	  day	  to	  analyze	  the	  
relative	  numbers	  of	  pulsed	  and	  unpulsed	  donor	  cells.	  Figure	  30	  shows	  that	  Pb1-­‐
specific	  CD8+	  T	  cells	  were	  highly	  cytolytic	  in	  all	  infections.	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  
cells	  were	  moderately	  cytolytic	  in	  almost	  all	  infections,	  except	  for	  the	  latter,	  which	  
had	  no	  activity	  in	  PbNK65-­‐infected	  mice.	  
	  
Malaria	  epitopes	  are	  cross-­‐presented	  on	  cells	  in	  the	  brain	  microvessels	  only	  in	  mice	  
infected	  with	  PbA	  
	  
As	  there	  was	  no	  contrasting	  difference	  in	  terms	  of	  induction	  and	  cytolytic	  
capability	  of	  malaria-­‐specific	  CD8+	  T	  cells	  between	  ECM	  and	  non-­‐ECM	  infections,	  the	  
attention	  was	  then	  turned	  towards	  the	  potential	  target	  cells	  in	  the	  brain.	  It	  has	  been	  
speculated	  that	  cells	  in	  the	  brain	  endothelium	  can	  phagocytose	  parasite	  materials	  
and	  cross-­‐present	  parasite	  antigens	  during	  inflammation	  (87,	  123,	  126,	  155).	  If	  this	  is	  
indeed	  the	  case,	  T	  reporter	  cells	  recognizing	  Pb1,	  Pb2	  or	  F4	  in	  the	  context	  of	  MHC	  
class	  I	  molecules	  can	  interact	  with	  cells	  that	  are	  cross-­‐presenting	  parasite	  antigens	  in	  
the	  brain	  vasculature	  fragments	  in	  vitro,	  which	  then	  trigger	  LacZ	  expression	  in	  the	  
former	  and	  turn	  blue	  upon	  X-­‐gal	  staining.	  Wells	  with	  brain	  microvessel	  fragments	  
from	  PbA-­‐infected	  mice	  had	  hundreds	  of	  blue	  spots	  when	  incubated	  with	  LR-­‐BSL8.4a	  
(figure	  31A),	  as	  compared	  to	  about	  10-­‐20	  blue	  spots	  from	  that	  of	  naïve	  mice.	  Py17X-­‐	  
and	  PbNK65-­‐infected	  brains	  gave	  spot	  counts	  that	  were	  not	  statistically	  different	  
from	  naïve	  mice.	  This	  clearly	  indicates	  that	  cross-­‐presentation	  of	  Pb1	  epitope	  on	  
cells	  in	  brain	  microvessels	  only	  occur	  in	  mice	  infected	  with	  PbA	  parasites,	  supporting	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the	  hypothesis	  that	  such	  cross-­‐presentation	  is	  necessary	  for	  mice	  to	  succumb	  to	  




Figure	  31.	  Cross-­‐presentation	  of	  malaria	  epitopes	  on	  the	  cells	  lining	  the	  brain	  
microvessels	  during	  infection.	  Brain	  microvessels	  from	  naïve	  or	  infected	  mice	  
were	  isolated,	  processed	  and	  incubated	  with	  (A)	  LR-­‐BSL8.4a	  (recognize	  H-­‐2Db-­‐
Pb1)	  and	  (B)	  LR-­‐BSL13.6b	  (H-­‐2Kb-­‐Pb2)	  overnight	  in	  96-­‐well	  filter	  plates.	  X-­‐gal	  
staining	  was	  performed	  the	  next	  day,	  and	  the	  number	  of	  blue	  cells	  were	  counted.	  
Bars	  represent	  medians.	  *	  p	  <	  0.05,	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001,	  ****	  p	  <	  0.0001,	  
one-­‐way	  ANOVA	  on	  log-­‐transformed	  data	  with	  Bonferroni’s	  multiple	  comparison.	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Table	  15:	  List	  of	  F4-­‐specific	  TCRα	  and	  TCRβ	  sequences	  and	  identities	  from	  single	  cell	  
clones,	  analyzed	  with	  IMGT/V-­‐QUEST.	  The	  most	  likely	  TCRαβ	  pair	  that	  was	  over-­‐
represented	  was	  shaded	  in	  gray,	  and	  were	  cloned	  into	  lectivector	  to	  generate	  LR-­‐
WH3.4	  T	  reporter	  cell	  line.	  Sequences	  for	  some	  clones	  could	  not	  be	  identified.	  
Clone	   TRAV	   TRAJ	   TCRα	  Junction	   TRBV	   TRBD	   TRBJ	   TCRβ	  Junction	  
A17	   3D-­‐3*02	  
or	  3N-­‐
3*01	  
6*01	   CAV#TSGGNYKPTF	  	  	   	   	   	   ✕	  
A18	   13-­‐4/DV7	   52	   CAMALGANTGKLTF	   12-­‐1	   1	   2-­‐1	   CASFTSNYAEQFS	  
A19	   13-­‐4/DV7	   52	   CAMALGANTGKLTF	   12-­‐1	   1	   2-­‐1	   CASFTSNYAEQFF	  
A20	   13-­‐4/DV7	   52	   CAMALGANTGKLTF	   12-­‐1	   1	   2-­‐1	   CASFTSNYAEQFF	  
A21	   	   	   	   1	   1	   1-­‐1	   CTCSGTEVFF	  
A23	   16N	   6	   CAMRAPGGNYKPTF	   20	   1	   2-­‐2	   CGASRDRNTGQLYF	  
A24	   	   	   ✕	   20	   1	   2-­‐2	   CGASRDRNTGQLYF	  
#	  -­‐	  unproductive	  TCR	  sequence	  that	  arose	  due	  to	  frame-­‐shifting.	  
✕	  -­‐	  failed	  sequencing	  result	  	  
	  
In	  order	  to	  see	  if	  the	  F4	  epitope	  is	  also	  cross-­‐presented	  on	  the	  cells	  lining	  the	  
brain	  microvessels,	  a	  T	  reporter	  cell	  line	  that	  recognizes	  F4	  in	  the	  context	  of	  H-­‐2Kb	  
MHC	  class	  I	  needs	  to	  be	  created.	  Single	  cell	  TCR	  sequencing	  was	  performed	  on	  
sorted	  F4-­‐specific	  CD8+	  T	  cells	  isolated	  from	  infected	  mice.	  Single	  cell	  PCR	  was	  
required	  in	  order	  to	  pair	  up	  the	  TCRα	  and	  β	  variable	  regions.	  The	  desired	  PCR	  
products	  of	  about	  500	  bp	  were	  purified	  and	  sequenced	  following	  gel	  electrophoresis	  
(figure	  32A).	  A	  list	  of	  the	  TCRαβ	  pairs	  obtained	  was	  tabulated	  in	  table	  15.	  The	  TCRαβ	  
pair	  that	  was	  found	  in	  more	  than	  one	  cell	  (highlighted	  in	  gray)	  was	  cloned	  into	  a	  
lentiviral	  construct	  to	  transduce	  NFAT-­‐LacZ	  reporter	  cells.	  The	  T	  reporter	  cell	  clone	  
LR-­‐WH3.4a	  was	  selected	  for	  high	  expression	  of	  TCR	  (figure	  32B)	  and	  excellent	  LacZ	  
activation	  upon	  stimulation	  with	  minimal	  background	  (figure	  32C).	  These	  cells	  were	  
then	  used	  to	  assay	  cross-­‐presentation	  of	  F4	  epitope	  on	  the	  brain	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microvessels	  of	  mice	  infected	  with	  malaria	  parasites.	  In	  agreement	  with	  the	  Pb1	  and	  
Pb2	  results,	  cross-­‐presentation	  of	  F4	  epitope	  only	  occurs	  efficiently	  when	  mice	  were	  
infected	  with	  ECM-­‐causing	  PbA	  parasites	  (figure	  32D),	  showing	  that	  such	  a	  finding	  is	  
likely	  to	  be	  generalized	  to	  all	  malaria	  CD8	  epitopes.	  
	  	  
Malaria-­‐specific	  CD8+	  T	  cells	  induced	  during	  infection	  can	  damage	  BBB	  in	  vivo	  
	  
We	  sought	  to	  further	  show	  that	  the	  epitope-­‐specific	  CD8+	  T	  cells	  that	  were	  induced	  
during	  PbA	  infection	  have	  the	  ability	  to	  exert	  cytolytic	  effects	  on	  cells	  in	  the	  BBB	  and	  
thereby	  lead	  to	  hemorrhages	  and	  edema	  as	  seen	  in	  CM	  cases.	  An	  experimental	  
setup	  was	  devised,	  where	  mice	  were	  infected,	  treated	  with	  anti-­‐malarial	  drugs	  at	  
day	  6	  post-­‐infection,	  injected	  with	  Pb1,	  Pb2	  or	  F4	  peptide	  multiple	  times	  (figure	  
33A).	  The	  rationale	  is	  to	  rapidly	  stop	  cross-­‐presentation	  by	  removing	  the	  source	  of	  
antigen,	  then	  to	  artificially	  pulse	  the	  brain	  endothelial	  cells	  with	  a	  particular	  peptide	  
epitope.	  Any	  subsequent	  damage	  to	  the	  BBB	  can	  be	  attributed	  to	  CD8+	  T	  cells	  
recognizing	  only	  this	  particular	  epitope.	  The	  use	  of	  chloroquine	  and	  artesunate	  in	  
combination	  decreased	  the	  parasite	  load	  in	  the	  body	  rapidly	  (figure	  33B),	  while	  the	  
numbers	  of	  Pb1-­‐specific	  CD8+	  T	  cells	  in	  treated	  mice	  did	  not	  differ	  significantly	  than	  
when	  left	  untreated	  (figure	  33C),	  corroborating	  earlier	  findings	  (122,	  202).	  Cross-­‐
Figure	  32.	  Creation	  of	  T	  reporter	  cell	  line	  recognizing	  F4	  epitope	  on	  H-­‐2Kb
	  
MHC	  
class	  I	  (LR-­‐WH3.4a).	  (A)	  Representative	  results	  of	  single	  cell	  amplification	  of	  the	  
variable	  regions	  of	  TCR	  α	  and	  β.	  Each	  lane	  corresponds	  to	  one	  CD8+	  T	  cell;	  desired	  
bands	  are	  ~500	  bp.	  	  were	  obtained	  in	  some	  cells.	  One	  TCRαβ	  pair	  from	  table	  15	  
was	  transduced	  to	  create	  T	  reporter	  cells.	  (B)	  TCRβ	  expression	  and	  (C)	  LacZ	  
activity	  upon	  stimulation	  with	  F4-­‐pulsed	  EL4	  cells	  (left)	  and	  unpulsed	  EL4	  cells	  
(right)	  of	  the	  selected	  reporter	  clone	  LR-­‐WH3.4a.	  (D)	  LR-­‐WH3.4a	  was	  used	  to	  
assess	  cross-­‐presentation	  of	  F4	  epitope	  in	  the	  brain	  microvessels	  of	  mice	  infected	  
with	  malaria	  parasites,	  as	  described	  in	  figure	  31.	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presentation	  of	  Pb1	  in	  the	  brains	  of	  mice	  was	  abolished	  following	  treatment	  (figure	  
33D).	  After	  repeated	  injections	  of	  Pb1	  peptide	  to	  pulse	  the	  endothelial	  cells	  in	  vivo,	  
mice	  developed	  slight	  ECM	  signs	  (hunched	  back,	  ruffled	  fur	  and	  lethargy)	  without	  
progressing	  further	  to	  paralysis,	  coma	  and	  death.	  We	  thus	  sought	  a	  clearer	  readout	  
of	  BBB	  damage.	  From	  the	  literature,	  Hermsen	  et	  al	  reported	  that	  i.v.	  injection	  of	  folic	  
	  
Figure	  33.	  Pb1-­‐specific	  CD8+	  T	  cells	  can	  damage	  BBB	  on	  their	  own,	  causing	  mice	  
to	  be	  susceptible	  to	  folic	  acid	  challenge.	  The	  experimental	  setup	  is	  shown	  in	  (A),	  
where	  mice	  treated	  with	  chloroquine	  and	  artesunate	  (CQ/ART)	  after	  PbA	  
infection	  were	  injected	  with	  100	  µg	  peptide	  thrice,	  before	  challenged	  with	  folic	  
acid.	  The	  parasitaemia	  of	  mice	  decreased	  drastically	  in	  both	  Pb1-­‐	  and	  OVA-­‐treated	  
groups	  (B),	  but	  Pb1	  CD8+	  T	  cells	  in	  the	  brains	  remain	  unchanged	  (C).	  This	  was	  
accompanied	  with	  a	  drop	  in	  cross-­‐presentation	  of	  Pb1	  epitope	  (D).	  Results	  of	  the	  
folic	  acid	  challenge	  in	  Pb1-­‐	  and	  OVA-­‐treated	  mice	  was	  shown	  in	  (E).	  Bars	  
represent	  medians.	  *	  p	  <	  0.05	  in	  (C),	  Mann-­‐Whitney	  U	  test.	  p	  =	  0.0033	  in	  (E),	  
Fisher’s	  exact	  test.	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acid	  into	  C57BL/6J	  mice	  infected	  with	  ECM-­‐causing	  P.	  berghei	  K173	  parasites	  
induced	  strong	  convulsions	  and	  death	  in	  mice,	  and	  this	  is	  due	  to	  increased	  BBB	  
leakage	  (203).	  When	  folic	  acid	  administration	  was	  added	  to	  the	  experimental	  
schedule	  (figure	  33A),	  mice	  injected	  with	  Pb1	  peptide	  developed	  convulsions	  and	  
subsequently	  died	  during	  the	  observation	  window	  (figure	  33E).	  In	  contrast,	  mice	  
with	  irrelevant	  OVA	  peptide	  injections	  remain	  largely	  unaffected.	  	  
	  
	  
When	  the	  same	  experiment	  was	  carried	  out	  to	  analyze	  Pb2-­‐	  and	  F4-­‐specific	  
CD8+	  T	  cells,	  no	  damage	  to	  the	  BBB	  was	  observed.	  Given	  the	  lesser	  cytolytic	  
capability	  of	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  cells	  (compared	  to	  Pb1)	  in	  vivo,	  we	  sought	  
to	  increase	  the	  sensitivity	  of	  the	  experiment.	  The	  protocol	  was	  modified	  (figure	  34A)	  
such	  that	  folic	  acid	  injections	  were	  done	  on	  the	  same	  day	  as	  the	  peptide	  injections,	  
Figure	  34.	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  cells	  synergistically	  damage	  BBB	  and	  
render	  mice	  susceptible	  to	  folic	  acid	  challenge.	  The	  schematics	  of	  the	  modified	  
protocol	  is	  illustrated	  in	  (A),	  where	  the	  duration	  of	  peptide	  (100	  µg	  for	  each	  
peptide)	  and	  folic	  acid	  injections	  were	  shortened	  to	  detect	  cytolytic	  effects	  of	  
these	  CD8+	  T	  cells.	  The	  survival	  graphs	  of	  mice	  after	  injected	  with	  (B)	  Pb2,	  (C)	  F4	  
or	  (D)	  both	  Pb2	  and	  F4	  were	  shown.	  In	  (D),	  control	  mice	  were	  given	  200	  µg	  OVA	  
peptide	  per	  injection.	  p	  =	  0.0391	  for	  result	  in	  (D),	  Fisher’s	  exact	  test.	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so	  that	  the	  recovery	  window	  for	  BBB	  repair	  was	  reduced.	  In	  this	  modified	  setup,	  
mice	  that	  were	  treated	  with	  Pb2	  (figure	  34B)	  and	  F4	  (figure	  34C)	  peptide	  separately	  
were	  largely	  resistant	  to	  folic	  acid	  challenge.	  When	  both	  peptides	  were	  combined	  
and	  injected	  into	  mice,	  the	  majority	  of	  mice	  convulsed	  and	  died	  after	  injection	  with	  
folic	  acid,	  as	  opposed	  to	  mice	  treated	  with	  equal	  amounts	  of	  OVA	  peptide	  (figure	  
34D).	  Together,	  these	  experiments	  demonstrate	  that	  malaria-­‐specific	  CD8+	  T	  cells	  
have	  the	  ability	  to	  damage	  the	  BBB	  in	  an	  additive	  manner,	  and	  this	  presumably	  leads	  
to	  the	  onset	  of	  ECM.	  	  
	  
Suppressing	  the	  induction	  of	  Pb1-­‐,	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  cells	  is	  not	  sufficient	  to	  
protect	  mice	  against	  ECM	  
	  
In	  a	  study	  on	  control	  of	  Trypanosoma	  cruzi	  infections	  by	  specific	  CD8+	  T	  cells,	  
Rosenberg	  and	  colleagues	  suppressed	  the	  induction	  of	  the	  latter	  by	  injecting	  large	  
quantities	  of	  specific	  peptides	  and	  found	  them	  to	  be	  necessary	  for	  control	  of	  T.	  cruzi	  
infection	  (196).	  The	  method	  of	  tolerizing	  mice	  against	  induction	  of	  specific	  CD8+	  T	  
cells	  was	  applied	  into	  this	  study,	  in	  order	  to	  see	  if	  Pb1-­‐,	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  
cells	  are	  largely	  responsible	  for	  ECM	  pathology.	  As	  depicted	  in	  figure	  35A,	  mice	  were	  
injected	  thrice	  with	  OVA	  or	  a	  combination	  of	  Pb1,	  Pb2	  and	  F4	  peptides	  prior	  to	  PbA	  
infection.	  Mice	  given	  the	  3	  malaria	  peptides	  were	  not	  protected	  against	  ECM	  and	  all	  
mice	  were	  dead	  by	  day	  9	  post-­‐infection	  (figure	  35B).	  In	  separate	  experiments,	  
tetramer	  stainings	  were	  performed	  at	  day	  7	  post-­‐infection	  to	  ascertain	  if	  the	  
targeted	  CD8+	  T	  cells	  were	  indeed	  suppressed	  during	  infection.	  In	  the	  spleens,	  the	  
numbers	  of	  CD8+	  T	  cells	  specific	  for	  Pb1	  (figure	  35C)	  and	  Pb2	  (figure	  35D),	  but	  not	  F4	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(figure	  35E),	  decreased	  following	  peptide	  tolerization	  regimen.	  Since	  F4-­‐specific	  CD8+	  
T	  cells	  were	  not	  highly	  cytolytic	  (figure	  30B)	  and	  cannot	  cause	  enough	  damage	  to	  the	  
BBB	  on	  their	  own	  to	  render	  mice	  susceptible	  to	  folic	  acid-­‐induced	  convulsions	  (figure	  
Figure	  35.	  CD8+	  T	  cells	  of	  other	  malaria	  specificities	  contribute	  to	  ECM.	  The	  
workflow	  for	  the	  tolerization	  experiment	  is	  illustrated	  in	  (A),	  with	  the	  amount	  of	  
each	  peptide	  to	  be	  given	  i.v.	  to	  each	  mouse	  indicated	  before	  PbA	  infection.	  To	  
equalize	  the	  amount	  of	  peptides	  given	  in	  both	  groups,	  the	  amount	  of	  OVA	  peptide	  
given	  to	  the	  control	  mice	  was	  3	  times	  the	  amount	  stated.	  Survival	  of	  mice	  after	  
tolerization	  with	  OVA	  or	  3	  malaria	  epitopes	  and	  infection	  were	  depicted	  in	  (B).	  
Analysis	  of	  (C)	  Pb1-­‐,	  (D)	  Pb2-­‐	  and	  (E)	  F4-­‐specific	  CD8+	  T	  cells	  in	  the	  spleens	  of	  mice	  
were	  shown.	  (F)	  Total	  and	  (G)	  malaria-­‐specific	  CD8+	  T	  cells	  in	  BSL	  from	  infected	  
mice	  were	  also	  analyzed.	  Due	  to	  the	  small	  number	  of	  BSLs	  obtained	  in	  each	  brain,	  
the	  analysis	  of	  tetramer-­‐positive	  cells	  in	  the	  brains	  were	  incorporated	  together.	  
Bars	  represent	  medians.	  *	  p	  <	  0.05,	  Mann-­‐Whitney	  U	  test.	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34C),	  it	  is	  unlikely	  that	  they	  are	  the	  main	  reason	  for	  the	  failure	  to	  protect	  mice	  
against	  ECM.	  In	  the	  brains,	  the	  total	  numbers	  of	  CD8+	  T	  cells	  (figure	  35F),	  as	  well	  as	  
those	  specific	  for	  the	  3	  malaria	  epitopes	  (figure	  35G),	  were	  reduced	  after	  tolerization	  
of	  the	  3	  malaria-­‐specific	  CD8+	  T	  cells.	  It	  is	  likely	  that	  the	  remaining	  CD8+	  T	  cells,	  
largely	  specific	  to	  other	  PbA	  epitopes,	  were	  sufficient	  to	  damage	  the	  BBB	  during	  PbA	  
infection	  and	  cause	  mice	  to	  succumb	  to	  ECM.	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Discussion	  
	   	  
It	  is	  the	  first	  time	  that	  CD8+	  T	  cells	  specific	  for	  endogenous	  malaria	  epitopes	  
can	  be	  targeted	  and	  analyzed	  during	  ECM	  pathogenesis.	  Before	  this,	  such	  studies	  
were	  restricted	  to	  either	  total	  CD8+	  T	  cells	  (91,	  122,	  128)	  or	  CD8+	  T	  cells	  specific	  for	  a	  
non-­‐endogenous	  epitope,	  SIINFEKL	  from	  ovalbumin	  (94,	  127).	  When	  Lau	  and	  
colleagues	  reported	  the	  first	  malaria	  epitopes	  discovered,	  they	  were	  limited	  to	  
detection	  of	  IFNγ	  secretion	  by	  peptide-­‐stimulated	  spleen	  cells	  and	  in	  vivo	  cytolysis.	  
They	  could	  not	  analyze	  epitope-­‐specific	  CD8+	  T	  cells	  in	  the	  brain	  due	  to	  high	  
background.	  In	  this	  study,	  we	  confirmed	  that	  CD8+	  T	  cells	  specifically	  recognizing	  the	  
novel	  epitopes	  Pb1	  and	  Pb2	  and	  the	  recently	  reported	  F4	  epitope	  (130)	  are	  induced	  
during	  PbA	  infection	  and	  migrate	  to	  the	  brain.	  Pb1-­‐	  and	  Pb2-­‐specific	  CD8+	  T	  cells	  
were	  present	  at	  similar	  numbers	  in	  the	  spleen	  during	  ECM	  induction,	  but	  in	  the	  
brain,	  Pb1-­‐specific	  CD8+	  T	  cells	  were	  much	  more	  numerous.	  CD8+	  T	  cells	  recognizing	  
F4	  epitope	  were	  induced	  at	  similar	  levels	  as	  those	  recognizing	  Pb1.	  	  
	  
It	  was	  initially	  speculated	  that	  the	  inability	  of	  Py17X	  and	  PbNK65	  to	  induce	  
ECM	  in	  infected	  mice	  could	  be	  due	  to	  the	  failure	  to	  induce	  cytotoxic	  parasite-­‐specific	  
CD8+	  T	  cells.	  As	  the	  Pb1,	  Pb2	  and	  F4	  epitopes	  are	  conserved	  between	  P.	  berghei	  and	  
P.	  yoelii,	  we	  were	  able	  to	  compare	  the	  specific	  CD8+	  T	  cell	  responses	  to	  these	  
epitopes	  in	  PbA	  versus	  non-­‐ECM	  strains.	  Unexpectedly,	  mice	  infected	  with	  non-­‐ECM-­‐
causing	  parasites	  Py17X	  and	  PbNK65	  did	  induce	  CD8+	  T	  cells	  recognizing	  these	  3	  
epitopes.	  Indeed,	  induction	  of	  Pb1-­‐specific	  CD8+	  T	  cells	  was	  especially	  strong	  in	  
Py17X	  infection	  as	  compared	  to	  mice	  infected	  with	  PbA	  or	  PbNK65,	  clearly	  indicating	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that	  there	  was	  no	  shortage	  of	  antigen-­‐specific	  CD8+	  T	  cells	  in	  this	  non-­‐ECM	  mouse	  
model.	  	  
	  
Changes	  in	  chemokine	  levels	  during	  steady	  state	  and	  inflammatory	  
conditions	  play	  an	  important	  role	  in	  immune	  regulation	  [reviewed	  by	  (204)].	  In	  the	  
context	  of	  ECM,	  increased	  production	  of	  chemokines	  RANTES	  (Regulated	  on	  
activation,	  normal	  T-­‐cell	  expressed	  and	  secreted),	  CXCL9	  and	  CXCL10	  were	  observed	  
in	  the	  brains	  of	  infected	  mice	  (135,	  139).	  This	  is	  concomitant	  with	  the	  essential	  role	  
of	  CXCR3	  receptor	  in	  ECM,	  as	  mice	  deficient	  in	  CXCR3	  expression	  were	  protected	  
when	  infected	  with	  PbA	  (136,	  142).	  In	  this	  study,	  activated	  malaria-­‐specific	  CD8+	  T	  
cells	  in	  the	  spleen	  were	  positive	  for	  CCR5	  and	  CXCR3,	  but	  these	  populations	  down-­‐
regulated	  the	  latter	  receptor	  upon	  reaching	  the	  brain.	  Binding	  of	  CXCR3	  receptors	  to	  
its	  ligands	  was	  shown	  to	  result	  in	  internalization	  of	  the	  whole	  complex	  (205).	  We	  
postulate	  that	  in	  the	  context	  of	  ECM,	  the	  concentration	  levels	  of	  CXCL9	  and	  CXCL10	  
are	  highest	  in	  the	  brain	  and	  lowest	  in	  the	  vicinity	  of	  the	  lymphoid	  organs.	  CXCR3	  
internalization	  in	  response	  to	  ligand	  binding	  may	  be	  important	  for	  continued	  
migration	  up	  the	  concentration	  gradient,	  as	  increasing	  levels	  of	  chemokines	  are	  
needed	  to	  maintain	  the	  chemotactic	  response.	  It	  remains	  to	  be	  seen	  if	  other	  
chemokine	  receptor-­‐ligand	  interactions	  operate	  in	  a	  similar	  fashion	  in	  ECM.	  
	  
The	  absence	  of	  ECM	  in	  mice	  infected	  with	  non-­‐ECM-­‐causing	  parasites	  could	  
not	  be	  attributed	  to	  the	  lack	  of	  cytolytic	  activity	  in	  malaria-­‐specific	  CD8+	  T	  cells.	  
Rather,	  we	  demonstrated	  in	  this	  study	  that	  the	  cross-­‐presentation	  of	  Pb1,	  Pb2	  and	  
F4	  epitopes	  in	  the	  brain	  microvasculature	  was	  found	  to	  occur	  only	  during	  PbA	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infection,	  leading	  us	  to	  propose	  that	  this	  is	  the	  crucial	  difference	  between	  ECM	  and	  
non-­‐ECM	  infections.	  This	  finding	  strengthens	  the	  proposed	  mechanism	  that	  malaria-­‐
specific	  CD8+	  T	  cells	  migrate	  to	  the	  brain	  and	  exert	  their	  cytolytic	  effects	  on	  the	  
cross-­‐presenting	  cells	  lining	  the	  BBB,	  leading	  to	  BBB	  leakage	  and	  the	  manifestations	  
of	  ECM.	  A	  possible	  explanation	  for	  the	  differences	  in	  cross-­‐presentation	  is	  that	  PbA	  
iRBCs	  sequester	  efficiently	  in	  the	  brain	  as	  compared	  to	  Py17X	  or	  PbNK65	  iRBC	  (132,	  
202),	  which	  may	  promote	  uptake	  of	  parasite	  material	  by	  the	  activated	  brain	  
endothelial	  cells.	  In	  addition,	  PbA	  parasites	  may	  form	  unique	  receptor-­‐ligand	  
interactions	  with	  host	  cells	  in	  the	  brain,	  which	  the	  non-­‐ECM	  parasites	  may	  not.	  
Identification	  of	  such	  molecular	  interactions,	  if	  any,	  could	  suggest	  alternative	  options	  
for	  intervening	  with	  ECM.	  	  
	  
In	  the	  in	  vivo	  cytolysis	  assays,	  Pb1-­‐specific	  CD8+	  T	  cells	  exerted	  very	  strong	  
cytotoxic	  activity	  against	  target	  cells	  whereas	  cells	  recognizing	  Pb2	  and	  F4	  had	  only	  
modest	  activity.	  On	  a	  similar	  note,	  injection	  of	  Pb1	  peptide	  alone	  could	  trigger	  death	  
in	  convalescent	  mice	  during	  folic	  acid	  challenge	  assay.	  Pb2	  and	  F4	  had	  to	  be	  
combined	  to	  render	  mice	  susceptible	  to	  folic	  acid-­‐induced	  convulsions.	  These	  
findings	  suggest	  that	  Pb2	  and	  F4	  epitopes	  are	  less	  immunodominant	  than	  Pb1.	  In	  a	  
study	  conducted	  by	  Lin	  and	  colleagues,	  the	  expression	  of	  the	  model	  epitope	  SIINFEKL	  
from	  chicken	  ovalbumin	  at	  different	  compartments	  within	  the	  parasite	  influences	  
the	  magnitude	  of	  specific	  CD8+	  T	  cell	  response,	  with	  localization	  at	  the	  PVM	  inducing	  
a	  stronger	  response	  than	  expression	  in	  the	  cytosol	  (206).	  Correlating	  to	  this	  finding,	  
GAP50	  is	  localized	  near	  to	  the	  PVM,	  bergheilysin	  in	  the	  food	  vacuole	  deep	  within	  the	  
parasite,	  and	  replication	  factor	  A	  being	  in	  the	  nucleus	  (which	  harbours	  F4	  epitope).	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Thus,	  the	  localizations	  of	  the	  corresponding	  antigens	  may	  be	  one	  reason	  for	  their	  
contrasting	  immunodominance.	  	  
	  
The	  folic	  acid	  challenge	  assays	  demonstrated	  that	  CD8+	  T	  cells	  of	  the	  three	  
specificities	  tested	  were	  capable	  of	  damaging	  the	  BBB	  in	  convalescent	  mice,	  
following	  the	  introduction	  of	  corresponding	  exogenous	  peptides.	  However,	  the	  
extent	  of	  BBB	  damage	  was	  limited;	  severe	  neurological	  symptoms	  and	  death	  
occurred	  only	  after	  injection	  of	  neurotoxic	  folic	  acid.	  This	  implies	  that	  there	  are	  likely	  
additional	  unknown	  specificities	  of	  CD8+	  T	  cells	  that	  can	  inflict	  BBB	  damage,	  and	  the	  
synergistic	  effects	  of	  these	  known	  and	  unknown	  CD8+	  T	  cells	  are	  required	  to	  initiate	  
full-­‐blown	  ECM.	  The	  tolerization	  experiment	  results	  also	  point	  towards	  the	  presence	  
of	  additional	  CD8	  epitopes,	  as	  successful	  suppression	  of	  the	  CD8+	  T	  cell	  response	  
against	  Pb1	  and	  Pb2	  had	  no	  effect	  on	  ECM	  onset	  or	  incidence.	  Another	  possibility	  
suggested	  by	  the	  tolerization	  experiment	  is	  that	  multiple	  specificities	  may	  have	  
redundant,	  mutually	  compensating	  roles	  in	  destroying	  BBB	  integrity	  during	  PbA	  
infection.	  With	  Pb1-­‐,	  Pb2-­‐	  and	  F4-­‐specific	  CD8+	  T	  cells	  representing	  only	  a	  fraction	  of	  
total	  CD8+	  T	  cells	  in	  the	  brains	  during	  ECM,	  it	  is	  highly	  likely	  that	  there	  are	  more	  
players	  than	  the	  3	  specificities	  that	  were	  characterized	  here.	  The	  recent	  report	  on	  
the	  discovery	  of	  yet	  another	  CD8+	  T	  cell	  epitope,	  PbT-­‐I,	  by	  Lau	  et	  al	  (207)	  is	  a	  good	  
example.	  It	  will	  be	  interesting	  to	  investigate	  if	  the	  CD8+	  T	  cell	  response	  induced	  by	  
the	  PbT-­‐I	  epitope	  and	  brain	  microvessel	  cross-­‐presentation	  of	  PbT-­‐I	  share	  similar	  
characteristics	  with	  what	  has	  been	  reported	  here.	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The	  discoveries	  of	  two	  novel	  malaria	  CD8+	  T	  cell	  epitopes,	  Pb1	  and	  Pb2,	  
together	  with	  the	  application	  of	  MHC	  tetramers	  that	  can	  label	  these	  specific	  CD8+	  T	  
cells,	  represent	  considerable	  progress	  in	  understanding	  the	  CD8+	  T	  cell-­‐mediated	  
pathogenesis	  of	  ECM.	  Analysis	  of	  these	  CD8+	  T	  cells	  induced	  during	  infection,	  
together	  with	  those	  recognizing	  the	  contemporaneously	  reported	  F4	  epitope,	  
showed	  that	  they	  are	  cytolytic	  in	  nature	  and	  are	  able	  to	  participate	  in	  damaging	  the	  
BBB,	  leading	  to	  ECM	  development.	  The	  quest	  to	  demonstrate	  the	  latter	  proved	  
difficult.	  Unlike	  Lau	  and	  colleagues,	  who	  demonstrated	  through	  adoptive	  transfer	  
that	  PbT-­‐I	  CD8+	  T	  cells	  from	  transgenic	  mice	  could	  cause	  ECM	  (207),	  we	  are	  still	  in	  
the	  process	  of	  generating	  transgenic	  mice	  for	  two	  years	  thus	  far.	  Instead,	  we	  
indirectly	  demonstrated	  this	  by	  removing	  the	  parasite	  load	  in	  infected	  mice	  and	  
loading	  exogenous	  peptides	  onto	  MHC	  class	  I	  molecules	  in	  their	  brains	  and	  using	  
folic	  acid	  to	  detect	  BBB	  damage.	  
	  
From	  this	  study,	  we	  conclude	  that	  ECM	  pathogenesis	  is	  likely	  caused	  by	  the	  
concerted	  actions	  of	  CD8+	  T	  cells	  recognizing	  multiple	  specificities.	  This	  was	  inferred	  
from	  two	  observations.	  One,	  CD8+	  T	  cells	  of	  one	  specificity	  alone	  were	  unable	  to	  
replicate	  ECM-­‐like	  symptoms	  in	  convalescent	  mice	  when	  the	  corresponding	  peptide	  
was	  introduced	  into	  the	  circulation.	  Instead,	  the	  damage	  to	  the	  BBB	  could	  only	  be	  
reliably	  detected	  when	  challenged	  with	  foilc	  acid	  injection.	  Two,	  mice	  that	  were	  
tolerized	  against	  Pb1,	  Pb2	  and	  F4	  epitopes	  still	  developed	  ECM,	  despite	  a	  decrease	  in	  
accumulation	  of	  total	  and	  epitope-­‐specific	  CD8+	  T	  cells	  in	  their	  brains.	  However,	  this	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is	  not	  surprising	  given	  that	  Plasmodium	  parasites	  possess	  over	  5,000	  genes.	  The	  CD8	  
epitope	  repertoire	  that	  is	  presented	  by	  the	  host	  immune	  system	  can	  be	  much	  
greater	  than	  that	  from	  viruses	  or	  bacteria.	  One	  can	  imagine	  that	  the	  combined	  effect	  
of	  all	  the	  parasite-­‐specific	  CD8+	  T	  cells	  recognizing	  their	  cognate	  epitopes	  cross-­‐
presented	  on	  the	  cells	  constituting	  the	  BBB	  is	  massive	  enough	  to	  lead	  to	  edema	  and	  
hemorrhages,	  the	  characteristics	  of	  ECM.	  In	  our	  tolerization	  system,	  there	  could	  be	  
other,	  yet	  to	  be	  discovered	  epitope-­‐specific	  CD8+	  T	  cells	  that	  can	  cause	  BBB	  
breakdown.	  This	  brings	  up	  the	  notion	  that	  when	  a	  certain	  threshold	  of	  damage	  has	  
been	  inflicted	  onto	  the	  brain	  microvessels,	  that	  is	  beyond	  the	  ability	  of	  the	  body	  to	  
repair,	  fatal	  ECM	  will	  occur.	  Multiple	  specificities	  must	  be	  targeted	  at	  the	  same	  time	  
in	  order	  to	  bring	  down	  the	  damage	  below	  this	  speculated	  threshold,	  which	  is	  a	  
challenging	  and	  impractical	  approach.	  	  
	  
Despite	  being	  recognized	  by	  pathogenic	  CD8+	  T	  cells	  during	  blood-­‐stage	  
malaria	  infection,	  the	  epitopes	  discovered	  in	  this	  study	  may	  have	  potential	  in	  
conferring	  protection	  against	  liver-­‐stage	  malaria.	  Experiments	  with	  liver-­‐stage	  
infections	  showed	  that	  parasite-­‐specific	  CD8+	  T	  cells	  are	  essential	  in	  mediating	  sterile	  
immunity	  in	  humans	  (39,	  42,	  208)	  and	  mouse	  models	  (209,	  210).	  If	  the	  epitopes	  in	  
this	  study	  are	  also	  presented	  by	  infected	  hepatocytes	  (211),	  then	  vaccines	  to	  mount	  
CD8+	  T	  cell	  immune	  responses	  against	  them	  may	  be	  able	  to	  prevent	  blood-­‐stage	  
infection	  by	  killing	  the	  liver-­‐stage	  parasites	  before	  they	  release	  merozoites	  into	  the	  
circulation.	  Malaria-­‐specific	  CD8+	  T	  cells	  are	  pathogenic	  in	  blood-­‐stage	  infections,	  
where	  almost	  all	  of	  them	  must	  be	  suppressed	  in	  order	  to	  combat	  ECM	  pathogenesis.	  
Conversely,	  in	  asymptomatic	  liver-­‐stage	  infection,	  CD8+	  T	  cells	  of	  one	  or	  a	  few	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specificities	  could	  be	  enough	  to	  recognize	  infected	  hepatocytes	  and	  eliminate	  them	  
before	  they	  mature	  and	  release	  merozoites	  into	  the	  circulation.	  Finally,	  the	  epitope	  
discovery	  strategy	  that	  was	  outlined	  in	  this	  study	  could	  be	  useful	  to	  search	  for	  
additional	  protective	  epitopes	  in	  both	  mice	  and	  humans.	  
	  
In	  areas	  where	  malaria	  infections	  are	  endemic,	  victims	  suffering	  from	  severe	  
malaria,	  including	  HCM,	  are	  most	  often	  admitted	  into	  hospitals	  when	  life-­‐
threatening	  symptoms	  have	  already	  manifested.	  Even	  with	  medical	  attention	  and	  
prompt	  anti-­‐malarial	  treatment,	  mortality	  is	  unacceptably	  high	  at	  about	  20%	  (212).	  
Many	  trials	  have	  been	  conducted	  on	  combining	  anti-­‐malaria	  drugs	  with	  adjunctive	  
therapies,	  ranging	  from	  anti-­‐inflammatory	  drugs	  (213-­‐218),	  monoclonal	  antibodies	  
against	  tumor	  necrosis	  factor	  α	  (219,	  220),	  injections	  of	  immunoglobulin	  from	  semi-­‐
immune	  individuals	  (221),	  anti-­‐sequestration	  drugs	  (222,	  223),	  anti-­‐seizures	  (224-­‐
226),	  osmotherapy	  to	  reduce	  oedema	  (227-­‐229),	  iron	  chelation	  (230,	  231),	  
correcting	  metabolic	  acidosis	  (232-­‐235),	  and	  managing	  circulatory	  shock	  (236,	  237).	  
All	  these	  trials	  failed	  to	  provide	  substantial	  benefits	  to	  HCM	  patients.	  Based	  on	  post-­‐
mortem	  HCM	  observations	  and	  experimental	  results	  from	  ECM	  studies,	  the	  
underlying	  cause	  of	  HCM	  is	  speculated	  to	  be	  the	  cytoadhesion	  of	  infected	  
erythrocytes	  to	  the	  brain	  endothelium.	  Whether	  this	  subsequently	  leads	  to	  cross-­‐
presentation	  of	  parasite	  antigens	  in	  the	  brains	  of	  infected	  patients	  remains	  to	  be	  
validated.	  The	  mechanisms	  of	  HCM	  may	  turn	  out	  to	  be	  vastly	  different	  from	  that	  in	  
ECM.	  Epitopes	  and	  tools	  to	  examine	  this	  in	  the	  human	  context	  are	  lacking,	  but	  the	  
strategy	  described	  in	  this	  study	  may	  be	  applicable	  for	  such	  a	  purpose.	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Preventing	  the	  interactions	  between	  T	  cells	  and	  antigen	  presenting	  cells	  has	  
been	  a	  major	  approach	  in	  treating	  T	  cell-­‐mediated	  autoimmune	  diseases	  and	  in	  
preventing	  transplant	  rejections.	  Some	  of	  these	  treatments	  may	  be	  relevant	  to	  HCM	  
as	  we	  have	  shown	  here	  that	  ECM	  is	  a	  disease	  mediated	  by	  antigen-­‐specific	  CD8+	  T	  
cells.	  The	  main	  targets	  are	  usually	  the	  TCR	  itself	  (238),	  the	  accompanying	  adhesion	  
molecules	  such	  as	  CD11a	  (239),	  or	  the	  co-­‐stimulatory	  molecules	  such	  as	  CD80	  (240).	  
Blocking	  these	  interactions	  may	  prevent	  T	  cell	  activation	  and/or	  recognition	  to	  the	  
target	  cells,	  thereby	  averting	  further	  T	  cell-­‐mediated	  damage	  and	  disease	  remission.	  
In	  particular,	  we	  demonstrated	  that	  epitope-­‐specific	  CD8+	  T	  cells	  in	  ECM	  express	  
elevated	  levels	  of	  LFA-­‐1,	  a	  heterodimer	  of	  CD11a	  and	  CD18.	  Injection	  of	  antibodies	  
against	  CD11a	  into	  PbA-­‐infected	  mice	  one	  day	  before	  ECM	  symptoms	  develop	  
completely	  abrogated	  the	  neurocomplication	  (145,	  192).	  Despite	  this	  discovery,	  it	  
was	  never	  translated	  into	  use	  in	  humans.	  Efalizumab,	  the	  humanized	  recombinant	  
antibody	  that	  binds	  to	  CD11a,	  was	  introduced	  into	  the	  market	  as	  a	  long-­‐term	  
psoriasis	  treatment	  in	  2003.	  After	  6	  years,	  this	  drug	  was	  withdrawn	  from	  the	  market	  
after	  some	  patients	  developed	  fatal	  brain	  infections,	  due	  to	  the	  reactivation	  of	  latent	  
viral	  infections	  (241-­‐243).	  This	  has	  essentially	  halted	  further	  development	  of	  CD11a	  
blockers,	  which	  is	  a	  pity	  as	  these	  drugs	  could	  prove	  to	  be	  efficacious	  as	  short-­‐term	  
treatments	  for	  CM.	  There	  is	  little	  incentive	  for	  for-­‐profit	  drug	  companies	  to	  
reinitialize	  the	  development	  and	  marketing	  of	  CD11a	  blockers	  for	  treating	  HCM,	  
even	  with	  the	  approval	  from	  health	  regulatory	  authorities,	  as	  almost	  all	  the	  patients	  
cannot	  afford	  them.	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Therapies	  directed	  towards	  the	  brain	  endothelial	  cells	  may	  also	  prove	  useful	  
in	  HCM,	  either	  by	  inhibiting	  uptake	  or	  cross-­‐presentation	  of	  parasite	  protein,	  or	  by	  
encouraging	  the	  repair	  of	  the	  damaged	  BBB.	  One	  example	  of	  the	  former	  approach	  
could	  come	  in	  the	  form	  of	  proteasome	  inhibitors.	  Proteasomes	  play	  a	  role	  in	  
breaking	  down	  proteins	  within	  the	  cell	  into	  short	  peptides	  that	  can	  be	  loaded	  onto	  
MHC	  molecules	  [reviewed	  in	  (244)].	  It	  is	  likely	  that	  they	  are	  also	  involved	  in	  cross-­‐
presentation	  of	  malaria	  epitopes	  in	  endothelial	  cells	  lining	  along	  the	  brain	  
vasculature,	  since	  these	  cells	  can	  acquire	  characteristics	  of	  APCs	  in	  a	  pro-­‐
inflammatory	  milieu	  (156).	  If	  this	  process	  can	  be	  interrupted,	  cross-­‐presentation	  of	  
parasite	  epitopes	  would	  be	  reduced,	  making	  the	  endothelial	  cells	  poorer	  targets	  for	  
CD8+	  T	  cell-­‐mediated	  cytolysis.	  Current	  proteasome	  inhibitors	  in	  the	  market,	  such	  as	  
bortezomib	  and	  carfilzomib,	  could	  be	  assessed	  for	  such	  potential.	  On	  the	  other	  hand,	  
repairing	  the	  destruction	  in	  the	  BBB	  could	  take	  the	  form	  of	  growth	  factors	  and	  
hormones	  that	  induce	  wound	  repair	  and	  angiogenesis.	  Erythropoietin	  (EPO)	  is	  a	  
potential	  candidate	  for	  this	  purpose.	  PbA-­‐infected	  mice	  treated	  early	  in	  infection	  
with	  EPO	  were	  protected	  from	  ECM,	  with	  reduced	  inflammation,	  decreased	  T	  cell	  
trafficking	  and	  decreased	  leakage	  in	  the	  brain	  (245).	  When	  combined	  with	  
artesunate	  one	  day	  before	  ECM	  develops,	  the	  majority	  of	  infected	  mice	  survived	  and	  
ECM	  was	  abolished	  (246).	  The	  exact	  mechanism	  behind	  the	  protective	  effects	  of	  EPO	  
is	  not	  completely	  defined,	  but	  it	  is	  thought	  to	  generate	  anti-­‐apoptotic	  signals	  in	  
endothelial	  cells	  in	  a	  protein	  kinase	  B-­‐dependent	  manner	  (247).	  In	  addition	  to	  its	  
effects	  on	  endothelial	  cells,	  EPO	  has	  also	  been	  shown	  to	  inhibit	  death-­‐related	  
signaling	  pathways	  in	  neurons	  (248).	  Another	  neuroprotective	  molecule,	  neuregulin-­‐
1,	  was	  shown	  to	  confer	  protection	  against	  ECM	  to	  PbA-­‐infected	  mice,	  with	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concomitant	  decreases	  in	  pro-­‐inflammatory	  markers	  in	  the	  brain	  (249).	  The	  
immunomodulatory,	  neuroprotective	  effects	  of	  EPO	  and	  neuregulin-­‐1	  in	  ECM	  
suggest	  that	  neuroprotective	  therapies	  may	  be	  effective	  in	  ameliorating	  HCM	  in	  
patients	  when	  used	  in	  combination	  with	  anti-­‐malarial	  drugs.	  	  
	  
In	  conclusion,	  the	  discovery	  of	  novel	  malaria	  CD8+	  T	  cell	  epitopes	  and	  
characterization	  of	  cognate	  CD8+	  T	  cells	  in	  ECM	  mouse	  models	  demonstrate	  that	  the	  
destruction	  of	  BBB	  integrity	  during	  ECM	  is	  caused	  by	  CD8+	  T	  cells	  of	  multiple	  malaria	  
specificities.	  The	  observation	  that	  cross-­‐presentation	  of	  malaria	  epitopes	  by	  cells	  
lining	  the	  BBB	  is	  restricted	  to	  PbA-­‐infected	  mice	  suggests	  that	  this	  is	  the	  crucial	  
difference	  that	  defines	  susceptibility	  to	  ECM.	  Further	  research	  into	  the	  requirements	  
and	  mechanisms	  of	  such	  cross-­‐presentation	  may	  open	  up	  new	  avenues	  for	  adjunct	  
therapy	  that	  can	  rapidly	  halt	  ECM	  progression,	  and	  hopefully	  HCM	  in	  humans.	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